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Summary
HIV has attained a global distribution and the number of infected people reached an
estimated 28.1 million in sub-Saharan Africa at the end of 2001. HIV-1 subtype C is
overwhelmingly prevalent in Botswana and South Africa and to date no interventions
have been successful enough to curb the rapid spread of the virus. A number of
HIV-1 vaccine strategies are being developed, however the breadth and efficacy of
such candidate vaccines, many of which are based on the HIV-1 structural genes pol,
gag and env, have mostly been found to be inadequate.
The HIV-1 accessory genes are attractive components of HIV vaccines due to their
role in viral pathogenesis, early expression and the high ratio of conserved CTl
epitopes. Yet, because of undesirable properties questions regarding their safety as
vaccine components are raised. In this study candidate tat, rev and nefmutants were
assessed for efficient expression and inactivation of undesirable functionality.
/
Plasmid constructs that encode the South African HIV-1 subtype C consensus Tat,
Rev and Nef proteins were constructed. The coding sequences of the genes were
codon-optimised for optimum protein expression and these synthetic genes were
constructed using overlapping 50-mer oligonucleotides. Furthermore, the proteins
were mutated at previously described sites by PCR-based site-directed mutagenesis
to render them inactive for their respective functions. Corresponding wild-type Tat,
Rev and Nef constructs were also made from viral isolates that were least dissimilar
to the respective consensus amino acid sequences. tn vitro expression of the
different constructs were assessed in 293 cells by Western blotting with polyclonal
mouse sera, which were generated by DNA immunisation with one of the Tat, Rev
and Nef constructs. The transactivation activity of Tat variants and Rev-mediated
nuclear export activity of RRE-containing transcripts were studied in cotransfection
experiments using reporter-gene-based assays while Nef functionality was assessed
in a cotransfection assay with subsequent flow cytometric analysis of surface CD4
and MHC-I expression on 293 cells.
Sequence analysis of the South African HIV-1 subtype C consensus sequences of
Tat, Rev and Nef revealed a high degree of similarity with a consensus sequence
that was drawn up from a large number of viruses from southern Africa. These
consensus sequences were also closer to individual viral isolate sequences than any
individual sequences were, indicating that the use of a consensus sequence may
serve to reduce genetic diversity between a vaccine and circulating viruses.
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Expression levels of the sequence-modified tat and nef gene constructs were not
significantly higher than the wild-type constructs, however, the codon-optimised rev
mutant exhibited markedly higher expression than the wild-type rev construct.
Immunoreactivity of the protein with the mouse sera demonstrates expression and
immunogenicity of the Tat, Rev and Nef immunogens in mice. In the background of
the subtype C Tat, a single C22 mutation was insufficient to inactivate l TR-
dependent CAT expression in 293T and Hela cells. Yet, this activity was significantly
impaired using the single mutation, C3?, or the double mutation, C22C3? Compared
to the wild-type Rev, the function of the Rev with a double mutation, M5M10, was
completely abrogated. Similarly, while the wild-type Nef and native, codon-optimised
consensus Nef proteins mediated CD4 and MHC-I downregulation, CD4
downregulation was completely abrogated in one of the mutants, while both Nef
mutants were entirely deficient for MHC-I downregulation.
These data demonstrate the high expression levels and impaired functionality of
sequence-modified HIV-1 subtype C consensus Tat, Rev and Nef DNA immunogens
that may be used as single-standing vaccine components or form part of a multi-
component HIV-1 vaccine.
III
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Opsomming
Sedert die eerste gevalle van MIV in die vroeë 1980's beskryf is het die virus
wêreldwyd versprei en 'n beraamde 28.1 miljoen mense in sub-Sahara Afrika was
teen die einde van 2001 geïnfekteer. MIV-1 subtipe C kom verreweg die meeste voor
in Botswana en Suid-Afrika en tans is daar geen suksesvolle tussenkoms wat die
vinnige verspreiding van die virus kan stuit nie. 'n Aantal MIV-1 subtipe C
entstofstrategieë word tans ontwikkel maar die spektrum en effektiwiteit van sulke
entstowwe, waarvan baie op die MIV strukturele gene gag, pol en env gebaseer is, is
tans onvoldoende.
Die MIV-1 bykomstige gene is aantreklike entstofkomponente omdat hulle vroeg
uitgedruk word, 'n belangrike rol in virale patogenese speel en omdat hulle 'n hoë
verhouding van gekonserveerde sitotoksiese T-limfosiet (STL) epitope tot grootte
besit. Vanweë hierdie gene se verskeie ongewenste eienskappe word vrae ten
opsigte van hul veilige insluiting in enstofstrategieë geopper. Hierdie studie omskryf
die evaluasie van kandidaat tat, reven nef mutante vir doeltreffende
proteïenuitdrukking en funksionele onaktiwiteit.
Plasmiedkonstrukte wat vir die Suid-Afrikaanse MIV-1 subtipe C konsensus Tat, Rev
en Nef proteïene kodeer is saamgestel. Die koderingsvolgordes van die gene is
geoptimiseer vir optimale uitdrukking en die sintetiese gene is van oorvleuelende 50-
mer oligonukleotiede vervaardig. Deur van PKR-gebaseerde site-directed
mutagenese gebruik te maak is hierdie proteïene gemuteer op posisies wat voorheen
geïdentifiseer is. Ooreenstemmende wilde-tipe Tat, Reven Nef konstrukte is gemaak
vanaf virale isolate waarvan die aminosuurvolgordes die meeste ooreenstem met dié
van die konsensusvolgorde. In vitro uitdrukking van die konstrukte in 293 selle is met
behulp van immunoklad met poliklonale muissera bepaal. Die serum is gegenereer
deur DNS immunisasie van muise met een elk van die Tat, Reven Nef konstrukte.
Die transaktiverings-aktiwiteit van Tat variante en Rev bemiddelde uitvoer van RRE-
besittende transkripte uit die nukleus is in verklikkergeen kotransfeksie-eksperimente
bestudeer. Nef se funksionaliteit is deur kotransfeksie en die daaropvolgende
vloeisitometriese analise van 293 selle se oppervlak-CD4 en MHC-I uitdrukking
bestudeer.
Nukleotiedvolgorde-analise van die Suid-Afrikaanse MIV-1 subtipe C konsensus Tat,
Reven Nef proteiëne toon 'n hoë vlak van ooreenkoms met 'n konsensusvolgorde
wat afgelei is vanaf 'n groot aantal suider-Afrikaanse virusse. Hierdie
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konsensusvolgordes is ook meer soortgelyk aan individuele virale isolate as enige
individuele volgordes. Vanuit hierdie data kan afgelei word dat die gebruik van so 'n
konsensusvolgorde die genetiese diversiteit tussen 'n entstof en sirkuierende virusse
kan verminder.
Uitdrukkingsvlakke van die volgorde-geoptimiseerde tat en nef geenkonstrukte is nie
merkbaar hoër as die van die wilde-tipe konstrukte nie. In teenstelling het die
volgorde-geoptimiseerde rev mutant merkbaar hoër uitdrukkingsvlakke as die wilde-
tipe getoon. Immunoreaktiwiteit van die proteïene met die muissera demonstreer dat
die Tat, Reven Nef proteïene uitgedruk word en immunogenies in muise is. 'n
Enkele C22 mutasie in Tat is nie genoeg om lTR-afhanklike CAT uitdrukking in 293T
en Hela selle te inaktiveer nie. In teenstelling is hierdie aktiwiteit geïnhibeer vir Tat
proteïene met die enkel mutasie C37 en die dubbel mutasie C22C37. In vergelyking
met die funksionele aktiwiteit van die wilde-tipe Rev is dié van die Rev mutant
M5M10 heeltemal geïnhibeer. Die wilde-tipe en geoptimiseerde, konsensus Nef
proteïene het seloppervlak-CD4 en -MHC-I uitdrukking verlaag, maar hierdie effek
van afregulering van CD4 uitdrukking was heeltemaal opgehef in een Nef mutant en
van MHC-I uitdrukking in beide Nef mutante.
Hierdie data demonstreer die hoë uitdrukkingsvlakke en geïnhibeerde funksionaliteit
van volgorde-gemodifiseerde MIV-1 subtipe C konsensus Tat, Reven Nef DNS
immunogene wat as enkelstaande enstof kan optree of deel kan uitmaak van 'n
multi-komponent MIV-1 entstof.
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CHAPTER 1
1.1 Introduction and Literature Review
1.1.1 The historyofHIV-1
In 1978, Robert Gallo et al. isolated the first human retrovirus from the
lymphocytes of a leukemia patient and named it human T cell leukemia virus
type I (HTLV-I) (Poiesz et ai., 1980). In the following years a second
retrovirus, HTLV-II, was discovered and in 1981 a novel clinical syndrome
characterised by the unexpected onset of immunodeficiency and opportunistic
infection was recorded in homosexual men (Gottlieb et ai., 1981). It was
termed acquired immunodeficiency syndrome (AIDS). Two years later, in
1983, Montagnier and Barré-Sinoussi were the first to isolate a retrovirus from
an AIDS patient (Barre-Sinoussi et ai., 1983) and it was subsequently called
human immunodeficiency virus type 1 (HIV-1) (Coffin et ai., 1986). HIV-2, the
fourth human retrovirus, was isolated from immune-suppressed patients in
west Africa (Brun-Vezinet et ai., 1985). Since these discoveries extensive
research has been devoted to HIVand its origin. Genetic similarities with the
simian immunodeficiency virus (SIV), which naturally infects a variety of
African primates, led researchers to postulate that HIV originated in Africa
where the close contact between monkeys and humans could have been
responsible for the bridging between the species. Indeed, AIDS as a zoonosis
has recently been demonstrated elegantly using phylogenetic analysis and
this evidence indicates that the SIV counterparts of HIV-1 and HIV-2 were
introduced into the human population on at least seven occasions (Hahn et
ai., 2000). More specifically, phylogenetic data supported by geographic
linkage reveal that HIV-2 originated from the transmission of SIVsm (Gao et
ai., 1992),which naturally infects the sooty mangabey monkey whereas HIV-1
infection arose from the transmission of SIVcpz from chimpanzees to humans
(Gao et ai., 1999). These zoonotic transmissions have been attributed to the
direct contact between humans and infected sooty mangabey and
chimpanzee blood and have been dated to an estimated 1930 (range 1910 to
1950) (Hahn et ai., 2000).
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1.1.2 HIV·1 genetic diversity
Since the discovery of HIV, an ever-increasing effort to characterise strains
from different global sources has generated substantial sequence data
representing large numbers of viruses. Although HIV-2 is still primarily
restricted to West Africa, HIV-1 has spread throughout Africa and some
lineages have been dispersed around the globe (UNAIDS 2001). Phylogenetic
analyses of the numerous HIV-1 strains have revealed three distinct
monophyletic groups, which have been termed groups M (main) (Louwagie et
ai., 1993), N (new or non-M, non-O) (Simon et ai., 1998a) and 0 (outlier)
(Vanden Haesevelde et ai., 1994). Further analyses of the viruses that were
classified as group M revealed that most sequences fell into a number of
distinct clades, which led to the assignment of discrete subtypes (Louwagie et
ai., 1993). Initially, five subtypes were identified, but extensive global
characterisation has revealed at least nine to date, designated A to D, F to H,
J and K, with a number of viruses that do not fall within these clades. The
group M subtypes are approximately equidistantly related displaying amino
acid sequence dissimilarities of 25 to 30% in their envelope proteins (Peeters
and Sharp, 2000).
There are a number of factors that can collectively be held responsible for the
extremely high genetic variability of HIV. The first one is that of the previously
described multiple zoonotic transmissions from at least two different primate
sources (Gao et ai., 1999; Gao et ai., 1992). Second, since the transmission
into the human population, HIV has accumulated additional genetic diversity
through the rapid turnover of virions in infected individuals (Ho et al., 1995)
during which the high error rate of the viral reverse transcriptase incorporates
mutations in the course of synthesizing a deoxyribonucleic acid (DNA) copy of
the ribonucleic acid (RNA) genome (Preston et ai., 1988; Roberts et ai., 1988).
Furthermore, reverse transcriptase is highly recombinogenic, which facilitates
genomic recombinations between genetically different viruses infecting a
single individual to yield mosaic virus genomes (Hu and Temin, 1990). The
first mosaic or recombinant virus MAL was first identified in Zaire in 1986
(Alizon et ai., 1986) and since then many recombinant viruses with different
subtype combinations have been characterised. Recently, an intergroup
recombinant virus was identified, which contained genomic segmental
exchanges between group 0 and M (Takehisa et ai., 1999). Some of the
intersubtype mosaic viruses are unique, however recombinant genomes with
similar breakpoints and subtype representation have been identified in
2
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apparently unlinked individuals (Carr et a/., 1998). The latter have been
designated as circulating recombinant forms (CRFs) and play an important
role in the global AIDS epidemic. A final factor which leads to the
diversification of HIV is the pressure on the virus to mutate in such a way so
as to evade various detrimental effects exerted by forces such as immune
pressure (Borrow et a/., 1997; Price et a/., 1997). It has been demonstrated
that strong immune responses, in the form of antibodies (McLain et a/., 2001;
Ciurea et a/., 2000; Cheng-Mayer et a/., 1999) and cell mediated immunity
(Barouch et a/., 2002; Goulder et a/., 2001; Phillips et a/., 2001; Allen et a/.,
2000a; Price et a/., 1997), drive selection for randomly occurring mutants,
which eventually may lead to fixation of previously subdominant quasispecies.
Similar selective pressures, which drive viral escape from anti-HIV drugs that
typically target viral enzymes, have emerged since the administering of
antiretroviral treatment (Mayers, 1996). These factors all contribute to the
extreme diversification of HIV, which leads to challenging implications in fields
such as serological and molecular diagnostic testing, antiretroviral treatment
and vaccine development (Peeters and Sharp, 2000).
1.1.3 The AIDS pandemic and its impact on South Africa
The global state of the AIDS pandemic has acquired enormous proportions
and according to United Nations AIDS statistics, an estimated 40 million
people worldwide were living with HIV or AIDS at the end of 2001 of which
28.1 million lived in sub-Saharan Africa (UNAIDSIWHO Report 2001). During
the year 2001 alone, 3 million people died of AIDS related diseases and 5
million people were newly infected with the virus. Although AIDS is no longer
one of the top 10 causes of death in the United States (Essex, 1998), it is one
of the leading causes of death in Sub-Saharan Africa and developing
countries in South America and East Asia (UNAIDSIWHO Report 2001). On a
national level in South Africa, it was estimated that 24.8% of pregnant women
were infected with HIV by the end of 2001. The KwaZulu-Natal province has
the highest estimated prevalence at 33.5%, while the Western Cape has the
lowest at 8.6% (Department of Health, 2001). The two confidence limits, from
which the true HIV-1 prevalence estimates are estimated and the estimated
true values for the nine provinces of South Africa are tabulated in Table 1.
HIV/AIDS has also recently been shown to be the single leading cause of
death in South Africa (Dorrington et a/., 2002). While the global distribution of
3
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distribution of HIV was initially characterised by predomination of specific
subtypes in certain geographical locations, such as subtype B in Europe and
North America, an increasingly wider variety of subtypes are being
documented on most continents (McCutchan, 20(0).
Table 1: Provincial HIV prevalence estimates laken from antenatal clinic attendees at the end of 2001.
province estimatedprevalence (%) confidence limits
KwaZulu-Natal
Mpumalanga
Gauteng
Free State
NorthWest
Eastern Cape
Limpopo
NorthernCape
Western Cape
National
33.5
29.2
29.8
30.1
25.2
21.7
14.5
15.9
8.6
24.8
30.6 - 36.4
25.6 - 32.8
27.5 - 32.1
26.5- 33.7
21.9 - 28.6
19.0 - 24.4
12.2 -16.9
10.1-21.6
5.8-11.5
23.6 - 26.1
The true prevalence is estimated to fall within the two confidence limits. Source:
National HIVand Syphilis sero-prevalence survey of women attending public antenatal
clinics in South Africa - 2001 (HIV Seroprevalence Survey, 2001).
The statistics paint a desperate picture, which emphasizes the urgent need for
control and more optimistically, the eradication of HIV. The development of
antiretroviral treatment has had limited success even though immense
attention has been devoted to this subject. A number of drugs aimed at
inhibition of viral replication by targeting essential retroviral enzymes such as
reverse transcriptase and viral protease have proven to be effective at curbing
disease progression and reducing transmission (Harrington and Carpenter,
2000). However, the incredible mutation rate of HIV-1 results in quick
acquisition of drug resistance mutations and combination therapies, which
have to be altered regularly, are necessary to stem viral replication over
extended periods of time. The extreme costs of such therapies and
unavailability of sufficient funding in developing countries confine the
availability of such drug regimes, which are often short, transient programmes,
to a minority of infected people or patients with late-stage disease. The
necessity for a preventative or therapeutic HIV-1 vaccine is blatant.
4
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1.1.4 Structure of the HIV-1 virion and genome
The HIV-1 virion is an icosahedral structure as identified by high-resolution
electron microscopy and consists of a membrane envelope, which is
comprised of a host derived lipid membrane with interspersed glycoproteins
gp120 (surface protein, SU) and the transmembrane protein gp41 (TM)
(Figure 1) (Gelderblom et aI., 1987a). The lipid bilayer is also studded with
various host proteins such as major histocompatibility complex (MHC) class I
and II, which are acquired during viral budding (Gelderblom et aI., 1987b). The
membrane surrounds the viral matrix, which is made up of the myristylated
structural protein p17 (MA). p17, along with p24, p9 and p6 are nucleocapsid
proteins that are cleaved by the viral protease from a 55kD Gag precursor
(Pr55gagcoded for by the gag gene); see also 1.3.6. The phosphorylated p24
polypeptide forms the major component of the viral core, which is
encapsulated by the viral matrix. The viral core contains two copies of single
stranded genomic RNA molecules bound to p7 and associated with p9 as well
as the preformed viral enzymes reverse transcriptase (RT), protease (Pro)
and integrase (IN). The viral enzymes are coded for by the pol gene and are
also derived by proteolytic cleavage of a precursor protein. The two precursor
proteins Pr55gagand Pol are expressed from a single gag-pol mRNA which is
translated in two different reading frames (Varmus, 1988).
Lipid bilayer
Glycoproteins (Env)
Matrix (p17)
Core (p24)
RNA genome
Figure 1: Graphical representation ol the HIV virion structure.
In addition to the three genes gag, pol and env that are required for replication
by all retroviruses, the more complex genome of the lentivirus HIV-1 encodes
six additional genes (Figure 2). These additional genes are classified into two
groups termed the regulatory (tat and rev) and accessory genes (vif, vpr, vpu
5
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and net) (Greene, 1991). Although the regulatory genes are essential, the
accessory genes are dispensable for viral replication and the latter play an
important role in pathogenesis and disease progression. Finally, the genome
is flanked by regions of nucleotide sequence repeats termed the long terminal
repeat (LTR). These repeat regions are involved in host integration of the HIV-
1 genome and the 5'LTR acts as transcriptional promoter for viral gene
expression.
I!!!J
IS'LTRII-I l__g_a_g..,.... _~ __ .... _ .. ..,. ... ....-I1r-3-'L-TR.....1
- - pol ~ I~ e_nv ~ - -
Ivifl Dvpu
D----_ ----~
~--------~~;---~----~-"..,-_ ..---
HIV-1genome
rev
Flgure2: Graphical representation olthe HIV-1 genome.
1.1.5 The replication cycle of HIV-1 and it's proteins
HIV-1 employs a very efficient utilisation of coding sequences by expressing
the nine different gene products in a small genome of less than 10 kilo bases
(kb). This is accomplished by making use of a variety of splicing events and
overlapping reading frames. In addition, HIV-1 also translates unconventional
mRNAs that are incompletely or unspliced and thus retain introns, an event
that is very unusual in eukaryotic cells (Figure 3) (Greene, 1991). This is
because normally the splicing of mRNA must be completed before it can move
from the nucleus to the cytoplasm to be translated. HIV gets around this by
expressing the protein Rev, which functions as efficient exporter of unspliced
or partially spliced viral mRNAs from the nucleus to the cytoplasm (Feinberg
et aI., 1986). mRNAs that are completely spliced are exported to the
cytoplasm by the cellular mRNA export pathways and therefore are Rev-
independent.
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Figure 3: Splicing events of viral RNA transcripts of the HIV-1 genome. Unspliced and partially spliced transcripts
contain a Rev-responsive element (RRE, depicted as a semi-filled circle), which renders the expression of
the proteins they encode Rev-dependent and thus "late proteins". Expression of Tat, Rev and Nef is Rev-
independent as these are translated from completely spliced mRNA, which is exported from the nucleus
by cellular pathways.
Env
The envelope protein Env (gp160) is expressed from singly- or partially
spliced mRNA (Figure 3). After synthesis in the endoplasmic reticulum (ER),
Env migrates through the Golgi complex where it undergoes extensive
glycosylation, which is required for functionality of the protein and infectivity of
the virus (Capon and Ward, 1991). Subsequently, the gp160 is cleaved by a
host cellular protease to generate gp120 and gp41. gp41 contains the
transmembrane (TM) domain of Env, while gp120 is located on the surface of
the virion through noncovalent interactions with gp41 (Figure 1). Viral entry
into a host cell is mediated by interactions between specific domains of gp120
on the viral particle and the HIV-1 viral receptor molecule CD4 (Landau et a/.,
1988). The structure of gp120 plays an important role in tropism of HIV-1 and
the polypeptide has nine highly conserved intrachain disulphide bonds.
Moreover, the enormous heterogeneity between HIV-1 isolates is largely
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driven by five hypervariabie regions in gp120 designated V1 through V5. One
such region, the V3 loop, is not required for CD4 binding, but is a determinant
of the preferential tropism of HIV-1 for either T lymphoid cell lines or
macrophages (Hwang et ai., 1991). Interactions between sequence motifs in
the V3 loop and the HIV-1 coreceptors CCR5 and CXCR4, which are part of
the family of chemokine receptors, playa role in the susceptibility of cell types
to infection (Deng et ai., 1996). Once attachment has occurred, viral entry
through fusion of the viral and cellular membranes is mediated by the gp41 N-
terminal fusogenic domain, allowing the delivery of the inner components of
the virion into the cytoplasm of the now infected cell (Camerini and Seed,
1990).
Pol
The pol gene products protease (Pro), integrase (IN), RNase H and reverse
transcriptase (RT) are expressed from a Gag-Pol fusion protein designated
p160 which is generated through a ribosomal shift during p55 translation
(Jacks et ai., 1988). This frameshift occurs at an approximate frequency of 5%
of gag translation events, resulting in a 1:20 ratio of Gag-Pol to Gag precursor
molecules. During maturation of the viral particle, the viral protease cleaves
the Gag-Pol precursor to release the Pol polypeptide and subsequently
cleaves the latter further to separate the protease (p10), reverse transcriptase
(p50), RNase H (p15) and integrase (p31) proteins (Figure 3). Some of these
cleavages are not very efficient and this results in uncleaved polypeptides
such as the RNase H-linked RT polypeptide p65, which makes up
approximately 50% of all RT protein (Jacks et ai., 1988). Generation of a
double-stranded DNA copy of the viral RNA genome is the function of the HIV-
1 polymerase (Poi), which predominantly occurs as a heterodimer consisting
of p65 and p50. Pol has RNA-dependent and DNA-dependent polymerase
activities. After viral entry, during the process of reverse transcription, reverse
transcriptase generates a DNA copy using the viral RNA genome as template,
which is subsequently removed from the first DNA strand by RNase H,
allowing the synthesis of the complementary strand (Greene, 1991). This
process requires the interaction of many cis-acting elements in the viral RNA
such as the transactivation region (TAR), which contains the binding site for
the HIV-1 transactivator of transcription Tat (Harrich et ai., 1996). The HIV-1
polymerase does not possess a proofreading activity, which results in error-
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prone replication that is a major contributing factor to the enormous
heterogeneity of HIV-1 (Preston et ai., 1988; Roberts et ai., 1988). The last
enzyme that is cleaved from the Pol precursor is integrase (IN), which
mediates insertion of the newly synthesized double-stranded DNA copy
(proviral DNA) into the genomic DNA of the infected host cell (Bushman et ai.,
1990). IN has three distinct functions which contribute to this process, the first
of which is an exonuclease activity that trims two nucleotides from each 3' end
of the viral DNA duplex. Thereafter, IN cleaves the host DNA at the integration
site using it's double-stranded endonuclease activity and finally ligates the
proviral DNA into the site by using its ligation activity (Bushman et al., 1990).
Gag
The gag gene encodes the 55-kilodalton (kO) Gag precursor protein p55,
which is expressed from unspliced viral mRNA and is thus also Rev-
dependent. During translation a myristic acid is bound to the N-terminus of
p55 (myristoylation), which effects its association with the cell membrane
(Bryant and Ratner, 1990). Membrane-associated p55 recruits two copies of
the viral genomic RNA as well as other cellular and viral proteins to initiate
budding of a new viral particle from the cell. After budding, the viral protease,
which was taken up into the immature virion during budding, cleaves the p55
polyprotein into four smaller proteins designated p17 (matrix, MA), p24
(capsid, CA), p9 (nucleocapsid, NC) and p6 (Gottlinger et ai., 1989). As
described under the HIV-1 virion structure heading, p24 (CA) forms the
conical core of viral particles and the majority of MA or p17 remains attached
to the inner surface of the virion membrane to stabilize the particle. Some MA
is engaged in deeper layers of the virion where it forms part of the complex
that escorts viral DNA to the nucleus (Gallay et ai., 1995). p9 (NC) is
responsible for recognition of the packaging signal, in the form of stem-loop
structures, at the 5' end (5' LTR) of the HIV genomic RNA, to facilitate
incorporation of RNA into the virion (Harrison and Lever, 1992). The last gag
gene product p6 is used as a functional component in the Gag precursor
protein p55 and is involved in the interaction between p55 and the accessory
protein Vpr, leading to the incorporation of Vpr into the virion (Paxton et ai.,
1993). In addition, the p6 region contains the "late domain", which mediates
efficient release of budding virion from the infected cell.
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1.1.6 The HIV-1 regulatory genes
Tat
In 1985 Sodraski et al. (1985b) showed that the HIV LTR has the ability to act
as an inducible promoter by placing genes under the control of the LTR and
noting expression levels of 200- to 300-fold higher in cells that had been
previously infected with HIV. They postulated that this transactivation was due
to the presence of a novel transcription factor, which they named Tat
(transactivator of transcription). It was subsequently shown that the presence
of Tat is associated with a dramatic increase in the levels of long transcripts,
pointing to an involvement in transcription elongation (Kessler and Mathews,
1992; Ratnasabapathy et al., 1990; Toohey and Jones, 1989; Kao et al.,
1987). Tat's exclusive function at the level of elongation was subsequently
confirmed (Keen et al., 1997; Graeble et al., 1993; Marciniak and Sharp,
1991) and interestingly, it was noted that through interaction with other cellular
factors, Tat is able to stimulate phosphorylation of the carboxyterminal domain
(CTD) of RNA polymerase in elongation complexes to create a novel form of
RNA polymerase called RNA polymerase" (Isel and Karn, 1999). The ability
of Tat to stimulate transcription from viral LTRs has been demonstrated to be
modulated by the direct binding of Tat to the transactivation region (TAR) in
the 5' -LTR, which functions as a highly stable RNA stem-loop structure
(Dingwall et al., 1989). Transactivation activity of TAR-bound Tat is dependent
on an association with cyclin T1, a subunit of the protein kinase complex TAK
(Tat-associated kinase) (Fujinaga et al., 1999; Herrmann and Rice, 1993).
HIV-1 Tat is a small nuclear protein of 72 to 101 amino acids (aa) in length
that is encoded from two separate exons. Tat is normally expressed early from
completely spliced mRNA (101 aa), but does exist in the form of the first exon
only (72 aa) when it is expressed from partially spliced mRNA (Figure 3). The
sequence of the protein has been subdivided into five distinct functional
regions on the basis of residue composition (Kuppuswamy et al., 1989): an N-
terminal activation region (aa 1-21), a cysteine-rich domain (aa 22-37), a core
region (aa 40-48), a basic domain (aa 49-72) and a glutamine-rich region,
which makes up the second exon of Tat (aa 73-101). The basic region serves
as a nuclear localization signal (Hauber et al., 1989; Ruben et al., 1989), while
along with the core and glutamine-rich domains, it is involved in TAR-RNA
binding (Roy et al., 1990; Dingwall et al., 1989;). The cysteine-rich domain
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plays a vital role in Tat's transactivation function, correct protein folding and
activity. A single cysteine at position 37 has been shown to be essential for
homo-dimerization of Tat, and subsequently functional activity (Battaglia et ai.,
1994). In addition, mutation in six of the seven cysteines in the cysteine-rich
domain eliminates Tat function (Kuppuswamy et ai., 1989; Ruben et ai., 1989)
and mutation of noncysteine residues within this region also reduces activity,
in some cases drastically (Rice and Carlotti, 1990). It was further
demonstrated that the cysteines are critical for the formation of disulphide
bands within Tat (Koken et ai., 1994; Frankel et ai., 1988). Recent studies
have led to the belief that the cysteines are involved in metal ion binding
(Bieniasz et ai., 1998; Garber et ai., 1998). Furthermore, Tat proteins with
mutated cysteine residues (Tat22 and Tat22J37) were shown to lack
transactivation activity in Jurkat cells and these mutations effected inhibition of
HIV reactivation from latency in Jurkat cells and primary PBMCs (Rossi et ai.,
1997; Caputo et ai., 1996; Balboni et ai., 1993). Such Tat transdominant
negative mutants have been extensively characterised and developed as
potential prophylactic and/or therapeutic vaccines, showing very good
immunogenicity and safety (Betti et aI., 2001; Caselli et al., 1999;).
The second exon of Tat was initially thought to be functionally insignificant as
the first exon was shown to be fully sufficient for transactivation (Battaglia et
ai., 1994; Kuppuswamy et ai., 1989; Garcia et aI., 1988; Seigel et aI., 1986)
and no apparent function could be targeted to the second exon. A very recent
study by Jeang et al. revealed that the presence of two-exon Tat in infecting
SIVmac239 and HIV (HXB2) viruses inversely correlated with high CD4
counts and correlated with viral loads. Furthermore, it was shown that
whereas rhesus macaques infected with two-exon Tat progressed rapidly and
died of AIDS, those infected with SIVmac239 containing a Tat with a
premature stop mutation controlled viremia post-acutely. Interestingly,
reversion of the viruses to the full-length Tat was observed in some animals.
Similar associations and reversions were recorded in humans infected with
the HIV-1 strain HXB2, which contains a pseudo-1exon HIV-1 Tat gene
(Jeang et aI., 2002).
Tat is secreted from infected cells, taken up into uninfected cells and, in
previously infected cells, initiates activation of latent HIV proviruses and new
rounds of replication (Ensali et ai., 1993; Heiland et aI., 1991). Cells treated
with Tat overproduce interferon-a (IFN-a) (Zagury et aI., 1998a), which, along
with the direct action of Tat, increases expression of chemokine receptors
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including the major receptors for HIVentry, CCR5 and CXCR4 (Secchiero et
al., 1999; Huang et al., 1998; Li et al., 1997) and thus rendering bystander
cells more susceptible to infection. Moreover, Tat has been shown to be a
potent immunosuppressant that stimulates apoptosis in T cells in vitro.
Yet, by inactivation through oxidation, it was demonstrated that Tat preserved
its immunogenicity and is considered a good component of an antibody-based
HIV-1 vaccine (Cohen et aI., 1999b; Gringeri et aI., 1998). Interestingly, Tat
has been identified as a target for gene therapy. By transfer of a protein
termed antitat, which sequesters Tat protein and blocks tat translation from
mRNA, the function of the transactivator in vivo is inhibited (Li et aI., 2000).
This therapeutic action was shown to be effective in inhibiting HIV-1
replication and may be a key alternative to antiretroviral therapy.
The immunogenicity of Tat has been receiving an increasing level of attention
and the use of Tat as vaccine component is becoming increasingly popular.
Allen et al. (Allen et aI., 2000a) showed that Tat is targeted frequently by CTL
in acute HIV infection and may thus contribute considerably to the
containment of initial viremia. Strong CTL responses to a number of defined
epitopes within Tat have been identified in patients representing a wide range
of HLA class I alleles (Addo et aI., 2001; Novitsky et aI., 2001; Allen et aI.,
2000a; HIV Molecular Immunology, 2000). In addition, immunisation with Tat
has been shown to elicit potent humoral and cellular immune responses in
mice (Billaut-Mulot et aI., 2001; Cafaro et aI., 2001; Kjerrstrom et aI., 2001;
Morris et aI., 2001a; Boykins et aI., 2000; Pauza et aI., 2000; Cafaro et aI.,
1999; Caselli et aI., 1999; Gallo, 1999; Chenciner et aI., 1997; Hinkuia et aI.,
1997b) and non-human primates (Chenciner et aI., 1997).
A strong association has also been verified between anti-Tat immune
responses and delayed disease progression to AIDS in a number of studies.
Van Baaien et al. showed that rapidly progressing HIV-1 infected persons
have less Tat-specific CTL compared to those that progressed slowly (1997).
Moreover, high levels of anti-Tat antibodies were also correlated with non-
progression (Fiorelli et aI., 2002; Demirhan et aI., 1999; Zagury et aI., 1998b)
and slow disease progression to AIDS (Re et aI., 1995; Reiss et aI., 1990).
Finally, vaccination with chemically inactivated Tat toxoid was shown to
attenuate replication and disease progression of the highly pathogenic
SHIV89.6PD in rhesus macaques (Pauza et aI., 2000). Vaccination with HIV-1
biologically active Tat, has been demonstrated to control replication of
SHIV89.6P to undetectable levels in 5 out of 7 macaques, slowing disease
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progression for extended periods (Cafaro et ai., 2001; Cafaro et ai., 2000;
Cafaro et ai., 1999). In addition, a Tat-Rev vaccine protected rhesus
macaques from pathogenic SIV challenge (Osterhaus et al., 1999).
Rev
The rev gene codes for the regulatory protein Rev, which as previously
mentioned, is responsible for the transportation of unspliced or singly spliced
viral mRNAs from the nucleus to the cytoplasm (Feinberg et ai., 1986). Thus,
through the expression of the Rev protein, HIV possesses the ability to
regulate the export and subsequent expression of intron-containing mRNAs.
HIV Rev is a small, 18-kDa phosphoprotein, which localises within the nuclei
and nucleoli (Malim et ai., 1989a). The protein consists of at least three
functional domains that are responsible for its subcellular localisation in the
nucleus, binding to RRE-RNA through a sequence-specific interaction and
after multimerisation with other Rev molecules, interacts with cellular cofactors
to shuttle between the nucleus and cytoplasm (Thomas et ai., 1998; Hope et
ai., 1990b; Malim et ai., 1989a). The homomultimerisation domain is essential
for oligomerisation of Rev and appears to be divided into two subdomains,
which overlap on either side with the arginine-rich domain (Thomas et ai.,
1998; Hope et ai., 1992; Zapp et ai., 1991). The arginine-rich domain
mediates both RNA binding (RNA binding domain, RBD)(Kjems et ai., 1992;
Cochrane et ai., 1990a) and nuclear/nucleolar localisation (Nuclear
localisation signal, NLS) (Cochrane et ai., 1990b; Malim et ai., 1989a) and
seems to be multimerisation dependent(Szilvay et ai., 1997). The nuclear
export signal (NES) is also referred to as activation/effector domain and as
suggested by the name is responsible for mediating export from the nucleus of
a exportin-1 complexed Rev (Thomas et ai., 1998; Cole et ai., 1993; Hope et
ai., 1992; Zapp et ai., 1991). Multimerisation of Rev appears to be very
important for biological activity and it was demonstrated to be responsible for
maintaining threshold levels of intracellular Rev. This Rev threshold must be
overcome in order to establish productive HIV-1 infection and this mechanism
was demonstrated to be responsible for regulation of viral latency (Pomerantz
et ai., 1992; Pomerantz et ai., 1990). In addition, oligomerisation of Rev and
subsequent binding to the RRE has been shown to be essential for RNA
export and thus biological activity of Rev (Cole et ai., 1993; Hope et ai., 1992;
Zapp et ai., 1991). Moreover, nuclear import has been shown to be mediated
by a direct interaction with importln-B, a cellular transport protein, to which Rev
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binds (Truant and Cullen, 1999). Following translocation into the nucleus,
disassembly of the lmportin-B'Rev complex is induced and the arginine-rich
domain becomes available to bind to the RRE (Pollard and Malim, 1998).
The Rev protein itself is expressed from a conventional, completely spliced
mRNA and the expression of Rev-dependent proteins is reliant on the level of
Rev in the cell (Felber et a/., 1990). This delay in expression of Rev-
dependent genes accounts for the designation of such as late genes, whereas
those translated from Rev-independent mRNAs are called early genes.
Besides nuclear export Rev can have a number of effects on HIV-1 RNA that
include increases in both stability and translation of HIV RNAs (Arrigo and
Chen, 1991; Felber et a/., 1989). It has also been shown that the expression
of Rev causes an increase in the half-life of HIV RNAs in the nucleus of a T-
cell line infected with HIV (Malim and Cullen, 1993).
In early characterisation experiments in which a non-functional mutant Rev
protein, RevM10, was cotransfected with wild-type Rev it was discovered that
RevM10 could strongly inhibit wild-type Rev function in a transdominant
manner (Hope et a/., 1992; Hope et a/., 1990b; Malim et a/., 1989a). RevM10
was also shown to inhibit HIV-1 replication through RevM10-mediated
prevention of functional Rev-mediated nuclear export of unspliced viral
transcripts and subsequent inhibition of Gag-Pol and Env protein expression.
This tmnsdominant-negative Rev has since been developed for gene therapy
in HIV-1 infected individuals and was shown to be clinically safe in human
trials (Ranga et a/., 1998; Woffendin et a/., 1996). RevM10-transduced T cells
were also found to have prolonged survival and it was proposed that antiviral
gene therapy with this transdominant-negative Rev mutant may contribute to
the reconstitution of immune function in AIDS.
CTL responses specific for a number of epitopes within Rev have been
identified in HIV positive patients expressing a number of different HLA class I
alleles (HIV Molecular Immunology, 2000; Addo et a/., 2001; van Baaien et a/.,
1997) and Rev-specific CTL have been inversely correlated with rapid disease
progression to AIDS (van Baaien et a/., 1997). Moreover, considerable
success has been obtained by immunisation with Rev vaccines in various
animal models (Calarota et a/., 1999; Osterhaus et a/., 1999; Boyer et a/.,
1997a; Chenciner et a/., 1997; Hinkuia et a/., 1997b; Kim et a/., 1997b; Wang
et a/., 1993). Vaccination with a Tat-Rev immunogen was shown to protect
rhesus macaques from pathogenic SIV challenge (Osterhaus et a/., 1999) and
promising results have also been obtained from human trials in which Rev
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was used as vaccine component along with Env (Boyer et aI., 2000;
MacGregor et aI., 1998).
1.1.7 The HIV·1 accessory genes
Nef
The negative factor (nef) gene is found in all primate immunodeficiency
retroviruses and thus appears to playa vital role during natural infection. Nef
is abundantly expressed during the early phase of HIV-1 gene expression to
the degree that its mRNA represents 75% of the viral mRNA load of the cell
(Klotman et aI., 1991; Guy et aI., 1987). The protein of around 206 amino
acids is modified through means of myristic acid binding, through which it is
anchored to host cellular membranes (Niederman et aI., 1993; Yu and
Felsted, 1992; Kaminchik et aI., 1991; Allan et aI., 1985). The protein is also
phosphorylated on serine and threonine residues, the function of which is as
yet unclear (Yang and Gabuzda, 1999; Coates et aI., 1997). Nef is packaged
into virions, where it is cleaved by the viral protease during virion maturation
(Chen et aI., 1998; Pandori et aI., 1996; Welker et aI., 1996; Freund et aI.,
1994). Studies in primates have shown that Nef is required for high viral loads
and progression to AIDS disease (Kestler et aI., 1991). In addition, HIV-1
particles produced in the presence of Nef have been shown to be up to ten-
fold more infectious than those produced in the absence of Nef (Miller et aI.,
1994). The importance of Nef in HIV pathogenicity was further highlighted by
studies in which attenuated forms of HIV-1 and HIV-2 with net deletions were
strongly associated with long term non-progression (Learmont et aI., 1999;
Salvi et aI., 1998; Switzer et aI., 1998; Mariani et aI., 1996; Deacon et aI.,
1995; Kirchhoff et aI., 1995).
Nef has a number of distinct functional activities of which the downregulation
of CD4 surface expression is perhaps the best understood. The protein
mediates rapid endocytosis of cell surface CD4 molecules resulting in their
degradation in Iysosomes (Aiken et aI., 1994; Rhee and Marsh, 1994; Mariani
and Skowronski, 1993; Garcia and Miller, 1991). Nef binding to CD4 is
mediated by a number of motifs. The so-called CD4 binding site, stretching
residues 57-59 binds the cytoplasmic tail of CD4 and internalisation of the
bound CD4 is mediated by a dileucine motif (Mangasarian et aI., 1999;
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Greenberg et al., 1998a; Rossi et al., 1996; Greenway et et., 1995; Aiken et
al., 1994; Harris and Neil, 1994). To achieve internalisation Nef interacts
directly with the AP-1 clathrin adaptor complex and recruits C04 to the
complex at the cell membrane after which degradation is effected through
lysosomal targeting (Bresnahan et al., 1998; Greenberg et al., 1998a). This
downregulation prevents superinfection and facilitates Env protein
incorporation into virions by preventing interaction between Env and C04
during virus budding (Lama et al., 1999; Little et al., 1994; Benson et al.,
1993). Further reports have shown that Nef-mediated C04 downregulation
stimulates HIV-1 production (Ross et al., 1999) and enhances HIV-1
replication in activated T lymphocytes (Lundquist et al., 2002).
A second activity of Nef, which is less well understood, is the downregulation
of class I major histocompatability complex (MHC-I) by rapid internalisation
and eventual degrading in the Golgi complex (Greenberg et al., 1998b; Le Gall
et al., 1998; Schwartz et al., 1996). This process serves to prevent the
recognition and lysis of infected cells by cytotoxic T-Iymphocytes, resulting in
cytolytic evasion (Mangasarian et al., 1999; Collins et al., 1998). A tyrosine
residue, which is located in the cytoplasmic tail of HLA-A and B, but not HLA-
C, was found to be critical for this interaction with Nef (Le Gall et al., 1998). In
the background of this, it was found that unlike HLA-A and HLA-B, Nef does
not downregulate HLA-C (Cohen et al., 1999a). This distinction allows infected
cells to escape from natural killer (NK) cells that would kill a cell completely
devoid of surface MHC-I.
Thirdly, Nef disrupts T cell transduction and activation in both positive and
negative contexts through a number of separate mechanisms. A recent study
has demonstrated that Nef downregulates another T-cell receptor, namely
C028 (Swigut et al., 2001). C028 is a major co-stimulatory T-cell receptor that
mediates efficient activation of T-cells and it is proposed that along with the
downregulation of C04 and/or C03, this function disrupts antigen-specific
signalling following productive antigen recognition (Swigut et al., 2001).
Moreover, Nef disrupts the T-cell receptor (TCR) machinery and signalling by
interfering with the C03- TCR complex on C04 cells, thereby blocking events
in the C03-TCR signalling cascade (Iafrate et al., 1997). In addition, Nef
modulates additional effector and signalling pathways in T cells such as p21-
activated kinase (PAK) and protein kinase C (PKC). Association of Nef with
serine-threonine kinase Pak-2, a complex termed Nef-associated kinase
(NAK) (Renkema et al., 1999), has been shown to correlate with the ability of
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Nef to enhance viral infectivity (Wiskerchen and Cheng-Mayer, 1996).
Furthermore, Nef modulates calcium signalling (Baur et al., 1994) and
activates nuclear factor of activated T cells 1 (NFAT1) (Manninen et al., 2001),
which along with IL-2, is known to regulate a number of genes involved in T-
cell function, such as the IL-4, tumour necrosis factor alpha (TNFa) and Fas
ligand (FasL) genes (Rao et al., 1997). Nef induction of FasL expression,
which interacts with its receptor Fas (CD9S) on neighbouring cells, induces
apoptosis. However, Nef also associates with and inhibits apoptosis signal-
regulating kinase 1 (ASK1), which leads to inhibition of Fas- and TNFa-
mediated apoptosis in the infected cell (Geleziunas et al., 2001). This function
of Nef results in the killing of bystander cells, including HIV-1-specific CTLs,
while inhibiting the same apoptotic signals in the infected cell to achieve
immune escape. Although Nef-mediated cellular events have not been fully
elucidated, these effects collectively support the model that Nef activates T-
cells to provide an optimal environment for viral replication (Steffens and
Hope, 2001).
Nef is the most immunogenic of the regulatory and accessory proteins. Anti-
Nef antibodies have been identified in HIV-1 infected individuals and AIDS
patients (Ayyavoo et al., 2000; Gahéry-Ségard et al., 2000; Mortara et al.,
1998). Very potent cytotoxic T lymphocyte responses targeting an increasingly
large number of Nef epitopes have been recorded in humans representing a
number of different population groups and expressing a wide range of HLA
class I molecules (Nixon et al., 1999; Ikeda-Moore et al., 1998; Bauer et al.,
1997; Goulder et al., 1997a; Goulder et al., 1997b; Price et al., 1997; Haas et
al., 1996a; Culmann-Penciolelli et al., 1994; Culmann et al., 1991; Koenig et
al., 1990). For the latest summary, refer to the HIV Immunology Database
(HIV Molecular Immunology, 2000). In addition, Nef-induced T cell proliferative
responses have been identified in vitro (Ayyavoo et al., 2000; Gahéry-Ségard
et al., 2000). Nef as vaccine component has also generated promising
humoral and cellular immune responses in mice and non-human primates
(Billaut-Mulot et al., 2001; Kjerrstrom et al., 2001; Ayyavoo et al., 2000;
Hinkuia et al., 1997b).
Vif
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Although initial studies suggested that the function of the HIV-1 virion
infectivity factor (vif) gene was dispensable for virus infection of transformed T
cell lines, it was found that this gene is required for HIV-1 infection of its
primary target cells, CD4-bearing T lymphocytes (Ma et aI., 1994; Strebel et
aI., 1987). In fact, the Vif protein appears make previously non-permissive
cells tolerant to HIV-1 replication. This is thought to be brought about by Vif-
mediated neutralisation of a cellular factor that inhibits HIV-1 replication and
thus renders the cell non-permissive (Madani and Kabat, 1998; Simon et aI.,
1998b). Vif is present in viral particles and associates with viral core structures
(Liu et aI., 1995). More recent data has revealed that Vif also binds to
intracellular genomic HIV-1 RNA (Khan et aI., 2001; Dettenhofer et aI., 2000;
Zhang et aI., 2000) and may stabilize the reverse transcription complex (RT
complex) to support reverse transcription (Dornaduia et aI., 2000). These
studies propose that Vif promotes efficient reverse transcription after virion
entry through regulation of nucleic acid components within the viral core.
HIV-1 infected subjects produce Vif-specific antibodies which indicates that Vif
is expressed and immunogenic and may thus play a role in vaccine
development (Ayyavoo et aI., 1997a). CTL responses specific for epitopes
within Vif have been identified in HIV positive patients (Altfeld et aI., 2001) and
Vif vaccination has been shown to elicit significant immune responses in mice
(Ayyavoo et aI., 2000; Ayyavoo et aI., 1997a).
Vpr
The viral protein R (Vpr) consists of 96 amino acids and was initially thought
to be as abundant in virions as Gag (Paxton et aI., 1993), but has recently
been shown to be incorporated in much smaller amounts (Singh et al., 2001;
Muller et aI., 2000). The protein, which is expressed from incompletely spliced
viral transcripts, has a number of functional activities which include
contribution towards nuclear import of the HIV genome (Heinzinger et aI.,
1994), induction of cell-cycle arrest, transactivation of viral and host cellular
gene expression and regulation of viral replication kinetics. Nuclear import of
the viral pre-integration complex is mediated by two putative nuclear
localisation signals (NLS) (Sherman et aI., 2001; Kamata and Aida, 2000;).
Virion associated Vpr is associated with the prevention of chronic HIV-1
infection (Hrimech et aI., 1999; Jenkins et aI., 1998). In addition, HIV-1
replication enhancement is achieved through Vpr-mediated inhibition of cell
division (Rogel et aI., 1995). This is achieved through the accumulation of
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cells arrested in the G2 phase of the cell cycle (Jowett et aI., 1995). Along with
the cell cycle arrest, Vpr's effect on cell differentiation also contributes to the
destruction of the immune system (Jenkins et aI., 1998) and suppresses
immune activation (Ayyavoo et aI., 1997b). Notably, it was shown that Vpr
may induce or abrogate apoptosis. Ayyavoo et aI., demonstrated that Vpr
induces apoptosis in the absence of T-cell receptor (TCR)-mediated cell
activation whereas Vpr works to inhibit the induction of apoptosis in TCR-
triggered activated cells (Ayyavoo et aI., 1997b). In addition, Vpr has the
ability to modulate transcription of HIV-1 LTR promoter activity and through
synergistic interaction with the viral transactivator Tat, Vpr enhances
transcription of the viral genome (Sawaya et aI., 2000). Although it was initially
believed that most of these functions were mediated by a common pathway,
recent evidence has shown that the cell-cycle arrest, induction of apoptosis
and gene activation activities are regulated through more complex and
divergent mechanisms (Zhu et aI., 2001). Interestingly, Vpr seems to possess
the additional ability to target specific gene products into the virus-like particle
(VLP) (Liu et aI., 1997; Wu et aI., 1996; Wu et aI., 1995) which makes Vpr a
potentially popular sub-unit in particle-based HIV-1 vaccines.
Anti-Vpr antibodies have been shown to inhibit HIV replication potential, which
may be a target for immune intervention (Levy et aI., 1995), and CTL
responses specific for epitopes within Vpr have been identified in HIV positive
individuals (Altfeld et al., 2001).
Vpu
The viral protein unknown (vpu) gene and its protein product are unique to
HIV-1. Vpu is not present in the virus particle but assembles as a homo-
oligomer, which is phosphorylated and primarily localized in the internal
membranes of the infected cell (Sato et aI., 1990). In infected cells, the HIV-1
envelope protein Env and the viral receptor CD4 form complexes within the
endoplasmic reticulum, trapping both proteins within the ER compartment.
This process impedes with virion assembly and formation and is overcome by
Vpu-mediated liberation of Env protein through activation of the ubiquitin-
mediated degradation of Env-complexed CD4 molecules (Willey et aI., 1992a;
Willey et aI., 1992b). The cytoplasmic domain of the Vpu protein is responsible
for this CD4 downregulation activity (Paul et aI., 1998; Schubert et ei., 1998;
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Willey et al., 1992b). The cytoplasmic domain of the Vpu protein is responsible
for this CD4 downregulation activity (Paul et al., 1998; Schubert et al., 1998;
Bour et al., 1995; Schubert and Strebel, 1994). The transmembrane domain of
Vpu is responsible for enhancement of virion release from the plasma
membrane: in the absence of Vpu, large numbers of virions can be seen
attached to the cell surface (Klimkait et al., 1990). Recent evidence has
targeted this Vpu-mediated mechanism of virion release to the formation of
ion-conducting channels in the membrane (Ma et al., 2002; Steffens and
Hope, 2001). Additionally, Vpu mediates increased sensitivity of HIV-1
infected cells to FAS-mediated apoptosis, which may contribute to the short in
vivo half-life of infected cells (Casella et al., 1999).
1.1.8 HIV/AIDS vaccine strategies and the CD8+response
Introduction
Since the time of the ancient Greeks, people have realized that those who
have survived smallpox, plague, yellow fever or a number of other infections,
rarely contracted these diseases again. Successful artificial immunisation was
started by Edward Jenner in the late eighteenth century by inoculation against
smallpox with the related cowpox virus. Since then, vaccination with a
pathogen, which is related to the one immunized against, derivatives of
pathogens or attenuated and killed pathogens have been exceedingly
successful in reducing disease, death and even in the case of smallpox,
eradication of the pathogen (Prescott et al., 1996).These successes led to the
initial hope that an AIDS vaccine could be quickly developed and
implemented. Yet the latent, non-curable nature of HIV infection has
complicated this matter considerably. HIV manages to effectively hide from
the immune system by integrating itself as proviral DNA in the genomic DNA
of the infected cell.
First generation vaccine strategies
Early HIV-1 vaccine strategies, which progressed from developmental through
clinical evaluation, were focused on generating neutralising antibodies with
Envelope (Env)-based recombinant protein subunit vaccines (Kahn et al.,
1994; Haigwood et al., 1992). These first generation vaccines elicited potent
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elicited neutralising responses against primary isolates (Connor et al., 1998;
Mascola et ai., 1996; VanCott et ai., 1995). In addition, these protein-based
vaccines were not able to elicit significant levels of CD8+ CTL responses and
failed to protect against infection in human phase 1/11 efficacy trials (Connor et
ai., 1998). It was subsequently decided in June 1994 to terminate the
proposed efficacy trials of two Env-based HIV vaccine candidates (Bolognesi
and Matthews, 1998). It was clear that in addition to neutralisation, strong
pathogen-specific cytotoxicity in the form of CTL responses were required.
Viral vectors
Due to these new challenges posed by HIV-1 infection, a number of novel
vaccine delivery systems have been developed during the last decade. These
include live viral and bacterial vector systems, which express genes that code
for HIV antigens. Such delivery systems mimic natural microbial infections and
thus allow synthesis of HIVantigens that are very effectively presented via
MHC-I molecule pathways resulting in the priming of strong cellular
responses. Popular systems employed currently include recombinant poxvirus
vectors (Zavala et ai., 2001), modified vaccinia virus Ankara (MVA) (Sutter
and Moss, 1992), avipoxviruses such as Canarypox virus (Taylor et ai., 1991)
and Alphavirus-based vector vaccines such as Venezuelan equine
encephalitis virus (VEE) (Caley et ai., 1999). While these delivery systems
provide pathogen-like deliveries, clinical safety concems for replication of
these viruses within individuals, which may include immunocompromised
persons, are relieved by the collective property of replication deficiency. Viral
vector-based deliveries are well established, can elicit innate immune
responses and have shown good cellular and humoral immunogenicity (Sutter
and Haas, 2001). However, concerns are raised because of strong immune
responses that may be raised against the antigenic vectors, many of which
are derived from pathogens to which humans have been previously exposed.
DNA vaccines
Another attractive delivery system, which relies on the vaccination with
plasmid vectors that encode the respective HIV-1 antigen under the control of
strong regulatory elements such as the cytomegalovirus (CMV) immediate-
early enhancer/promoter and bovine growth hormone (bGH) terminator. As
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such constructs can be injected as naked plasmid nucleic acid, this system is
termed DNA vaccine (Ulmer et ai., 1993). Initially DNA vaccines were thought
to elicit cellular immune responses through one- or a combination of three
antigen processing and presenting mechanisms: direct priming by somatic
cells such as myocytes, direct transfection of professional antigen presenting
cells (APCs) and cross-priming in which plasmid DNA transfects somatic
and/or APC and the secreted protein is processed by untransfected dendritic
cells (DCs) and presented to T cells (Gurunathan et ai., 2000). Early in the
1990's it was shown that muscle, which was directly injected with DNA, was
able to express protein and induce antigen-specific CD8+ CTL responses
(Ulmer et ai., 1993). Yet it was not known whether protein-expressing
myocytes could directly induce CTL responses or if the expressed protein was
transferred to professional APCs (termed cross priming). Subsequent studies
revealed that the responses are most likely raised through cross priming
although myocytes may playa role in regulation of immune responses (Torres
et ai., 1997). In addition, it has been demonstrated that CTL responses may
be elicited through the direct transfection of small numbers of DCs. DNA
vaccination can also be performed via the skin where somatic cells such as
keratinocytes, fibroblasts and potent APCs such as Langerhans cells are
found (Gurunathan et ai., 2000).
DNA vaccines have shown very promising results in terms of immune
responses. Humoral responses specific for a large range of antigens including
influenza NP and HA, hepatitis B surface antigen, bovine herpes virus
glycoproteins and papillamavirus have been generated (Donnelly et ai., 1997)
and HIV-1-specific antibodies raised by DNA vaccination were first shown by
Wang et al. (1995; 1993;), Lu et al. (1995) and Okuda et al. (1995). DNA
vaccines encoding a number of HIVand SIV antigens have been used in
many vaccine studies and have proven to be effective in priming long-lived
cellular and humoral responses in animals (Gurunathan et ai., 2000; Boyer et
ai., 1997a; Boyer et ai., 1997b; Yasutomi et ai., 1996; Fuller and Haynes,
1994; Wang et ai., 1993). Furthermore, DNA vaccines have been shown to
elicit immune responses and to be safe in a number of human trials (Calarota
et ai., 2001; Boyer et ai., 2000; Calarota et ai., 1999; Calarota et ai., 1998;
MacGregor et ai., 1998). A number of studies have also illustrated that
immunisation with nucleic acids are able to protect animals after pathogenic
challenge with a wide range of viral, bacterial and parasitic agents (Cafaro et
ai., 2001; Barouch et ai., 2000; Boyer et ai., 1997b; Donnelly et ai., 1997;).
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The importance of CD8+ cytotoxic T lymphocyte responses in HIV-1
pathogenesis and disease progression has been demonstrated elegantly.
HIV-1-specific CTL responses have been shown to control viral load during
acute and asymptomatic infection (Kalams et al., 1999; Musey et al., 1997;
Klein et al., 1995; Moss et al., 1995; Borrow et al., 1994; Koup et al., 1994)
and are inversely correlated with disease progression (Ogg et al., 1998).
Moreover, strong and cross-reactive CTL responses have been associated
with resistance to HIV-1 infection in highly exposed, seronegative commercial
sex workers in Kenya and the Gambia (Kaul et al., 2000; Rowland-Jones et
al., 1998; Rowland-Jones et al., 1995).
The achievement of protection against heterologous HIV-1 infection by
immunisation may only be reached through eliciting a combination of strong
cellular and humoral responses (Mooij and Heeney, 2001; Morris et al.,
2001b; Hinkuia et al., 1997a). Although many vaccination strategies show
much promise, the priming of strong humoral and cellular responses has been
difficult to achieve with single delivery systems and thus multifaceted
approaches such as prime-boost strategies are receiving increased interest
(Mooij and Heeney, 2001; Sutter and Haas, 2001). Indeed, greatly improved
immune responses have been obtained when DNA priming was followed by a
protein boost in non-human primates (Barnett et al., 1998; Barnett et al., 1997)
or MVA boost in non-human primates (Allen et al., 2000b) as well as humans
(Hanke and McMichael, 1999). In the same mould, increased durability and
breadth of CD8+ responses as well as markedly enhanced proliferative
responses were recorded when a SIV gag-env DNA vaccine was boosted with
the attenuated poxvirus-based vaccine NYVAC-SIV-gag-env-pol (Hel et al.,
2001).
Although such strong cellular and antibody responses are a necessity for a
vaccine, certain limiting factors, which undermine the efficacy of these
responses, remain. These include immune evasion and escape by the virus.
Numerous studies have generated evidence that HIV evolves to escape both
CTL responses (Barouch et al., 2002; Allen et al., 2000a; Pircher et al., 1990)
as well as CD4+ cell responses (Ciurea et al., 2001). Furthermore, amino acid
changes in the HIV-I envelope sequences permit viral escape from antibody
neutralization (McLain et al., 2001; Ciurea et al., 2000; Cheng-Mayer et el.,
1999). In combination with immune evasion through such escape
mechanisms, the high degree of viral diversity creates considerable problems
for vaccine design and selection of a viral vaccine strain. A method to address
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these issues is to increase the antigenic breadth of a vaccine in an attempt to
increase the range of virus-specific responses. Thus, in addition to Gag, Pol
and Env immunogens, vaccine strategies incorporating additional components
such as Tat, Rev and Nef are being employed (Hanke et al., 2002; Hel et al.,
2002; Kjerrstrom et al., 2001; Tëhtinen et al., 2001; Ayyavoo et al., 2000;
Calarota et al., 1999; Osterhaus et al., 1999 Calarota et el., 1998; Kim et al.,
1997b).
The inclusion of these early-expressed regulatory genes provide further
attractive factors such as priming regulatory protein-specific CTl, which may
kill infected cells prior to completion of viral replication and production of
mature virions (Hel et al., 2002; Addo et al., 2001; Mooij and Heeney, 2001;
van Baaien et al., 1997). Multicomponent vaccines incorporating structural
and regulatory genes would thus induce an array of immune responses that
may kill infected cells at various stages of the viral replication cycle as well as
recognize, bind and neutralize infectious virions.
Delivery method of multiple immunogens may be the next variable factor to
consider as vaccination with multiple or excessively large plasmids may have
inherent effects on protein expression and/or immunogenicity. Some studies
have been conducted to elucidate the interactions of single and combined
HIV-1 DNA vaccines and two studies have shown that the combination of up
to five different gene constructs was viable (Kjerrstrom et al., 2001; Hinkuia et
el., 1997a;).
1.2 Aim of the Study
The principal aim of this study is to develop accessory gene components,
which can be used in a multi-faceted DNA vaccine. To accomplish this a
number of steps need to be achieved:
Firstly, expression plasmids encoding the wild-type HIV-1 subtype C
accessorylregulatory proteins Tat, Rev and Nef have to be designed and
constructed.
In parallel, codon-optimised expression plasmids coding for consensus,
potentially non-functional, mutated Tat, Rev and Nef proteins have to be
designed and constructed.
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Verification of the resulting expression constructs will be done by sequencing
and subsequently, in vitro expression and comparison of expression levels.
Finally, the proteins will be subjected to functional analysis to determine
whether the mutations indeed render the proteins inactive for their respective
activities.
1.3 Rationale for selection of specific accessory and regulatory genes as
vaccine components
As described in the sections above, Tat, Rev and Nef make attractive vaccine
components because they-are expressed early in the viral life cycle, they are
highly immunogenic and their importance and success as immunogens have
been extensively highlighted in various models including humans. Significant
amounts of data concerning the inactivation and functional analysis of these
genes have been published, facilitating the development of non-functional
immunogens from such proteins. A number of vaccines based on Tat, Rev
and/or Nef have been approved and tested in human trials and these genes
have been demonstrated to be suitable for inclusion into HIV-1 vaccines
(Calarota et al., 2001; Boyer et al., 2000; Calarota et al., 1999 Gringeri et al.,
1998; MacGregor et aI., 1998). In addition, these genes make up a significant
portion of the open reading frames (ORF) of HIV-1 and they are well
conserved in relation to some of the structural and enzymatic genes (Ayyavoo
et al., 2000; Ayyavoo et aI., 1997a). In a recent study, which was aimed at
preparing for human Tat-based vaccine trials in Italy, Uganda and South
Africa, it was shown that the functional and immunogenic regions in Tat from
viruses representing a number of subtypes and geographic origins were highly
conserved (Butto et aI., 2002). In addition, it was shown that Tat-specific
antibody responses can be effective against infection with different HIV-1
subtypes (Fiorelli et aI., 2002).
It is well known that extracellular proteins do not ordinarily get taken up by
cells and thus are not processed by the MHC-I pathway through which antigen
is presented to stimulate CD8+ CTL responses (Cresswell, 1994). Vaccine
strategies that have focused on immunisation with recombinant Tat protein
(Cafaro et aI., 2000; Cafaro et aI., 1999) and/or chemically inactivated Tat
protein (Tat toxoid) (Gallo, 1999; Gringeri et aI., 1998; Zagury et aI., 1998b)
have shown very good immunogenicity. As expected though, it was
demonstrated that when the inoculated Tat was not biologically active, the
25
Stellenbosch University http://scholar.sun.ac.za
immunity elicited was predominantly humoral as biological activity is required
for Tat uptake into cells and subsequent processing through the MHC-I
pathway (Fanales-Belasio et al., 2002; Cafaro et a/., 2000;). It is precisely a
cell mediated CD8+ response that is desired to achieve protection against
intracellular pathogens such as HIV-1 (Kim et al., 1997a). Moreover, as the
Rev and Nef proteins are present only intracellularly, antibodies directed
against Tat, Rev and Nef will not effect the killing of the cell prior to completion
of viral replication. Thus the type of immunity aimed at by using these
accessory genes as DNA vaccine immunogens is of the cell mediated type,
which is adept at eradicating infected cells early.
The accessory proteins Vif, Vpr and Vpu were not selected for development
as potential vaccine components for a number of reasons. Firstly, Vif, Vpr and
Vpu are expressed from Rev-dependent, partially spliced transcripts and are
thus not early genes. In addition, like Tat, Rev and Nef, these proteins
possess intrinsic cytotoxic, immunosuppressive or undesirable activities,
which would have to be eliminated through mutagenesis or deletion. Studies
have demonstrated that Vpr plays a role in immune suppression, apoptosis
and CD4 cell depletion in HIV-1 infected patients (Ayyavoo et al., 1997b).
More recent studies have shown that co-immunisation of Vpr with other
immunogens compromises the antigen-specific immune responses as well as
effector cell function (Ayyavoo et al., 2002). This is thought to be achieved by
Vpr-mediated interference with co-stimulatory molecule expression of APCs.
As revealed by its name, Vif (viral infectivity factor) plays a crucial role in viral
infectivity and replication by possibly neutralizing a cellular factor that inhibits
HIV-1 replication. Although Vif is immunogenic, the poorly understood role that
it plays in viral replication (Janvier et al., 2000) and limited amounts of data
describing the inactivation of its intrinsic functions for it's safe incorporation as
vaccine component, speak against Vif as vaccine component.
As reviewed above, Vpu enhances virion release and contributes to the
downregulation of CD4 on the surface of infected cells. In addition, very little
data describing the immunogenicity of Vpu is available and the few studies
that produced such data reveal that Vpu is not particularly immunogenic.
The value of including a single HIV-1 gene as vaccine component may be
measured in terms of the immunogenicity shown in terms of CTL epitope
frequencies and response strength, immunogenicity in relation to protein size
and the cost in terms of research and development into making it suitable and
safe as well as immunogenic. Specifically when employing naked DNA
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vaccination strategies, the immunogenicity of a vaccine component may be
markedly reduced as a result of weak expression of the foreign gene that is
introduced. This is observed because the codon usage of viral genes is such
that transcribed messenger RNAs usually display instability and rapid turnover
(Haas et aI., 1996b; Hentze, 1991). This may be overcome by changing the
codon usage of a foreign DNA immunogen to that of highly expressed human
genes (Haas et al., 1996b), which requires expensive synthetic construction of
such a component. When these factors are taken collectively, the pathogenic
and/or undesirable functions and relatively low immunogenicity of Vif, Vpr and
Vpu did not warrant their inclusion into this study.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Viral Isolates and reagents
2.1.1 Isolation and characterisation of HIV-1 subtype C viral isolates
Blood samples from HIV-1 infected patients were obtained from the Infectious
Diseases Clinic at the Tygerberg Hospital in the Westem Cape during 1998
and 1999. Eighteen viruses were isolated from peripheral blood mononuclear
cells (PBMCs) by co-cultivation with donor PBMCs at the Department of
Medical Virology, Tygerberg and were allocated TV (Tygerberg Virology)
numbers 001 through 019 (no TV011). These primary isolates were initially
subtyped by serotyping as well as genotyping of the V3 region of the envelope
gene and 15 were identified as HIV-1 subtype C. Further analysis revealed
that these were all of the non-synsytium-inducing (NSI) phenotype and used
CCR5 as their principal co-receptor (Table 2) (Treurnicht et al., 2002).
Of the 15 patients infected with HIV-1 subtype C, all except one (TV019)
presented with clinical symptoms such as pulmonary tuberculosis, oral
candidiosis, diarrhoea, lymphadenopathy, and dermatitis. All patients were
heterosexual (8 female, 7 male) with infection sources from various
geographic regions (Table 2). These HIV-1 subtype C isolates were
subsequently characterised by sequence analysis of the gag and env genes
(Engelbrecht et al., 2001) as well as the vif, vpr and vpu genes (Scriba et al.,
2001). These genomic regions were all shown to fall within the subtype C
cluster using phylogenetic analysis. Recently, full-length genome analysis of
isolates TV001, TV002 and TV012 was completed, confirming the non-
recombinant phenotype of these subtype C viruses (zur Megede et al., 2002).
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Table2 Demographic and clinical data ol patients and viral isolates.
Sero- Geno Geographic source of
Sex
-type# Clinical SymptomsPatient type* infection
TVOO1 M C C Dermatitis Cape Town
TVOO2 M C C Oral Candidiosis Cape Town
TVOO3 M C C
Pulmonary TB Eastern Cape I Cape
Town
TVOO4 F C C TB adenitis NA
TVOO5 F C C Oral/tracheal Candidiosis Cape Town
TVOO6 F C C TB pleuritis Cape Town
TVOO7 F C C Dermatitis Gauteng
TVOO8 F C C Bladder infection Zimbabwe
TVOO9 M C C Pulmonary TB Cape Town
TV010 F C C Lymphadenopathy Cape Town
TV012 M C C Oral/nasopharyngeal CapeTown
Candidiosis, diarrhea
TV013 F C C Pneumonia Cape Town
TV014 M C C Pulmonary TB Namibia
TV015 M NR B Wasting, stomach ulcers Unknown
TV016 M BID B Loose stools Unknown
TV017 M B B Glandular fever, Unknown
Candidiosis, wasting
TV018 M C C Pulmonary TB
Eastern Cape I Cape
Town
TV019 F C C Asymptomatic CapeTown
M = male, F = lemale, C = coloured, B = black, W = white, NR = non reactive, NA = not available.
'determined with the V3 competitive peptide enzyme immunoassay as described by Engelbrecht et al. (1999)
# based on partial sequencing ol the gp120 region.
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2.1.2 Sequence characterisation of tat, rev and nefgenes from local South
African HIV-1 subtype C viruses
The regulatory genes tat and rev, the accessory gene net as well as the 5'
long terminal repeat (5' LTR) of fourteen of these fifteen HIV-1 subtype C
viruses were also sequenced. Similarly to the gag, env, vit, vpr and vpu genes,
these regions were identified as subtype C by phylogenetic analysis and the
tat, rev and net genes were further characterised by analysis of their deduced
amino acid sequences. It was found that thirteen of the fourteen isolates had
the subtype C-specific Rev truncation. Some isolates had length variations in
the second exon of Tat and the cysteine residue at position 31, which is highly
conserved in non-C subtypes, yet absent in most subtype C Tat proteins was
present in three isolates. Moreover, the net genes were intact and only single
residue variations were identified in the second glycine of the myristoylation
signal (G3) and motifs involved in CD4 and MHC-I downregulation. This work
was written up as a sequence note manuscript for the journal AIDS Research
and Human Retroviruses and was published in Volume 18, Number 2 in the
January 20, 2002 issue (Scriba et al., 2002). The manuscript is attached as
Appendix A. Phylogenetic trees and amino acid sequences as well as the
calculated consensus amino acid sequences for these proteins are included in
the manuscript.
2.1.3 Selection of viral strains for wild-type constructs
Genetic distances between viral isolates and the consensus protein sequence
calculated from the fourteen TV isolates, designated TV Cons, as well as the
overall consensus sequence representing all reference subtype C isolates and
designated C CONS (obtained from the Los Alamos HIV-1 Sequence
Database, http://hiv-web.lanl.gov/contenUhiv-db/mainpage.html) were
calculated using the PROTDIST program (Phylip ver. 3.6, Felsenstein, J) with
the Kimura distance matrix (Kimura, 1980) or the PAM distance matrix
(Dayhoff et al., 1978). All available reference subtype C Tat, Rev and Nef
protein sequences from the HIV sequence database, all subtype C sequences
from Botswana (including the 43 newly characterised ones (Novitsky et al.,
2002)), those from the four previously characterised full-length sequences
from South Africa (van Harmelen et al., 2001) and a number of consensus
sequences (see Table 3) were included for construction of phylogenetic trees
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using the Phylip programs SEQBOOT, PROTOIST, NEIGHBOR and
CONSENSE (Phylip [phylogenetic inference package] ver. 3.6, Felsenstein,
J). Manipulation of the trees was done in TREEVIEW. Based on phylogenetic
clustering, calculated minimum genetic distance as well as comparison of
amino acid sequences to the consensus, the isolate for which an individual
gene resembled the consensus the most was chosen for construction of a
wild-type expression plasmid for that gene. For amino acid sequences of the
individual genes, refer to Appendix C. The isolates chosen for each gene are
listed in Table 4.
Table3: Consensus sequences were constructed from viral sequences representing
different geographic sources.
Name Geographic origin Viral isolates
TV Cons South Africa Tygerberg Virology (TV) isolates
all Botswana, TV and other
South African isolates
all subtype C reference
sequences available from HIV
sequence database (consensus
downloaded directly from HIV
sequence database)
all sequences in this column
all Indian isolates
sA Cons southern Africa
Cons C
reference subtype C
consensus
(HIV sequence database)
Compl Cons
India Cons
global
India
Table 4: Viral isolates chosen as templates lor construction ol wild-type expression
plasmids.
Gene Viral isolate(s)
tat TV019
rev TV010
net TV002
2.1.4 Plasmid vectors
Three eukaryotic expression vectors were used in this study.
pCMVKm2 employs the human cytomegalovirus (hCMV) immediate-early
enhancer/promoter with its intron A and the bovine growth hormone (bGH)
poly-adenine (pA) terminator (Chiron Corporation, Emeryville CA (Chapman et
ai., 1991)). The plasmid incorporates the neomycin resistance gene, which
confers antibiotic resistance to Kanamycin. The incorporation of the
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immediate/early intron A allows for high level expression of glycoproteins and
other proteins that may be difficult to express with other vector systems.
The pCR3.1 vector (Invitrogen, CA, USA) is similar in that it contains a CMV
immediate/early promoter (without intron A) and bGH terminator, but contains
the additional bacterial T7 promoter and the f1 origin for rescue of single
stranded DNA. pCR3.1 contains the neomycin resistance gene under the
control of the simian virus 40 (SV40) promoter and terminator, which confers
resistance to gentamycin (G418) in mammalian cell culture. For selection in
bacterial cells, pCR3.1 employs the beta-taetamase gene, which confers
resistance to the antibiotic ampicillin. pCR3.1 is designed for simple and quick
cloning of Taq polymerase-amplified PCR products with TA overhangs and
unlike pCMVKm2 and pcDNA3.1, this vector is supplied in linear form with
single thymidine overhangs.
The pcDNA3.1 vectors (Invitrogen, CA, USA) are designed for high-level,
stable and transient expression in mammalian cells. These vectors are
essentially very similar to pCR3.1, but whereas pCR3.1 employs the pUC
origin for replication and maintenance of high copy numbers in E. coli,
pcDNA3.1 vectors employ the CoIE1 origin.
For technical data sheets of these plasmid vectors refer to Appendix D.
2.1.5 Cell lines
The cell lines used in this study as well as their characteristics are tabulated in
Table 5. All were propagated in Dulbecco's Modified Eagles Medium (DMEM)
containing heat-inactivated 10% fetal calf serum (FCS; Delta Bioproducts,
Kempton Park, South Africa) and 100mg/L penicillin (Novo-Pen; Novo Nordisk
(Pty) Ltd, Johannesburg, South Africa) and 100mg/L streptomycin (Novo-
Strep; Novo Nordisk) at 5% CO2, 95% humidity and 37°C.
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Table 5: Cell lines and their properties used for the various experiments.
Name Tissue Pro~erties Source
293 Human established from primary GibcoBRl, CA,
embryonic embryonal human kidney cells USA
kidney transformed with sheared human Cat #:11631
adenovirus type 5 DNA. The E1A
adenovirus gene is expressed in
293 cells and allows for very high
levels of protein expression.
293T Human derived from the 293 cell line, donated by Ms.
embryonic transformed with SV40 large T- Hanna Veenstra
kidney antigen. Allows for episomal Dept Medical
replication of plasmids containing Biochemistry,
the SV40 origin and early Tygerberg
promoter region.
Hela Human Hela cells are epithelial-like ATCC
cervical adherent cells that are commonly # CCl-2
adeno- used in a wide range of
carcinoma investigations. They are
transformed by the human
papillomavirus 18 (HPV-18)
RD Human The RD cell line was derived from ATCC
embryonal malignant embryonal rhabdomyo- # CCl-136
rhabdomyo- sarcoma.
sarcoma
COS-7 African This African green monkey kidney ATCC
green cell line was derived from simian # CRl-1651
monkey virus 40 (SV40)-trans-formed CV-
kidney cells 1 cells and expresses the SV40
large T antigen. It is commonly
used in virology studies and
assays requiring expression of
SV40 large T antigen.
2.2 Construction of wild-type expression plasmids
2.2.1 Optimising start and stop codon contexts
While studying features of eukaryotic mRNAs, it was found that the nucleotide
contexts of their translation initiation and termination codons affect their
translational efficiency and thus the expression level of the encoded protein
(Kozak, 1991). Subsequently, various studies have aimed at describing
consensus initiator and terminator nucleotide contexts for start and stop
codons from highly expressed eukaryotic mRNAs (Kochetov et al., 1998; Pain,
1996; Kozak, 1991). Such optimal consensus sequences that allow for strong
protein expression were defined as GCCACCATGG for the initiation of
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translation (start codon, ATG); and GCCTAAAG for the termination of
translation (stop codon, TAA) (Kochetovet a/., 1998; Kozak, 1991). These
optimised nucleotide contexts were incorporated into all expression plasmid
constructs in this study, to enhance the translation efficiency and subsequent
protein expression of the tat, rev and nef genes.
2.2.2 TAT
Tat is a small protein of 86 to 101 amino acid residues which is coded for by
two separate exons, the first of which makes up the bulk of tat's coding
sequence (approximately 72 amino acids). As the second exon is very small,
in the case of TV019 only 90 basepairs, it may have been problematic to
amplify and purify such a small fragment. As a consequence, it was decided to
construct the second exon of TV019 tat by assembly of two complementary
synthetic oligomers (T19X2FAvEc and T19X2RAvEc). The oligos (Operon
Technologies, Qiagen, Alameda, CA, USA) were designed to incorporate the
sticky end overhangs of the EcoRI restriction site behind the stop codon at the
3'-end of the tat coding region as well as the sticky end overhang of the Avril
restriction site at the 5'-end. The Avril site naturally occurs within the coding
sequence of the second exon of tat close to the 3'-end and could thus be used
to ligate the synthetic second exon in frame with the PCR-amplified, restriction
digested first exon to resemble the tat eDNA. Figure 4A illustrates the
assembled tat coding region. The sequences of the two complementary
oligomers and the primers used to amplify the first exon of tat are shown in
Figure 48. The forward PCR primer (T19wtFSal) incorporates the Sa/I site
and the reverse primer (T19wtRAvr) incorporates a short section (11 bp)
encoding exon 2 up to, and including the Avril restriction site.
The amplification reaction of tat exon one contained 10mM total dNTPs, 2.5U
of Pfu Turbo polymerase (Stratagene, CA, USA), 25pmol of each oligo primer
and 500ng of template DNA. The template was genomic DNA prepared from
cultured PBMCs from HIV-1 infected patient TV019. The amplification reaction
was performed by initial denaturing at 95°C for two minutes, followed by 23
cycles of denaturing at 95°C for 15 seconds, oligo annealing at 60°C for 30
seconds and elongation at 72°C for an initial 15 seconds and after that an
additional 5 seconds per cycle. This was followed by 17 cycles of denaturing
at 95°C for 15 seconds, oligo annealing at 60°C for 30 seconds and elongation
at 72°C for 30 seconds. A final elongation step was at 72°C for 10 minutes.
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The peR product was electrophoresed through a 1% agarose gel in Tris-
acetate EDTA buffer (40mM Tris-acetate, 1mM EDTA) and subsequently gel
purified using the QIAquick Agarose Gel Extraction Kit (Qiagen, GmbH,
Germany), following the manufacturers protocol. The purified DNA was
digested with 10 units (U) each of Sail and Avt11 (Roche Diagnostics, GmbH,
Germany) and thereafter purified of enzymes and buffer salts using the
QIAquick peR Purification Kit, following the manufacturers protocol. Assembly
of the first exon amplicon (10ng) and second exon oligonucleotides (5ng) was
done directly in a ligation reaction along with 25ng of the Sail and EcoRI (all
enzymes from Roche Diagnostics, GmbH, Germany unless otherwise stated)
pre-digested peMVKm2 plasmid vector using the Rapid Ligation Kit (Roche
Diagnostics, GmbH, Germany), as directed by the manufacturers protocol
(Appendix E).
A exon1Texon 2
T19wt~1 Avril T19X2FAvEc EcoRi
d Frtatexon1
SaIl II1II T19X2RAvEc
T19wtRAvr
B
primer sequence
T19X2FAvEc ctaggGGACCCGACAGGCTCAGAGGAATCGAAGAAGAAGGTGGA
GAGCAAGACAGAGACAGATCCGTTCGACTAAg
aattcTTAGTCGAACGGATCTGTCTCTGTCTTGCTCTCCACCT
TCTTCTTCGATTCCTCTGAGCCTGTCGGGTCCc
CTACGCgtcgacGCCACCATGGAGCCAGTAGATCCTAACC
ATcctaggGTTCTGGGTAAGGGCTGCTTTGATATAGGATTTTGA
TG
T19X2RAvEc
Tl9wtFSal
Tl9wtRAvr
Figure 4: Construction of the wild-type tat gene of isolate TV019 by assembly of the amplified, restriction digested
first exon fragment with synthetic oligomers representing the second exon.
A: Assembly of the fragments showing restriction sites and primer positions.
B: Sequences of the complementary oligomers making up the second exon (T19X2FAvEc and
T19X2RAvEc) as well as the oligo primers used to amplify the first exon of tat (T19wtFSaI and
T19wtRAvr). The restriction overhangs (Avril and EcoRI) and sites (SaIl and Avril) are indicated in
small letters.
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Two microlitres of ligation product was transformed into chemically competent
DH5a cells (Gibco BRL, Rockville Md, USA) by heatshock at 42°C for 45
seconds, following the manufacturers protocol. The transformed cells were
plated onto Luria Broth (LB; Pronadisa, Madrid, Spain) agar plates containing
50pg/ml kanamycin (Sigma-Aldrich, GmbH, Deisenhofen, Germany) and
incubated ovemight at 37°C.
The next day, single colonies were picked and inoculated into 5 ml LB media
containing 50pg/ml kanamycin and these minicultures were incubated for 16
hours at 37°C with vigorous shaking. Miniprep DNA was prepared using the
QIAprep Spin Miniprep Kit (Qiagen, GmbH, Germany), following the
manufacturers protocol (Appendix F).
Positive clones were identified by restriction digestion of miniprep plasmid
DNA with Sail and EcoRI and subsequent confirmation of insert size by
agarose gel electrophoresis. The plasmid insert was then verified for correct
sequence by sequencing (see Section 2.5) and the resulting expression
plasmid construct containing the wild-type tat coding sequence with optimised
start and stop codon contexts was named pCMVKm2-Tatwr.
2.2.3 REV
Similarly to Tat, the Rev protein is encoded by a bicistronic gene. However, in
this case the first exon (75 bp) of the 321 bp long TV010 rev is smaller than
the second exon (246 bp), and again only the second exon could be PCR
amplified from the primary lymphocyte culture extracted DNA of patient
TV010. A Kpnl site, which naturally occurs towards the 3' end of the second
exon of rev was incorporated into the forward PCR primer for amplification of
the second exon. This site was used as ligation point for joining the two exons
and because the length of the first exon (75 bp) added to the exon 2 section
up to the Kpnl site was quite large (112 bp), it was broken up into a set of four
overlapping oligonucleotides, which had to be assembled before they could be
ligated along with the Kpnl- and EcoRI-digested second exon into the
pCMVKm2 plasmid vector (Figure 5). The 3' end of these oligonucleotides
were designed to incorporate the sticky end overhang of the Sail site and the
5' end that of the Kpnl site.
The four oligonucleotides were added together and the pool was added to an
assembly mixture composed of 1X Pfu reaction buffer (Roche Diagnostics,
GmbH, Germany) at a final concentration of 5 ng/~1.This reaction mixture was
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exposed to three denaturing-annealing cycles of 9SoC for five seconds and
SO°Cfor ten seconds respectively, followed by a final annealing step of SO°C
for two minutes.
The second exon of rev was amplified from genomic DNA, prepared from
primary lymphocyte culture cells. Identical PCR conditions, cycles and
reaction mixtures to those used to amplify tat exon 1 were employed with the
primer pair Rwt10FKpnX2 and Rwt10REco and the PCR product was gel
purified and digested with Sail and EcoRI as described before. Again, ligation
of the two exons into the Sail and EcoRI pre-digested pCMVKm2 plasmid
vector, transformation and identification of positive clones were done as
described for tat. Again, the plasmid insert was then verified for correct
sequence by sequencing. The resulting expression plasmid containing the
wild-type rev coding sequence with optimised start and stop codon contexts
was designated pCMVKm2-RevwT.
A exon 1T.exon 2 Rwt1i'KpnX2
Rwt10FSaI Rwt10FKpnX1
I II -,fl
Sail 1 II r
Rwt10RSaI Rwt10RKpn Kpnl
revexon2
EcoRi
1::1
il
Rwt10REco
B primer sequence
RwtFl0Sal tcgacGCCACCATGGCAGGAAGAAGCGGAGACAACGACGAAGCG
CTTCTCCAAGCAGTAAGGATCATCAAAATCC
TATACCAAAGCAACCCCTACCCCAAGCCCGAGggtac
GTCGTTGTCTCCGCTTCTTCCTGCCATGGTGGCg
cCTCGGGCTTGGGGTAGGGGTTGCTTTGGTATAGGATTTTGATG
Rwtl0FKpnxl
Rwtl0RSal
Rwtl0RKpn
ATCCTTACTGCTTGGAGAAGCGCTTC
Rwtl0FKpnx2 ATCTACggtaccCGACAGGCCCGGAAGAAT
Rwtl0REco CGACCGgaattcCTTTAAGGGCTTCCCACCCCCTCTGTAGT
Figure 5: Construction ol the wild·type rev gene ol isolate TV010 by assembly of the amplified, restriction
digested second exon fragment with synthetic oligomers representing the first exon.
A: Illustration of the assembly of the fragments showing restriction sites, primer positions and the exon
breakpoint.
B: Sequences of the complementary oligomers making up the first exon as well as the oligomer
primers used to amplify the second exon of rev (Rwtl0FKpnX2 and Rwtl0REco). Restriction sites
and overhangs are indicated by small letters.
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2.2.4 NEF
The Nef protein is expressed from the monocystronic net gene, which is
approximately 620 bp in length, depending on the viral strain (Piguet and
Trono, 1999). During the characterisation study in which the tat, rev and net
genes were sequenced, the net genes were amplified from a 9kb HIV genomic
PCR amplicon, which was PCR amplified from primary lymphocyte culture
cell-extracted DNA previously (Appendix C) (Scriba et al., 2002). The primer
pair NefF and NefR (Table 5) was used to amplify the fragment of
approximately 660bp, which contained the net coding region along with short
flanking sequences on either side. The amplification was performed as
follows: two microlitres of 9kb PCR product template were added to the net
amplification reactions containing 40IJM of each primer, 2.5mM MgCI2, 10IJM
total dNTPs (Roche Diagnostics, GmbH, Germany) and 0.7U Expand High
Fidelity polymerase in Expand High Fidelity PCR System buffer 1 (Roche
GmbH, Mannheim, Germany). Thermal cycling was performed as follows:
initial denaturing at 94°C for two minutes followed by 40 cycles of denaturing
at 94°C for 90 seconds, primer annealing at 50°C for 90 seconds and
elongation at 72°C for 3 minutes. A final elongation step at 72°C for 10
minutes was employed.
The PCR products of selected isolates were selected to be cloned and these
were agarose gel-purified as described previously and cloned into the pCR3.1
bi-directional cloning vector by TA cloning as directed by the manufacturer
(Invitrogen, CA, USA, see Appendix D). Transformation into Top10F' cells
(Invitrogen, CA, USA), miniprep DNA preparation and identification of positive
clones by HindIII and Xhol (Promega, Madison, WI, USA) restriction analysis
were done as described previously. Orientation determination of the net
inserts was done by asymmetrical restriction analysis using the restriction
endonucleases San and Xhol (Promega, Madison, WI, USA) and the net
genes were verified by sequencing.
To construct a wild-type net expression plasmid with optimised start and stop
codon contexts, which could be used for expression level and functionality
comparisons with codon-optimised net constructs, the net gene of TV002
(clone pCR-Nef2.11) was selected and this clone was used as template for a
PCR amplification using primer pair NwtFXho and NwtREco (Table 5). This
PCR amplification was performed using identical reaction and cycling
conditions as described for the amplification of the wild-type tat and rev genes.
Similarly, cloning of the net amplicon into the pCMVKm2 vector was done over
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the Xhol and EcoRI restriction sites as described before and positive clones
were identified by restriction analysis of miniprep DNA with Xhol and EcoRI.
Positive clones were sequence verified and the resulting expression plasmid
was designated pCMVKm2-NefwT.
Table 5: Oligomer primers used to amplify the wild-type nef genes. The Xhd. and fcoR! sites incorporated into
NefwtFXho and NefwtREco are indicated in small letters.
Primer Sequence
NefF CCTAGAAGAATAAGACAGGGCTT
NefR CCTGGAACGCCCCAGTGG
NWtFXho CTACGCctcgagGCCACCATGGGGGGCAAGTGGTCAAAAA
NWtREco CGACCGgaattcTTTAGGCGCAGTCTTTGTAATACTCC
2.3 Construction of codon-optimised and mutant expression plasmids
2.3.1 Optimising codon-usage for eukaryotic expression
Although DNA vaccines have shown very promising results in terms of antigen
delivery and presentation, one constraint, which affects the immunogenicity of
plasmid vector delivered immunogens, is the poor expression of antigen
because the codon usage of such foreign viral genes is most likely not optimal
in eukaryotic organisms. Human mRNAs with elevated AU content
percentages have been shown to display instability, increased turnover and
generally low expression levels compared to those with higher GC content
(Hentze, 1991). Moreover, in their study, Haas et al. (1996b) compared codon
usage between the HIV-1 envelope gene gp120 and highly expressed human
genes and their results are illustrated in Figure 6. As can be seen, they found
a significant divergence between the codon prevalence of the coding regions
in highly expressed human genes and the HIV-1 envelope gene. Similar
codon usage patters are reported by Andre et al. (1998) for other HIV-1
genes. Upon subsequent replacement of native codons in gp120 with codons
more prevalent in highly expressed human genes, a striking increase in
expression was observed in eukaryotic cells (Andre et al., 1998; Haas et al.,
1996b). A similar increase in expression was shown when the codons of the
poorly expressed green fluorescent protein (GFP) from the jellyfish Aequerea
victoria was changed in the same way as gp120 (Haas et al., 1996b).
Moreover, markedly increased expression levels were obtained by zur
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Megede et al. (2000) by changing the codons of the HIV-1 protein Gag in a
similar fashion.
Thus, in an attempt to potentially optimise expression in mammalian tissues
over and above optimised start and stop codon contexts, the codon usage of
the genes encoding the HIV-1 subtype C consensus Tat, Rev and Nef proteins
was altered to that of highly expressed human genes as presented in Figure 6
whenever it was permissible by the degeneracy of the genetic code .
s: >C"l c::f LJ.J
Ala C 53 27
T 17 18
GC
A 13 50
G 17 5
Arg C 37 0
T 7 4
CG
A 6 0
G 21 0
A 10 88
AG
G 18 8
Asn
s: >.2> c:
J: LJ.J
Cys
TG
Gin
CA
Glu
GA
Gly C 50 6
T 12 13
GG
A 14 53
G 24 28
His
CA
lie C 77 25
T 18 31
AT
A 5 44
Lys A 18 68 Thr C 57 20
AA G 82 32 T 14 22
AC
A 14 51
G 15 7
Pro C 48 27
T 19 14 Tyr
CC A 16 55 TA
G 17 5
Val C 25 12
T 7 9
GT
Phe A 5 62
TT G 64 18
s: >C"l c::f LJ.J
Leu C 26 10 Ser
T 5 7
CT TC
A 3 17
G 58 17
A 2 30
TT AG
G 6 20
>c:
LJ.J
AA
Asp
GA
C 28 8
T 13 8
A 5 22
G 9 0
C 34 22
T 10 41
Figure 6: Codon usage of Ihe HIV·l gp120 coding region (Env) and Ihat of highly expressed human genes
(High). The third nucleotide for each amino acid codon is tabulated with its frequency for bolh systems
inside each box. The frequencies of the individual codons for each amino acid are shown as a
percentage value and the most prevalent codon is in boldface. Source: (Haas et al., 1996b).
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2.3.2 Selection of a representative vaccine strain
It is well known that the extreme diversity of HIV-1 makes vaccine
development and especially selection of a candidate strain, clone or isolate for
the development of a vaccine a major issue. Because a homologous vaccine
is not possible, the next best approach may be using a consensus sequence,
which is constructed from a panel of viral strains that represent the viral
population in the local epidemic (Novitsky et ai., 2002). Such a consensus
drawn up from subtype C sequences from South Africa may display a higher
degree of homology to local circulating viruses than a single viral strain.
Indeed, such an approach was recently proposed by Novitsky et al. (2002),
who analysed consensus sequences that represent the entire subtype C
sequences as well as a number of subpopulations including one for southern
Africa. It was demonstrated that such approaches may be effective at
overcoming the high genetic diversity and thus facilitate vaccine development.
Because the codon-optimised genes had to be constructed synthetically they
did not necessarily have to be acquired from an existing physical template
such as a viral isolate. The comparison of wild-type amino acid sequences
with the respective consensus sequences (TV Cons) constructed from the 14
subtype C TV isolates revealed no sequence differences in the consensus that
might account for loss of function or change in protein folding. It was thus
decided to use the consensus amino acid sequences to design the codon-
optimised tat, rev and nef constructs.
2.3.3 Design of codon-optimised gene sequences
Consensus amino acid sequences constructed from HIV-1 subtype C isolates
from Tygerberg (Scriba et ai., 2002), designated TV Cons, were used as
template for deriving the codon-optimised nucleotide sequences. The codons
of the tat, rev and nef coding regions were changed to those more prevalent in
highly expressed human genes by altering the codons to those described in
Figure 6 wherever it was permissible by the degeneracy of the genetic code
to retain an unchanged protein sequence. This was done using the MacVector
software program (Oxford Molecular Ltd., Oxford, UK).
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2.3.4 Synthetic construction of DNA sequences
All codon-optimised gene sequences were constructed by PCR assembly of
overlapping 50mer oligonucleotides. Briefly, the gene sequences were
subdivided into 50mer single-stranded fragments, of which the positive and
negative strand fragments overlap by 25 bases as illustrated in Figure 7.
Oligos were synthesised by Operon Technologies (Qiagen, Alameda, CA,
USA) and were purified by double polyacrylamide gel electrophoresis (PAGE).
synthetic SOmer oligos
fOIWrd
lassemblyreaction
lsecondround peR
....
reverse
ds synthetic gene
Figure 7: Assembly and amplification of overlapping 50mer oligonucleotides to construct the
synthetic double-snanoeo gene sequences.
Oligonucleotides were reconstituted in nuclease-free water (Promega,
Madison, WI) to a concentration of 11-1g/1-I1and added together to create an
oligo pool, which was diluted to a final concentration of O.4l-1g/1-I1.Using serial
dilutions, 21-1g,200ng and 20ng of pooled oligonucleotides were added to an
assembly PCR reaction containing 0.2mM total dNTPs and 1.25U of Pfu
Turbo polymerase (Roche Diagnostics, GmbH, Germany). The assembly
reaction was performed by initial denaturing at 95°C for two minutes, followed
by 55 cycles of denaturing at 95°C for 15 seconds, oligo annealing at 52°C for
30 seconds and elongation at 72°C for 30 seconds.
One and a half microlitres of the assembly product were transferred to a
second amplification reaction containing O.4mM total dNTPs, 20pmol forward
and reverse primer (the first positive strand oligo and last negative strand oligo
respectively) each and 1.25U of Pfu Turbo polymerase. The amplification was
performed by initial denaturing at 95°C for two minutes, followed by 23 cycles
of denaturing at 95°C for 15 seconds, oligo annealing at 600C for 30 seconds
and elongation at 72°C for 45 seconds. The entire volume of amplification
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product was loaded onto a 1% agarose gel, electrophoresed and gel extracted
as described before.
2.3.5 TAT
Designing non-functional Tat mutants
As reviewed in Section 1.1.6, the Tat protein consists of distinct functional
regions, which include an N-terminal activation region, a cysteine-rich domain,
a core region, a basic domain and a glutamine-rich region (Kuppuswamy et
aI., 1989). Mutational analysis has identified a number of Tat inactivating
mutations and it has been shown that the cysteine residues are critical for Tat
function in several studies (Battaglia et aI., 1994; Kuppuswamy et aI., 1989;
Ruben et aI., 1989). Specifically, Tat proteins with either a mutated cysteine at
position 22 or double mutations at cysteine 22 (to glycine) and cysteine 37 (to
serine) have been shown to be functionally inactive (Rossi et aI., 1997;
Caputo et aI., 1996) and immunisation with such mutated Tat-encoding
plasmid DNA induced humoral and cellular immune responses which
recognised wild-type Tat (Caselli et aI., 1999). This study as well as one that
followed further revealed that such mutated Tat proteins, when excreted,
interfered in a competitive manner with the transactivating function of
extracellular wild-type Tat, suggesting applications as therapeutic agents
(Betti et aI., 2001; Caselli et aI., 1999).
In this study, we designed three different mutants (Tatc22, TatC37and Tatc22c37)
and a native consensus Tat (TatoPT) (Table 6) that were tested for functional
activity to identify a non-functional Tat with a maximum number of unmutated
CTl epitopes within the conserved regions of Tat.
Exon 1 Exon2
acidic C22 C37 core basic glutamine
richcysteines
Flgure8: Diagrammatic representation of the lOl-aa Tat protein showing the functional domains.
The two critical cysteines to be mutated are indicated as black lines. Adapted from
(Jeang, 1996).
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Constructing the TatoPtC22 expression vector
Because of the relatively small size of tat and rev, these genes were
synthesised as a single polygene cassette. Thus the codon-optimised Tatc22
and RevM5M10(Section 2.3.6) genes were designed to incorporate the coding
sequences of both genes in the same reading frame (Figure 9). An Xmal site
divided the two coding regions, while the San and EcoRI sites were
incorporated upstream of the optimised start (tat) and downstream of the
optimised stop (rev) codon contexts respectively. This Tat-Rev cassette was
synthesised as described in section 2.3.4 and cloned into the pCMVKm2
plasmid vector over the Sail and EcoRI sites. Ligation, transformation and
selection of positive clones were done as described for the wild-type plasmid
construction.
san Xmal EcoRI
Tatc22 ReVM5M10
TatCFSal+St......
IPCA
~
TatCREc+Sp
Figure 9: Diagrammatic representation ol the synthetic Tal-Rev polygene cassette Ihal was used lo amplify the
Talc22 and RevM5M1ogenes (section 2.3.6).
The resulting plasmid construct was used as template for the amplification of
the Tatc22 gene, using primer pair TatCFSal+St and TatCREc+Sp (Table 7).
The latter was designed to introduce an optimised stop codon context with a
EcoRI site downstream of the stop. PCR conditions and cycling using Pfu
polymerase were done as described before. The resulting amplicon was gel
purified, digested with Sail and EcoRI, ligated into pCMVKm2 and transformed
into DH5a cells. Preparation of miniprep DNA, identification of positive clones
and sequence verification were all done as described before. The resulting
expression construct was named pCMVKm2-Tatc22.
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Site-directed mutagenesis
Background
In order to construct plasmids expressing Tat with no mutations (native
consensus Tat protein) or different mutations to C22, site-directed
mutagenesis was used to induce single nucleotide changes. Various methods
of site-directed mutagenesis have been established, most of which produce
very efficient mutation frequencies of above 80% of colonies screened.
In this study, we decided to use a PCR-based oligonucleotide-directed
mutagenesis system (QuickChange Site Directed Mutagenesis Kit,
Stratagene, CA, USA) in which a pair of complementary oligonucleotide
primers, which consist of the sequence with the changed nucleotide, anneal to
the positive and negative strand of the plasmid DNA template at sites flanking
the site to be mutated. The entire DNA plasmid is amplified by PCR, resulting
in the newly synthesized DNA strands containing the nucleotide mutation. By
digestion with the restriction enzyme Dpn I, which only cleaves methylated
DNA templates, the plasmid template containing the original sequence is
digested. Since the new DNA strands, which contain the induced mutation,
have been synthesized in vitro, they are not methylated and are subsequently
not digested and will therefore be the only functional, replicating plasmids
upon transformation, lending antibiotic resistance to bacterial cells. This
system, therefore, selects for bacterial cells, which have been transformed
with the PCR amplified, mutated plasmid.
Construction of TatoPT, Tatc37 and Tatc22C37 by mutation of Tatc22
The oligonucleotide primers used to induce mutations to construct the mutants
Tatc37and Tatc22c37as well as the native Tat protein TatoPT are listed in Table
6, while the primer sequences are shown in Table 7. Mutagenesis PCR
amplification was performed in a total reaction volume of 501J1,containing
0.125 IJgof each primer, 10 mM total dNTPs, 1 U Pfu polymerase and 20 ng
plasmid DNA template (pCMVKm2-Tatc22).Amplification was performed by
initial denaturing at 95°C for two minutes, followed by 12 cycles of denaturing
at 95°C for 30 seconds, primer annealing at 60°C for 1 minute and elongation
at 68°C for 13 minutes. A final elongation step at 68°C for 12 minutes
completed the amplification. Followinq the amplification, 1 IJl Dpnl (10 U)
restriction endonuclease was added directly to the PCR reaction and
incubated at 37°C for 90 minutes, after which 1 IJlwas transformed into XL1-
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Blue supercompetent cells (Stratagene, CA, USA) by heats hock as described
by the manufacturer. Miniprep DNA preparation and identification of positive
transformants was performed as described previously.
Table 6: The four different tat variants. The mutations induced and primers that
were used to do so are tabulated.
Construct Mutations Primers
TatoPT native consensus protein SiteTaCwtF, SiteTaCwtR
Tatc22 Cys22Gly synthesised directly
Tab7 Cys37Glu
SiteTaCwtF, SiteTaCwtR
SiteTa37CF, SiteTa37CR
Tatc22C37 Cys22Gly, Cys37Glu SiteTa37CF, SiteTa37CR
Table 7: Sequences ol the oligonucleotide primers lor PCR amplification ol the cooon-opamseo tat
gene (TatCFsal+St and TatCREc+Sp) and those designed to induce site-directed mutations
to construct tat variants. The restriction sites are indicated in smailielters and changed
bases (site.<Jirectedmutagenesis) are underlined.
Primer Sequence Mutationinduced
TatCFSal+St CTACGCgtcgacGCCACCATGGAGCCCGTGGAC
CCC
PCR
primer
TatCREc+Sp CGACCGgaattcTTTAGTCGAAGGGGTCGGTCT
CGGTCTTGCTCTCCA
PCR
primer
SiteTacwtF GCAGCCAGCCCAAGACCGCCTGCAACAAGTGCT
ACTGCAAG
Gly22Cys
SiteTacwtR CTTGCAGTAGCACTTGTTGCAGGCGGTCTTGGG
CTGGCTGC
SiteTa37CF GCAGCTACCACTGCCTGGTGAGCTTCCAGACCA
AGGGCCTG
SiteTa37CR CAGGCCCTTGGTCTGGAAGCTCACCAGGCAGTG
GTAGCTGC
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Positive transformants were verified for correct sequence and the presence of
mutations by DNA sequencing (see Section 2.4). The newly mutated,
sequence verified tat variants were excised from the plasmid vector
pCMVKm2 by digestion with Sail and EcoRI, re-ligated into the original pre-
digested pCMVKm2 vector and transformed into DH5a cells as described
previously. This subcloning step serves to eliminate potential mutations that
may have arisen during PCR amplification within the plasmid vector sequence
and could affect plasmid replication, antibiotic resistance or expression of the
Tat proteins.
2.3.6 REV
Designing a non-functional Rev mutant
The functional and structural domains of HIV-1 Rev have been well studied
and various critical positions and sequence motifs have been identified that
are essential for a functional Rev protein (Figure 10). The amino-proximal
arginine-rich domain spanning amino acids 35 to 50 has been shown to serve
as nuclear localisation signal (NLS) and RNA binding domain (RBD) (Kjems et
al., 1992; Cochrane et al., 1990b; Malim et al., 1989b). The nuclear export
signal (NES), which spans residues 75-93 presents as a leucine-rich domain
(Fischer et al., 1995; Wen et al., 1995; Hope et al., 1991; Malim et al., 1991;
Malim et al., 1989a). Additional sites governing the multimerisation of Rev and
its high-specificity binding to the RRE flank the NLS and RBD (Hope et al.,
1992; Zapp et al., 1991). Although all domains are important for the nuclear
export of unspliced or incompletely spliced viral mRNAs, a number of studies
have identified single amino acid residues or short motifs that seem to
abrogate Rev's functionality in vitro (Thomas et al., 1998; Malim et al., 1991;
Hope et al., 1990b; Hope et al., 1990a; Mermer et al., 1990; Malim et al.,
1989a).
Again, in an attempt not to excessively mutate the protein sequence of Rev in
order to retain a maximum of potential cytotoxic T-Iymphocyte (CTL) epitopes,
we selected two well-defined Rev-inactivating mutations first described by
Malim et al. (1989a), M5 (RR to DL at positions 38,39 in the arginine-rich
RNA-binding NLS) and M10 (LE to DL at positions 78,79 in the activation
domain of the NES) (Figure 10). Both mutations have been shown to be
sufficient for functional inactivation and the M10 mutant has been shown to be
a trans-dominant repressor of wild-type Rev function (Malim et al., 1991; Hope
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et a/., 1990b; Malim et a/., 1989a). Hope et al. (1990b) also substituted R38R39
for GG, rendering Rev inactive, to confirm the importance of this site for
functional Rev activity. Although the subtype C Rev proteins (consensus and
wild-type) displayed residue differences in the M5 (RK) and M10 (IE) motifs to
the subtype B proteins described in the literature (M5: RR; M10: LE), the
amino acids (basic: Arginine (R), Lysine (K); nonpolar: Leucine (L), Isoleucine
(I)) retain their physiochemical properties. Thus these mutations in the
subtype C RevM5Ml0protein are M5: RK 38,39 DL; M10: IE 78,79 DL.
M5 M10
Figure 10: Diagrammatic representation of the 116-aa Rev protein showing the
functional domains. MI and Mil represent the multimerisation domains.
The two double inactivating mutations M5 and Ml0are indicated as
black lines. Adapted from (Thomas et ai., 1998).
Constructing the RevM5M10expression vector
Similarly to Tatc22, RevM5Ml0 was PCR amplified from the synthetically
constructed Tat-Rev polygene cassette (Figure 11) using the primer pair
RoptFSal and RoptREco (Table 8). Primer RoptFSal was designed to
incorporate a San site upstream of an optimised start codon context in frame
with the coding region of RevM5Ml0' The amplification, cloning and clone
selection was done as described before, the inserts were sequence verified
and the resulting expression plasmid was named pCMVKm2-RevM5Ml0.
SaIl Xmal EcoRI
Tale22 ReVM5M10
RoptFSal.......
!peR
.....
RoptREco
Figure 11: Amplification of the RevMsM10gene from the synthetic Tat-Rev cassette. The
primers RoptFSaI and RoptREco incorporated an optimised start context and Sa~
site as well as an optimised stop context and EcoRt site respectively.
Table 8: Sequences of the oligonucleotide primers designed to amplify RevM5Ml0 from the Tat-Rev
polygene cassette and to incorporate a Sail site and an optimised start codon context. The
restriction sites are indicated in small letters.
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Primer Sequence
Roptl"Sal
RoptREco
CTACGCgtcgacGCCACCATGGCCGGCCGCAGCGGCGACAGC
CGACCGgaattcCTTTAGGCGCTGCCCACGCCCTCGGTGGT
2.3.7 NEF
Designing non-functional Nef mutants
A number of studies describe a range of mutations that partially or totally
inactivate the different functionalities of Nef. Nef is myristoylated on glycine at
position 2 and phosphorylated on serine and threonine residues (Niederman
et aI., 1993). The Nef core (aa70-77) consists of a type II polyproline helix,
which forms the main binding site for Src family kinases. Adjacently, stretching
residues 81-120, is a region consisting of two alpha helices, followed by a
four-stranded anti-parallel beta-sheet (aa121-186) and two additional alpha
helices (aa187 -203) (Grzesiek et al., 1996). More recently it was shown that
the N-terminal domain stretching from residue 6 through 22 forms another
alpha-helix (Bam ham et aI., 1997).
The myristoylation of Nef is essential for protein folding and association with
the cell membrane and thus activity of most Nef functions including
downregulation of CD4, MHC-I and a number of effects on T cell signalling
(Lundquist et al., 2002; Geleziunas et al., 2001; Manninen et aI., 2001; Penq
and Robert-Guroff, 2001; Aldrovandi et aI., 1998; Curtain et aI., 1998; Curtain
et aI., 1997; Iafrate et aI., 1997; Goldsmith et aI., 1995; Sawai et aI., 1995;
Aiken et aI., 1994; Niederman et aI., 1993;). Another study has identified a
single inactivating mutation within the beta-sheet domains of Nef: the D123G
mutation was reported to render Nef unable to downregulate CD4, MHC-I or
enhance virion infectivity (Liu et aI., 2000). Another well-defined mutation that
also falls within the beta-sheet domain is LL165AA, which disrupts the motif
essential for CD4 down-regulation and interaction with AP-complexes
(Lundquist et aI., 2002; Bresnahan et aI., 1998; Greenberg et aI., 1998a).
In order to minimize the elimination of important CTL epitopes, a minimum
number of mutations within the Nef protein were desirable. Consequently we
designed two different Nef mutants one in which the myristoylation signal (G2)
and aspartate at position 124 (D124, corresponding to the described D123G
mutation) were mutated (Nef.myrD124)'and one containing these two mutations
as well the additional LL 165AA mutation (Nef.mYrD124LLAA).
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Constructing the NefoPT• Nef-myrD124and Nef.myrD124LLAAexpression vectors
The different codon-optimised Nef variants along with the wild-type Nef
construct are tabulated in Table 9. Firstly, the Nef gene containing a mutated
myristoylation signal (G2A) and the single D124G mutation (Nef.myrD124)was
assembled and amplified from synthetic oligonucleotides. This was done using
the oligonucleotide assembly amplification method as described for Tat and
Rev. Similarly to Tat and Rev, this construct also incorporated optimised
contexts for start and stop codons. The assembled Nef.myr0124gene was
cloned into the pCMVKm2 plasmid vector over SaIl and EcoRI sites.
This construct was subsequently used as template to construct the two further
variants. The additional LL 165AA mutation was induced by PCR-based site-
directed mutagenesis to yield a myristoylation-deficient Nef mutant with the
D124G and LL 165AA mutations designated Nef.myrD124LLAA.The site-directed
mutagenesis was performed as described for construction of the Tat variants
using the primer pairs described in Table 10. The third Nef gene construct
was generated to encode the native consensus Nef protein. To obtain this
construct, the Nef.myrD124plasmid was again used as template for site-directed
mutagenesis PCR reactions. Thus, at position 2, the G2A mutation was
reversed by normal PCR using a forward primer (Nef+myrF, see Table 10),
which incorporates a glycine codon at position 2. The PCR conditions and
cycles were performed as described for construction of the wild-type net
constructs. Subsequently, to construct an optimised net gene coding for the
native protein sequence, the D124G mutation was reversed using primer pair
NefG123DF and NefG123DR using the QuickChange Site-directed
Mutagenesis Kit (Stratagene, CA, USA).
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Table 9: The three different codon-optimised net variants with the corresponding primers used to
induce site-specific mutations.
Construct Mutations Primers
Nef.myrD124 G2A,D124G synthesized directly
Nef.myrD124LLAA
G2A,D124G, NefLLAAFor & NefLLMRevLL165M
NefoPT
native consensus Nef+myrF & PCMVRev,
protein NefG123DF & NefG123DR
Table 10: Sequences of the oligonucleotide primers used to induce site-directed mutations to construct
net variants. Changed nucleotides are underlined.
Primer Sequence
NefLLAAFor
NefLLAARev
NefG123DF
NefG123DR
Nef+DWrF
pCMVRev
AGGGCGAGAACAACTGCGCGGCGCACCCCATGAGCCAGC
GCTGGCTCATGGGGTGCGCCGCGCAGTTGTTCTCGCCCT
CACCCAGGGCTTCTTCCCCGACTGGCAGAACTACACC
GGTGTAGTTCTGCCAGTCGGGGAAGAAGCCCTGGGTG
CTACGAGTCGACGCCACCATGGGCGGCAAGTGGAGC
GCTGGCAACTAGAAGGCACA
2.4 Constructing the human CD4 expression plasmid
The plasmid pBSKS(+)-hCD4 containing the eDNA of the human CD4 gene
(hCD4) was a generous gift from Dr. Gillis Otten (Chiron Corporation, CA,
USA). This construct was made by cloning the hCD4 gene into the pBluescript
KS(+) (pBSKS(+); Stratagene, CA, USA) cloning vector over the EcoRt and
Hindl/l restriction endonuclease sites.
The hCD4 fragment was excised from the pBSKS(+)-hCD4 vector by
digestion with EcoRt and Hindl/l and ligated into the Hindl/l- and EcoRt-
digested mammalian expression vector pcDNA3.1 (-) (Invitrogen, Gr6ningen,
The Netherlands) as described previously. Positive clones were identified by
asymmetrical restriction analysis and functional expression of CD4 was
determined by transfection into human embryonic liver cells (293), staining
with anti-CD4 APC-conjugated antibody and flow cytometry as described
under the methods for Nef functionality assays (Section 2.7.3).
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2.5 Sequencing of expression plasmIds
Sequencing reactions were carried out using the ABI Prism BigDyeTM
Terminator Cycle Sequencing kit (PE Applied Biosystems, CA, USA). Each
reaction contained 0.35 - 1IJgplasmid DNA and 5 pmoles primer in a reaction
mixture containing either 4 III Terminator Ready Reaction Mix (TRRM; a half
reaction) or 81J1TRRM (a full reaction) in a total volume of 10 or 20 III
respectively. Sequencing primers used for the pCR3.1 construct were the T7
and BGHrev sequencing primers (Invitrogen, CA, USA) and are described in
Table 11. Sequencing of the pCMVKm2 constructs was performed in the
sequencing core at Chiron Corporation (Emeryville, CA, USA) using custom
made in-house primers. Alternatively, the pCMVKm2 constructs made at the
Department of Medical Virology, Tygerberg were sequenced using the primer
pair pCMVFor and pCMVRev (Table 11).
The cycling reactions were performed using a program consisting of 25 cycles
of template denaturing at 96°C for 10 seconds, annealing for 5 seconds at the
respective primer annealing temperature (Table 11) and elongation at 60°C
for 4 minutes. The finished products were immediately purified using the
DyeEx Spin Kit following the manufacturer's protocol (Qiagen, GmbH,
Germany). Purified extension products were vacuum dried after which they
were resuspended in 251J1ABI Prism® Template Suppression Reagent (TSR,
Perkin Elmer, CA, USA). Prior to loading samples into the 310 Genetic
Analyzer (Perkin Elmer, CA, USA), the resuspended DNA was transferred to
Genetic Analyzer tubes (ABI PrismTM) and the DNA was denatured at 90°C for
5 minutes and immediately placed on ice. Analysis was done on an ABI
Prism® 310 Genetic Analyzer (Applied Biosystems) using Performance
Optimised Polymer 6, a 47 cm capillary, a polymer temperature of 50°C,
injection time of 45 seconds and a gel run time of 50 minutes (Perkin Elmer,
CA, USA).
Table 11: Sequences and annealing temperatures of the oligonucleotide primers
used to sequence all constructs made at Tygerberg.
Primer Sequence Annealingtemperature
T7forward TAATACGACTCACTATAGGG
BGHreverse TAGAAGGCACAGTCGAGG
pCMVPor AGTCTGAGCAGTACTCGTTG
pCMVRev GCTGGCAACTAGAAGGCACA
4S'C
SO'C
50°C
53°C
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Sequence analysis
Overlapping sequences were assembled using the DNAMAN ver. 4.0
Package (Lynnon Biosoft), multiple alignments were performed with
CLUSTALX ver. 1.81 (Thompson et a/., 1997; Higgins et a/., 1996) and
translation into the deduced amino acid sequences and layout of multiple
sequence alignments were performed with GENEDOC ver. 2.6.001 (Nicholas
and Nicholas, 1997) and verified manually.
2.6 Generation of mouse sera by immunisation with naked plasmid DNA
Background
Because of very limited availability of accessory protein-specific antibodies
representing any subtype and especially subtype C, alternative means to
obtain the necessary reagents were required. It was thus decided to generate
polyclonal antibody serum by immunising mice with the Tat, Rev and Nef
expression constructs.
Preparation of plasmid DNA
Plasmid DNA was prepared using the Qiagen Endo-Free Plasmid Giga Kit
(Qiagen GmBH, Germany, Appendix G). One litre of Luria Broth containing
50lJg/ml Kanamycin was inoculated with 1ml of the respective starter culture
and incubated at 37°C for 16 hours with vigorous shaking. The manufacturer's
protocol was followed and the DNA was resuspended in nuclease-free water
(Promega, MD, USA). DNA concentrations and purity were measured using a
spectrophotometer and confirmed by agarose gel electrophoresis. To
calculate the concentration and purity of a DNA solution, the optical densities
of the solution at the wavelength of 260nm (00260) and 280nm (00280) were
determined. Using the following two formulas, the concentrations and the
purity of the plasmid DNA were calculated.
DNA concentration (lJg/IJI):[DNA] = OD2so120 X dilution factor
plasmid DNA purity: purity factor = 00260100280
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The DNA was diluted to 1 jJg/jJl for further use and only DNA with a purity
factor within the range of 1.7 to 1.9 was suitable for immunisation.
Immunisation
Six to eight week old female CB6F1 mice (10 mice per group, n=10) were
immunized with the respective plasmid DNA coding for the HIV-1 subtype C
accessorylregulatory proteins Tat, Rev and Nef (Table 11). The dose of 75jJg
plasmid DNA in 100jJi 0.9% sterile endotoxin-free saline solution (Sigma-
Aldrich GmbH, Taufkirchen, Germany) per mouse was divided into two equal
dosages, each of which was administered into either tibia anterialis muscles.
Handling of the animals, immunisations and serum collection was performed
by animal house technicians at the animal facility at Chiron Corporation. The
mice were immunised twice, with a 4-week interval and sera were collected by
cardiac puncture 2 weeks after the second immunisation and pooled for each
immunogen group.
Table 11: Plasmid DNA constructs used to imrrunise temale CB6F1 mice to
generate HIV·1 subtype C Tat, Rev and Net-specific polyclonal
antibody sera.
Immunogen Plasmid vector Viral strain
Tatc22c37 pCMV-Km2 TV consensus
RevM5Ml0 pCMV-Km2 TV consensus
Nef.myrD124 pCMV-Km2 TV consensus
2.7 In vitro expression in human cells
2.7.1 DNA preparation
Plasmid DNA was prepared using either the QIAfilter Plasmid Maxi or Midi Kit
(Qiagen GmBH, Germany, Appendix H). One hundred and fifty (Maxi) or fifty
(Midi) millilitres of Luria Broth containing the appropriate selective pressure
antibiotic (kanamycin or ampicillin; Ranbaxy, (Pty) Ltd, South Africa) at a
concentration of 50jJg/mi were inoculated at a volume ratio of 1:500 with the
respective starter culture and incubated at 37°C for 16 hours with vigorous
shaking. The manufacturer's protocol was followed to extract plasmid DNA
and the DNA was resuspended in distilled water. DNA concentrations and
54
Stellenbosch University http://scholar.sun.ac.za
purity were measured by reading the absorbance at 260 and 280nm as
described previously and confirmed by agarose gel electrophoresis. Plasmid
DNA was diluted to 1j.Jg/j.J1and had to fall within the purity factor range of 1.7
to 1.9.
2.7.2 In vitro expression assays
Maintenance of mammalian cells
To assess the expression of the accessory gene constructs, in vitro
expression assays in mammalian cells were done. Human embryonic kidney
(293, American Type Tissue Collection [ATCC, Atlanta, Ga] no. 45504 or
National Institute of Health [NIH, Rockville, MD, USA] no. 103) cells were
maintained in Dulbecco's modified Eagle medium (DMEM; Gibco, Rockville
Md, USA) containing 10% fetal calf serum (FCS, Delta Bioproducts, Kempton
Park, RSA), 100mg/L penicillin (Novo-Pen, Novo Nordisk (Pty) Ltd,
Johannesburg, RSA) and 100mg/L streptomycin (Novo-Strep, Novo Nordisk
(Pty) Ltd) (designated 10% DMEM) at 37°C, 95% humidity and 5% CO2.
Transfections
When cells had grown to a confluence of approximately 70%, they were
treated with 0.25% active trypsin versene (ATV; 2.5g/L trypsin, 0.38g/L EDTA,
0.4 gIL KCI, 8 gIL NaCI, 0.35 gIL NaHC03, 0.01g/L Phenol Red) until they
detached from the flask sufficiently and washed once in 10% DMEM. Live
cells stained with 0.4% trypan blue (Gibco, Invitrogen, CA, USA) were counted
and cells were plated one day prior to transfection at a cell density of 1.4 X
106 cells per 35mm-diameter well (Corning, Schiphol-Rijk, The Netherlands) in
2ml 10% DMEM. For transfections, the 10% DMEM was replaced with serum-
free medium (OPTlmem I Reduced Serum Medium, Gibco, Rockville Md,
USA). Cells were transfected with 2j.Jgof plasmid DNA mixed with 10j.J1Mirus
TranslT-L T1 polyamine transfection reagent (Panvera, Madison, WI, USA) in
100j.J1OPTlmem per well. Transfected cells were incubated for five hours after
which the OPTlmem was replaced with 10% DMEM.
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Cell lysate harvesting
Twenty-four hours posttransfection the cells were washed twice in sterile
phosphate buffered saline (PBS) and then lysed with Reporter Gene Assay
Lysis Buffer (Roche, Mannheim, Germany) following the manufacturers
protocol (Appendix I). Cell Iysates were frozen at -7CfJC or used immediately.
2.7.3 Western Blotting
Electrophoresis and transfer
Eighteen microlitres of 293-cell lysate or 10~1 of Full-Range Rainbow Marker
(Amersham-Pharmacia Biotech, Buckinghamshire, UK), added to 2.5~1
NuPage Sample Reducing Agent and 6.5~1 Nupage SOS Sample Buffer, were
loaded on a NuPage Novex 4-12% BisTris SOS gel (Invitrogen, Groningen,
The Netherlands). Electrophoresis was performed in NuPage MOPS SOS
running buffer containing 0.1 % NuPage Antioxidant at a constant current of
115mA until the running front of the sample buffer had reached the bottom of
the gel. Following electrophoresis, the proteins were transferred onto a
nitrocellulose membrane (O.2~m pore size, Invitrogen) in NuPage Transfer
Buffer containing 10% Methanol at 150mA constant current for 60 minutes.
Blotting
Nitrocellulose membranes were rinsed in 1X PBS and blocking was performed
at 4°C for 16 hours in 1X PBS containing 0.1% Tween and 0.3% Bovine
Serum Albumin (BSA) DiluenUBlocking Solution (KPL, MD, USA). Blotting was
performed in the above mentioned blocking solution containing 0.0025% 293
cell extract, prepared by lysis of untransfected 293 cells as described, as well
as the previously prepared respective polyclonal mouse serum at a dilution of
1:250 (Section 2.5). As no positive protein control was available for Nef, these
Iysates were also blotted with subtype B (HIV-1JR•csF) Nef-specific monoclonal
antibody (NIH AIDS Research and Reference Reagent Program) at a dilution
of 1:1000. The secondary antibody in the same blocking solution containing
293 cell extract was horseradish peroxidase (HRP)-conjugated Goat anti-
Mouse IgG (Zymed, San Francisco, USA) at a dilution of 1:10 000. The
protein bands were visualized by chemo-Iuminescence using ECLPlus and
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2.8 Functionality Assays
2.8.1 TAT
Background
To determine the degree to which Tat mutants are able to perform the function
of transactivating the HIV-1 LTR, a transient reporter assay in which a reporter
plasmid pLTR-CAT previously described by Peterlin et al. (1986) was
cotransfected with tat variant plasmids as described by Kuppuswamy et al.
1989 and Neuveut et al., 1996. The plasmid pLTR-CA T contains the reporter
gene chloroamphenicol acetyl transferase (CAT) under the promoter control of
the amended HIV-1 LTR and with the SV40 polyadenylation signal (pA). The
HIV-1 5' LTR was amended by deletion of selected promoter elements to
leave the HIV enhancer, Sp1 binding sites, TATA box and TAR sequences,
rendering CAT expression from the pLTR-CAT plasmid virtually exclusively
Tat dependent (peterlin et ai., 1986). Figure 12 depicts the pLTR-CAT
reporter plasmid. Cotransfection of Tat with the pLTR-CAT reporter plasmid
thus provides a good system in which the level of CAT expression gives a
quantitative measure of the ability of that Tat protein to transactivate
transcription from the HIV-1 LTR in a subgenomic transient system.
Functionality assay
RD, COS-7 and HeLa cells were plated one day prior to transfection at a
density of 1 X 106 cells and 293T at 1.4 X 106 cells per 35mm well. Cells were
cotransfected with 1IJg tat plasmid DNA and 1IJg pLTR-CAT reporter plasmid
DNA (and 0.51Jg pSV-pGal (Promega, Madison, WI) internal control vector for
assays in HeLa cells) per 35mm well as described previously. Transfections
were always done in duplicate wells. Twenty-four hours posttransfection the
cells were washed with chilled PBS and lysed using 1X CAT ELISA lysis
buffer as described by the manufacturer (Roche Diagnostics, GmbH,
Germany). CAT enzyme levels in cell Iysates were determined using a CAT
ELISA and following the manufacturer's protocol (Roche Diagnostics, GmbH,
Germany, Appendix I). Transfection efficiency was controlled for by assaying
for p-galactosidase activity usirig the p-Galactosidase Enzyme Assay
(Promega, Madison, WI), following the manufacturer's protocol (Appendix K).
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Figure 12: Diagrammatic representation of the pLTR-CAT
reporter plasmid. The chloroamphenicol acetyl
transferase (CAT) gene is under the promoter
control of the Tat-dependent HIV-1 LTR and the
simian virus 40 polyaden~ation signal (pA).
2.8.2 REV
Background
Functional intactness of the Rev variants was determined by detecting the
ability of the Rev proteins to export unspliced or partially spliced rev-
responsive element (RRE)-coupled chloroamphenicol acetyl transferase
(CAT) transcripts from the cell nucleus to the cytoplasm. This assay has been
used extensively to determine the functional activity of HIV-1 Rev and was first
described by Hope et al. (1990a). The reporter plasmid pDM128 was a kind
donation from Prof. Thomas Hope (Chicago College of Medicine, University of
Illinois, Chicago, IL, USA). The pDM 128 plasmid contains the CAT gene,
which was inserted into the truncated HIV-1 genome, upstream of the HIV-1
RRE (Hope et a/., 1990a). This entire transcription unit, which is flanked by
splice donor and acceptor sites was inserted downstream of the simian virus
40 (SV40) promoter/enhancer and subeloned into the pUC18 plasmid to
produce pDM128 (Figure 13). Cells transfected with pDM128 alone translate
only fully spliced transcripts in the cytoplasm and thus yield only trace levels of
CAT enzyme as the cellular splicing events have cleaved the CAT coding
region from the promoter/enhancer elements. However, cotransfection with a
functional Rev expression vector allows Rev-mediated nuclear export and
subsequent expression of unspliced or partially spliced transcripts, increasing
CAT levels 75-100 fold (Hope et a/., 1990a).
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SO SA
FIgure 13: Diagrammatic representation of the pDM128 reporter plasmid.
The rev-responsive element (RRE)-coupled transcription unit
contains the CAT reporter gene under the control of the SV40
promoter and the HIV-1 transcription terminator, the 3'LTR.
The splice donor (SO) and acceptor (SA) sites are indicated.
Functionality assay
The pSV-~Gal reporter plasmid (Promega, Madison, WI), which expresses the
enzyme ~-galactosidase under the control of the Rous sarcoma virus (RSV)
promoter, was used as intemal transfection control. 293T cells were
cotransfected with 0.51Jg pSV-~Gal, 1IJg pDM 128 and 1IJg of the respective
rev variants in duplicate 35mm wells as described before. Cell Iysates were
harvested 24-hours posttransfection and CAT expression was determined
using a CAT ELISA as described before. Transfection efficiency was
controlled for by assaying for ~-galactosidase activity using the ~-
Galactosidase Enzyme Assay (Prom ega, Madison, WI), following the
manufacturer's protocol. The assay was done is triplicate.
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2.8.3 NEF
Background
As reviewed in chapter 1, the functional activity of Nef is multi pronged and
mediates several cellular events. Here, the CD4 and MHC-I down-regulation
activities of Nef were determined using an assay previously described (peng
and Robert-Guroff, 2001; Goldsmith et al., 1995). As 293 cells do not naturally
express CD4 on their cell surface, cells were transfected with a CD4
expressing plasmid to determine whether a cotransfected Nef variant would
be able to downregulate the level of surface CD4 expression.
Functionality assay
293 cells were cotransfected with 0.51Jg of the human CD4 expressing
plasmid pcDNA_hCD4 and 1IJg Nef expression plasmid DNA per 35mm well
as described previously. Forty-eight hours posttransfection, the cells were
washed with chilled PBS and treated with 2% EDTA to detach the adherent
cells from the plate surfaces. Subsequently, the cells were washed in PBS
containing 0.25% BSA (FACS staining buffer, SB) and stained with
allophycocyanin (APC}-conjugated anti-human CD4 antibodies and R-
phycoerythrin (PE)-conjugated anti-HLA-A,B,C monoclonal antibody (BD
Biosciences, San Diego, CA, USA) specific for MHC class I, which is naturally
expressed on the surface of 293 cells. Analysis of PE (second fluorescence)
and APC (fourth fluorescence) fluorescence was performed on 100000 cells
(events) gated by side scatter and forward scatter on a FACSCalibur flow
cytometer (Becton Dickinson Immunocytometry Systems).
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CHAPTER3:RESULTS
3.1 Design and construction of expression plasm ids
Codon-optimisation and sequence analysis
The codon usage of the gene constructs encoding the HIV-1 subtype C
consensus Tat, Rev and Nef proteins was optimised for high-level expression
in mammalian tissues by altering it to that of highly expressed human genes
as described by Haas et al (1996b) and Andre et al. (1998). Alignments of the
nucleotide and amino acid sequences of all expression constructs are
attached in Appendix A. The percent GC contents of the wild-type and
codon-optimised tat, rev and net genes are plotted along their coding
sequences in Figure 14. As can be clearly distinguished, a marked increase
in percent GC content was observed after codon optimisation across the
entire coding regions of the three genes. Taken as a mean value for each
reading frame, the percentage GC content was raised from an approximate
level of 50% in the wild-type genes to approximately 70% for codon-optimised
tat, rev and net genes (Table 12). These levels are consistent with increased
mRNA stability and translation efficiency (Haas et aI., 1996b; Hentze, 1991).
Table 12: Levels of 'YeGCcontent for the wild-type and oodon-optimised genes.
% GC content
wild type codon optimised
Difference
Tat
Rev
Nef
48%
52%
47%
67%
74%
68%
19%
22%
21%
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Figure 14: Comparison of GC content percentages between the wild-type (black) and oodon optimised (grey) nef, tat and rev genes
at a step size of 20 nucleotides along the ooding sequences, Calculation of the percentages was done manually,
Tat, Rev and Nef amino acid distances between the fourteen HIV-1 subtype C
isolates from Tygerberg Virology (TV) that were sequence characterised and
the South African subtype C TV consensus (TV Cons) were calculated using
two different protein distance models (Kimura and PAM) as described in
Materials and Methods. The distances between each viral isolate and the
consensus sequence were plotted for each protein in Figure 15. Although
small differences were distinguishable between the two distance models, the
amino acid distances calculated using the Kimura and PAM models between
each isolate and the TV Cons correlated well. The viral isolate that was least
dissimilar from the South African consensus (TV Cons) was selected as wild-
type for the Tat (TV019) and Nef (TV002) constructs.
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Figure 15: Amino acid distances between South Alrican subtype C viral isolates from Tygerberg Virology (TV) and the consensus
sequence drawn up from them (TV Cons) lor the Tat, Rev and Nel proteins. Genetic distances were calculated using the
PHYLIP program PROTDIST and the results obtained from the two distance models Kimura and PAM are compared. The
TV isolate, which was selected lor construction ol the wild-type construct lor the respective gene, is indicated with a "WT'.
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Although isolate TV005 displayed the least dissimilarity relative to TV Cons for
its Rev protein, this isolate did not contain the characteristic subtype C Rev
truncation (Appendix C; (Scriba et aI., 2002)) and was thus not selected as
wild-type rev because it did not encode a conventional subtype C Rev protein.
Several isolates including TV007, TV010, TV013 and TV018 displayed low
dissimilarity to TV Cons and additional analyses had to be performed to
differentiate between them in order to chose a wild-type candidate (see
below).
Subtype B HXB2-rooted phylogenetic trees representing the evolutionary
relationships of the Tat, Rev and Nef proteins between the South African
subtype C TV isolates and all reference subtype C protein sequences in the
HIV sequence database as well as additional sequences from Botswana,
India, South Africa and other geographic origins were constructed (Figure 16).
Five consensus sequences representing the TV isolates (TV Cons), southern
African (Botswana and South Africa) sequences (sA Cons), Indian isolates
(India Cons), the subtype C consensus available from the Los Alamos HIV
sequence database (CONS C) as well as one representing all these subtype
C sequences (Campi Cons) were drawn up as described in Materials and
Methods and were also included in the trees. The Phylip PROTOIST program
with the Kimura distance matrix (Kimura, 1980) was used to calculate genetic
distances and the tree topologies were inferred using the Phylip package
neighbor program. All three phylogenetic trees share the following properties:
the TV isolates and other South African sequences were dispersed across the
entire tree topologies; sequences from India (including the India Cons) formed
monophyletic clusters with single exceptions; and non-Indian consensus
sequences clustered closely together. Specifically, the TV Cons, sA Cons,
Campi Cons and CONS C sequences clustered as monophyletic clades in the
Tat and Nef trees. The Rev tree showed similar clustering of the TV Cons and
sA Cons, while the Campi Cons and CONS C clustered from a different
branch along with four viral isolate sequences. The consensus sequences fall
closer to the "backbone" of the three trees than virtually any single sequence,
demonstrating similarity to the so-called "ancestral sequence", which would
represent the ancestor of the HIV-1 subtype C. The wild-type TV isolates fall
relatively close to the TV Cons in the three trees and notably TV010 falls into
the TV Cons and sA Cons cluster in the Rev tree, warranting its selection as
wild-type Rev over the other similar isolates.
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Figure 16: Phylogenetic trees constructed with Tat (page 65), Rev (page 66) and Nef (page 67) amino acid
sequences representing viruses from Tygerberg Virology (TV), additional South African, Botswana,
India and other geographic origins. The TV isolates are in red and the five consensus sequences and
TV isolate selected for construction of the wild type plasmids are in boldface and boxed in grey. The
trees are rooted with the subtype B reference sequence HXB2 and horizontal branch lengths
represent genetic distance. Vertical branches are for clarity only and distance scales represent 0.1
residue replacements per site.
Of mention is the common phenomenon of short "backbone" branches
compared to the terminal branches of the Tat, Rev and Nef trees. These short
"backbones" accompany weak bootstrap support of the tree branching
implying unreliable topologies. For this reason, only single bootstrap values
represented significance and these were omitted from the phylograms as they
were all towards the terminal branches of the trees. Nevertheless, the trees
give a good representation of genetic distance between viral strain and
consensus sequences and demonstrate the dispersed nature of Tat, Rev and
Nef protein sequences from subtype C viruses originating from southern
Africa.
The amino acid distances between the TV Cons and the four other consensus
sequences as well as the isolate chosen as wild-type were determined using
the Kimura and PAM distance models and are plotted in Figure 17. As
supported by both models, the distance plots for Tat, Rev and Nef, which are
represented as single stacked bars for each sequence, show that the stacked
TV Cons, on which the Tat, Rev and Nef immunogens in this study are based,
is least dissimilar to the consensus representing sequences from southern
Africa (sA Cons). Significantly, these two consensus sequences differed by
only single amino acid residues for Tat and Nef. The overall ascending order
of dissimilarities of the different consensus sequences to the TV Cons were
sA Cons < Compl Cons < CONS C < India Cons. Notably, the stacked
distances representing the wild-type TV isolates, which were selected on the
grounds of being the closest individual isolate sequence to the TV Cons, were
only smaller than those of the India Cons, and markedly more distant than the
sA Cons and Compl Cons sequences. Amino acid distances of the Tat and
Nef proteins were quite similar while Rev displayed more distance and thus
dissimilarity than Tat and Nef.
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Figure 17: Stacked amino acid distances calculated with the Kimura and PAM distance models between
the TV consensus (TV Cons), which was used lor construction ol the codon-optimised Tat,
Rev and Nel variants, and lour other consensus sequences as well as the respective isolates
selected lor the wild-type constructs. See above for description ol various consensus
sequences.
Figure 18 shows the percentage similarities of the Tat, Rev and Nef protein
sequences of the fourteen individual TV isolates versus the TV Cons (red
lines) and the respective viral isolate chosen as wild-type (black lines) versus
the fourteen individual TV isolates along the alignments of the proteins.
Although not dramatic, all three plots demonstrate that the TV Cons is on
average more similar to individual protein sequences than the viral isolate
sequence of the wild-type strains is. It should be noted that the wild-type
sequences were chosen on the grounds of being most similar to the TV Cons
which means that if other individual isolate sequences were compared as
query sequence, possibly even less similarity would be displayed.
This phenomenon is more clearly illustrated when the amino acid distances of
the consensus sequences TV Cons and sA Cons or the individual HIV-1
subtype C isolates from Tygerberg Virology (TV isolates) versus the panel of
fourteen TV isolates were calculated for each protein with the Kimura distance
matrix. The values of the distances between each sequence and the panel of
14 TV sequences were added together for Tat, Rev and Nef and are
illustrated as stacked bars in Figure 19. As is clearly evident, the two
consensus sequences TV Cons and sA Cons display markedly less sequence
69
Stellenbosch University http://scholar.sun.ac.za
dissimilarity to the fourteen TV isolates than any individual TV isolate does for
Tat, Rev and Nef as stacked and individual bars.
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Figure 18: Similarity plots ol Tat, Rev and Nel amino acid sequences in which the percentage similarity ol the TV Cons versus TV
isolates (red lines) and wild-type sequence (Tat: TV019. Rev: TV010, Net. TV002) versus TV isolates (black lines) are
compared. The program SIMPLOT was used with step sizes ol 20 lor Tat and Rev and 40 lor Nel and a window size 0140.
Gaps were excluded from the alignments.
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Figure 19: Stacked bar plot illustrating the sum of genetic distances between the Tat (grey bars), Rev (white bars) and
Nef (black bars) amino acid sequences of the indicated isolate or consensus sequence and the panel of
fourteen HIV-1 subtype C isolates from Tygerberg Virology (TV isolates). Amino acid distances were
calculated with the Kimura distance matrix.
3.2 Expression of proteins
In vitro expression of all plasmid constructs in 293 cells was assessed by
sodium dodecylsulphate (SOS) gel electrophoresis and Western blotting. Cells
were transfected with 2~g plasmid DNA per 35mm well as described and cell
Iysates were harvested 24-hours posttransfection.
3.2.1 Tat
In vitro expressed Tat protein was detected by immunoblot analysis using
mouse serum that was generated by immunisation of CB6F1 mice with
plasmid DNA of construct pCMVKm2-Tatc22C37. The polyclonal mouse serum
was immunoreactive with single protein bands in Tat-transfected 293 cell
Iysates that were subjected to SOS polyacrylamide gel electrophoresis (SOS-
PAGE; Figure 20). No corresponding protein band was immunoreactive in
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mock-transfected 293 cell Iysates. A comparison of the expression levels of
the four codon-optimised Tat variants is shown on blot A in Figure 20. As can
be seen, the band intensities for the four Tat proteins are virtually identical,
indicating very similar expression levels. In addition, the codon-optimised Tat
proteins migrated at the same rate, which is consistent with these expression
constructs encoding reading frames of identical length (101 amino acids). A
comparison of expression levels of the codon-optimised tat constructs with the
plasmid construct encoding the wild type Tat protein of subtype C isolate
TV019 is shown on blot B in Figure 20. The TatwT (101 amino acids) band co-
migrated at the same rate as the codon-optimised Tat proteins. Although it
appears as if the wild-type Tat protein band is somewhat fainter than those of
the codon-optimised Tat proteins as also exhibited on Blot C in Figure 21, the
observed difference is not substantial enough to note a significant difference
in expression levels.
To determine whether the mouse serum would be immunoreactive to a
previously described Tat protein, ceillysates were electrophoresed along with
Tat protein obtained from the NIH AIDS Research Reference and Reagent
Program (Figure 21). Although this protein is encoded by the HIV-1 subtype B
virus HXB2 (Ratner et ai., 1985), the subtype C Tat-specific serum was
reactive to three separate, albeit somewhat smudged protein bands.
Figure 20: In vitro expression of Tal plasmid constructs and mock-transfected cells as delecled by
immunoblolling with Tal-immunised mouse serum. BioI A displays expression levels for the
four codon-optimised Tal variants TaIoPT, Tab2, Talc37 and Tab2C37. BioI B shows the
comparalive expression level between the wild-type Tal conslrucl Tafwr and the codon-
oplimised Tal Variants.
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Figure 21: Calculation of Tat protein size by plotting the molecular weight (Mr) versus the relative mobility
(Rf) of the Full-Range Rainbow Molecular Weight Marker. (A) The Tat protein control yielded 3
bands indicated on the blot by the arrows marked 1 - 3. (B) The Mr of the different subtype C
Tat variants were calculated from the distances migrated and are plotted on the standard curve
as hollow squares (mon, monomer; dim, dimer; subtype C Tat variants; the Tat control band 2
comigrated with the 10kDa marker protein). (C) Tabulated Rf and Mr of the different protein
bands.
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Calculation of molecular weight of the Tat protein bands was performed as
described in Current Protocols in Immunology (2000). The known log
molecular weight (Mr) of the Full-Range Rainbow Molecular Weight Marker
(Amersham Pharmacia Biotech, Buckinghamshire, UK) was plotted versus the
relative electrophoretic mobility (Rt) as measured on Tat blot C (Figure 21).
The Rt is defined as the difference between the distances migrated by the
query protein and that of the electrophoretic front. The Rt of all Tat protein
bands was plotted on the x-axis and interpolated onto the y-axis (0; Figure
21) to read off the corresponding molecular weights of the proteins. The
approximate Mr (y-intercept) of the wild-type and codon optimised Tat proteins
was thus calculated as 18 kDa, while the three control Tat protein bands were
calculated to migrate at rates corresponding to approximately 25 kDa, 14 KDa
and 10 kDa.
3.2.2 Rev
Similarly to Tat, expression levels of the codon-optimised and wild-type rev
expression plasmids were determined by immunoblotting with pooled antibody
serum raised in mice that were immunised with pCMVKm2RevM5M1o plasmid
DNA. As a positive control, 4IJg recombinant wild-type Rev protein, encoded
by the subtype B HXB2 virus (Arya et aI., 1985) (Cat No. 1457, NIH AIDS
Research and Reference Reagent Program, Rockville, MD), was analysed
along with the 293 cells Iysates. The mouse serum was immunoreactive to
single bands in RevwT- and RevM5M1o-transfectedcell Iysates (arrows) as well
as the recombinant Rev control protein (Figure 22). No corresponding protein
was reactive in the mock-transfected 293 cell Iysates. In vitro expression
levels of the codon-optimised, mutated Rev was markedly higher than the
wild-type Rev as indicated by the greater band intensity of the RevM5M1o
protein. Interestingly, the mutant RevM5M1oprotein migrated more rapidly than
the wild-type Rev, while the subtype B recombinant Rev protein, which was
used as positive control migrated even slower than the two subtype C Rev
proteins.
The molecular weights of the Rev proteins were determined by measuring the
relative mobility of the Rev protein bands to calculate the Mr by plotting Mr and
Rt of the High Range Molecular Weight Marker (Amersham Pharmacia
Biotech, Buckinghamshire, UK) (Figure 23). Thus the codon-optimised,
mutated RevM5M1omigrated at an Rt representing approximately 14.5 kDa
while the wild-type Revwt migrated slower than RevM5M1o,to lie at an
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approximate 17 kDa. The subtype B recombinant Rev control protein had an
approximate molecular weight of 18kDa.
Rev
Protein
45K~
2O.1K·
14.3K-
3OK-
Figure 22: Immunoblot showing in vitro expression of the Rev expression constructs as well
as mock-transfected cells. The Rev protein bands are indicated by the arrows.
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Figure 23: Molecular weight detennination of Rev proteins using a standard curve plotted
from the relative mobility and molecular weight of the High-Range Rainbow
Molecular Weight Marker proteins as detected in the Rev imrnunoblot (Figure
22). The interpolated relative mobility of the Rev proteins are also plotted (opt-
RevM5Ml0,wt - RevwT, Prot - Control Rev Protein).
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3.2.3 Nef
Similarly to Tat and Rev, Nef expression was assessed by SOS-PAGE and
immunoblotting using subtype C Nef-specific mouse serum. As can be seen in
Figure 24 Blot A, the mouse serum was not immunoreactive to any distinct
protein bands in mock-transfected 293 cells. Reactivity was observed to
proteins in cell Iysates prepared from NefwT, NefoPT, Nef.myrD124and Nef.
myrD124LLAA-transfected293 cells. As no positive protein control was available,
the proteins were also blotted against a known subtype B (HIV-1JR.csF) Nef-
specific monoclonal antibody (NIH AIDS Research and Reference Reagent
Program, Rockville, MD) (Blot B), to which they were all immunoreactive. The
codon-optimised nef genes appeared to express at somewhat higher levels
than the wild-type nef gene from isolate TV002 as indicated by band
intensities. Notably, the wild-type Nef protein migrated more rapidly than the
mutant and native codon-optimised Nef proteins, which migrated somewhat
faster than the 30kDa protein standard. All four nef constructs encoded
proteins consisting of 208 amino acids (Appendix A). Molecular weight
determination of the Nef proteins was done as described for the Tat and Rev
proteins by plotting a standard curve with the known molecular weights of the
Full-Range Rainbow Molecular Weight Marker (Amersham Pharmacia
Biotech, Buckinghamshire, UK) and the Rt of these proteins. The relative
electrophoretic mobilities of the wild-type and codon-optimised Nef proteins
were interpolated onto the standard curve (Figure 25) and the molecular
weights were determined to be as follows: NefwT migrated to an approximate
26 kDa while the codon-optimised Nef proteins migrated to an approximate 28
kDa. The bands of the codon-optimised proteins were relatively thick and the
Rt was read off from the estimated centre of the protein band.
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Figure 24: Immunoblots showing in vitro expression of the wild-type (WT) and codon optimised Nef expression constructs as well as
mock-transfected cells, Proteins on Blot A were immunoreactive to the polyclonal mouse serum whereas blot B was blotted
with a Nef-specific monoclonal antibody, The Full-Range Rainbow Molecular Weight Marker was included and the protein
bands of the standards are demarcated with their molecular weights,
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Figure 25: Calculation of the molecular weights of the wild-type and codon-optimised Nef
proteins. The standard curve was plotted from the known molecular weights of
proteins from the Full-Range Rainbow Molecular Weight Marker (Amersham
Pharmacia Biotech, Buckinghamshire, UK) and their relative electrophoretic mobility
(Rf), The interpolated R,of the NefwTand NefoPTare shown as hollow squares,
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3.3 Functionality Assays
3.3.1 Tat
The transactivation activities of the different Tat variants were assessed in an
in vitro reporter assay previously described by Kuppuswamy et al. (1989). Tat
variants were cotransfected with the pl TR-CAT plasmid, which encodes the
reporter gene chloroamphenicol acetyl transferase (CAT) under the control of
Tat-dependent promoter elements of the HIV-1 lTR (Petertin et aI., 1986).
Preliminary experiments
A round of preliminary experiments, in which a limited number of tat plasmids
were tested in various cell lines, was performed to compare the transactivation
assay in these cell lines. CAT enzyme levels in cell Iysates that were
cotransfected with the functional Tat-expressing plasmid SF162-Tat (Tat from
HIV-1 subtype B isolate SF162, Chiron Corporation) were set to 100% Tat
activity for each cell line and CAT levels in the other cell Iysates were
calculated as a percentage of SF162-Tat activity. It was found that mock-
transfected cells and cells transfected with the pl TR-CAT reporter plasmid
only were unable to induce CAT expression in single experiments in RD,
COS-?, 293T and Hela cells (Figure 26). As expected, CAT expression was
induced in all four cell lines when pl TR-CAT was cotransfected with the
subtype B expressing Tat-expressing plasmid SF162-Tat. Cotransfection with
the Tatc22plasmid also induced strong CAT expression in COS-?, 293T and
Hela cells and at a lower level in RD cells, while Tatc22c37seemed to be
unable to induce transactivation of CAT expression in RD, 293T and Hela
cells (not done in COS-? celis). Although only a single repeat was done of
these preliminary experiments, the results served in showing that the four cell
lines displayed similar systems in which comparable transactivation results
seemed to be obtained. As these experiments were completed at Chiron
Corporation in Emeryville, California and had to be reproducible in the
laboratory at the Department of Medical Virology at Tygerberg in South Africa,
availability of cell lines had to be considered and the Tat functionality
experiments were thus done in 293T and Hela cells.
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Figure 26: Preliminary Tat transactivation assays in RD, COS-7, 293T and Hela oells. The CAT expression levels are presented
on the y-axis as a peroentage ol that in oells that were transfected with SF162-Tat (set to 100% ,. ND, not determined.
Transactivation of Tat in 293T and HeLa cells
Subsequent Tat plasmid cotransfections with the pl,TR-CAT reporter plasmid
in 293T and Hela cells were performed independently in triplicate and while
those in 293T cells were not, the assays in Hela cells were controlled by
cotransfection with the internal transfection control plasmid pSV-pGal, a
plasmid expressing the common reporter protein p-galactosidase. The raw
data of CAT enzyme and p-galactosidase levels in Hela cells as well as the
normalisation of CAT enzyme levels are included as Appendix B. The results
of these experiments in the two cell lines are presented separately in terms of
CAT levels for each experimental repeat in Figures 27 and 28 for 293T and
Hela respectively. In addition, the mean, standard deviation and standard
error, the latter of which is also plotted on the graphs, are tabulated in both
figures. The results in 293T and Hela cells confirmed the preliminary data by
showing that mock-transfected cells and cells transfected with the reporter
plasmid alone showed no induction of CAT expression. Furthermore, an
induction in excess of 230-fold was observed when pl TR-CATwas
cotransfected with the plasmids TatwTand TatoPTin 293T and Hela cells as
well as SV40-Tat in 293T cells.
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Figure 27: Transactivation activity of the Tat constructs in 293T oells. The mean CAT enzyme conoentrations along with the standard
error for three independent experiments are plotted on the graph. The individual CAT enzyme levels, the mean, standard
deviation and standard error are tabulated above. Tatwr was assayed only onoe while only two repeats were done of SV40-
Tat and Ta1c37.NfA, not applicable; NfD, not determined.
As indicated by the single preliminary repeats in 293T, Hela, RD and COS-7
cells, cotransfection of pl TR-CAT with Tatc22 strongly induced transactivation
of CAT expression by more than 160-fold in both 293T and Hela cells, while
cells cotransfected with the double mutant Tatc22c37 showed negligible
induction of CAT expression in both cell lines. Moreover, negligible induction
of CAT expression was also recorded in both cell lines by cotransfection with
the plasmid encoding the singly mutated Tat protein Tab7.
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Figure 28: Transactivation activity ol the Tat constructs in Hela cells. Again, the individual (3-galactosidase normalised CAT enzyme
levels, the mean, standard deviation and standard error are tabulated and the mean and standard error for the three
independent experiments are plotted on the chart. For (3-galactosidase raw data and normalisation ol CAT enzyme values,
see Appendix B. NO, not done.
These Tat functionality results are expressed as a percentage of native Tat
(TatoPT, set to 100%) activity in Figure 29. As the difference in expression
levels between the two cell lines is eliminated by presenting the data this way,
the assays in 293T and Hela cells could be compared directly. As already
evident from the reported CAT expression levels, analogous transactivation
activity levels between 293T and Hela cells were recorded for all constructs,
except SV40-Tat, which was not done in Hela cells.
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Figure 29: Mean transactivation activity of the Tat variants in 293T and Hela (l3-gactosidase normalised) cells as expressed in
percent native (unmutated, codon-optimised TaIoPT,set to 100%) Tat activity. Error bars represent the standard error for
three independent experiments. TalwT was only assayed once in 293T cells (1 rep) and SV40·Tat was not tested in Hela
cells (NO).
3.3.2 Rev
The functional activity of the Rev variants was assessed by determining the
level of the reporter enzyme chloroamphenicol acetyl transferase (CAT) in
293T cell Iysates, which is indicative of the efficiency of RRE-coupled CAT
transcripts to be exported from the nucleus by the Rev protein (first described
by Hope et al. (1990a), who also kindly provided the pDM128 and pRSV-Rev
plasmids). The ~-galactosidase-normalised CAT levels from three
independent experiments are tabulated and plotted in Figure 30. The raw
data of CAT enzyme and ~-galactosidase levels that were used to calculate
these normalised CAT enzyme values are included as Appendix B. The
mean, standard deviation and standard error (error bars on chart) for the three
experiments are also tabulated in Figure 30. These values are also expressed
as a percentage of wild-type Rev activity in Figure 31. The results show that
mock-transfected 293T cells as well as cells transfected with the pDM128
reporter plasmid only yielded no more than basal CAT expression levels. Cell
Iysates of cells cotransfected with the subtype B Rev-expressing plasmid
pRSV-Rev displayed strong CAT expression while the wild-type subtype C
Rev-transfected cells yielded somewhat lower albeit noteworthy levels of CAT
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(taken as 100% in Figure 31 as no codon-optimised, native Rev plasmid was
constructed). Taken from the mean and compared to cells transfected with
pOM128 only, cotransfection with pRSV-Rev induced an increase in CAT
expression greater than 85-fold while RevwT induced a 25-fold increase. In
contrast, cells cotransfected with the codon-optimised, mutant RevM5M10
plasmid displayed no induction of increased CAT levels in any of the three
experiments. The significance of these results is highlighted by the small error
bars seen for the three experiments when expressed as normalised CAT
levels and especially when expressed as percentage of wild-type Rev activity.
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Figure 30: Rev nuclear export activity of RRE-coupled CAT mRNA as deterrrined by CAT levels in 293T cells. Three independent
repeats were performed and the CAT levels were normalised for the internal control ~-galactosidase (for raw data and
normalisation, see Appendix B). The CAT enzyme levels as well as the mean, standard deviation and standard error of the
maan are tabulated above. The pRSV-Rev control plasmid was not included in one experiment repeat (N/D).
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Figure 31: In vitro functional Rev activity expressed as percenlage of wild-type activity, which was sella 100% (no codon-optimised,
native Rev). The error bars represent slandard errors for three independent experiments.
3.3.3 Net
Functional activity of the Nef proteins was analysed by flow cytometric
determination of CD4 and MHC-I expression on the surface of 293 cells 48-
hours after cells were cotransfected with a CD4-expressing plasmid (pcDNA-
hCD4) and the corresponding Nef-expressing vector. Cell surface CD4 was
stained with APC coupled anti-CD4 antibodies, while MHC-I was stained with
PE-coupled anti-HLA A,B,C antibodies. To select single 293 cells of specific
size and composition, cells were gated on dot and density plots, which sort
cells according to size on a forward scatter scale and according to granularity
on a side scatter scale. The cells that were used for CD4 and MHC-I analysis
fall within the gate demarcated R1 in Figure 32.
Because 293 cells do not naturally express CD4 on their cell surface, these
cells had to be transfected with a CD4-expressing plasmid (pcDNA-hCD4) to
study Nef-mediated CD4 downregulation. Figure 33 shows the number of
cells cotransfected with empty pCMVKm2 vector (vector), NefOPT or Net.
myr0124LLAA, showing CD4 APC fluorescence at intensities ranging from 0 to 104.
By using these plots, cells that fluoresce at levels of 101 or higher
(demarcated as M1) were set as positively CD4 expressing cells and could be
measured as a fraction (percentage) of the total number of gated cells.
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Figure 32: Flow cytometric analysis ef 293 oolls shown as oot plot (A, 10% of oolls shewn) and density plot (B). MHC-I PE and
CD4 APC fluoresoonoo was determined on oolls gated (Rl) by ferward scatter and side scatter, which discriminate
between oolls on the grounds ef size and granularity respectively.
Plot A in Figure 33 illustrates the comparative CD4 expression profiles of cells
cotransfected with empty vector (grey area) and cells transfected with the
functional Nef-expressing plasmid NefoPT (area below/outlined in black). From
the graph areas and data output it was determined that 34% of vector-
transfected cells typically expressed CD4 while only 9.3% of NefoPT-
transfected cells expressed CD4, indicating a marked Nef-mediated
downregulation of cell surface CD4.
~~------~------------------~
Figure 33: Flew cytometric determinatien ef percentage CD4 expressien en forward and side scatter-gated 293 cells, APC
fluorescenoo above 1 leg (101) was set as CD4 pesitive (demarcated as Ml). Thirty-feur percent ef cells
cotransfected with pCMVKm2 vector, shewn in grey, were CD4 posltvs, while these cotransfected with NefoPT (A)
and Nef-myr0124LLAA(B) displayed 9.3% and 40% CD4 expressien respectively (be lew /eutlined in black).
From plot B, it can be seen that typically 40% of cells cotransfected with the
non-functional Nef variant Nef_myrD124LlAAexpressed CD4, indicating no CD4
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down regulation. These flow cytometric analyses were done for cells
cotransfected with all Nef variants and the results of three independent
experiments, expressed as percent CD4 expression of cells cotransfected with
empty pCMVKm2 vector (set to 100%) are presented in Figure 34. To
compare the way in which the flow cytometry data was recorded and
interpreted, the CD4-APC mean fluorescence was also recorded and is
included in Figure 34 on the chart in black and the values for the three
independent experiments in brackets in the table. Only base-level CD4
fluorescence was detected in mock-transfected cells and as expected, CD4
down regulation was observed in cells cotransfected with the functional Nef-
encoding plasm ids NefwT and NefoPT. Notably, NefoPT, which encodes the
subtype C consensus (TV Cons) Nef protein, downregulated CD4 by up to
70%, while the wild-type Nef protein mediated a reduction in CD4 expression
by approximately 50%. Both mutants exhibited abrogation of this activity
compared to the unmutated Nef proteins. However, Nef.myr0124still appeared to
mediate an approximate 20-30% downregulation, depending on the method of
data readoff (% CD4 expression vs mean fluorescence). CD4 surface
expression in Nef.myrD124lLAA-transfectedcells was comparable to that of cells
transfected with vector, indicating complete abrogation of functional CD4
downregulation activity. Although not identical, the CD4 expression values that
were recorded as percentage CD4 positive cells and those recorded as mean
APC fluorescence were very comparable and exhibited the same results in
terms of NefwT and NefoPTdownregulating cell surface CD4 dramatically while
Nef.myrD124downregulated CD4 expression to a small degree. Similarly,
Nef.mYr0124lLAAexhibited no CD4 downregulation activity. The significance of
these data is validated by the small error bars.
Similarly to CD4 expression, the effects of the Nef variants on cell surface
MHC-I expression were evaluated flow cytometrically on R1 gated cells. The
PE-fluorescence of 293 cells transfected with 11Jg/35mm well NefwT,
Nef.myrD124LLAAor pCMVKm2 vector are compared in cell count histograms in
Figure 35. As is clearly visible from the plots, no MHC-I downregulation could
be distinguished in Nefwr-transfected cells when compared to vector-
transfected cells.
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Figure 34: Effect ol Nel variants on cell surface CD4 expression expressed as percentage CD4 expression in Nel-Iranslected cells in
relation to cells Iranslected with pCMVKm2 vector only (set to 100%). Percentages were determined either by recording the
percentage CD4 positive cells (grey bars) or by recording mean APC-fluorescence (black bars). The percentages lor three
independent experiments lor CD4 positive cells (and mean fluorescence) are tabulated along with their mean, standard
deviation and standard error. The standard error is represented by error bars on the chart.
In addition, an apparent upregulation of MHC-I is exhibited for Nef.myro124LLAK
transfected cells. This finding is contrary to expected and previously reported
results and further analysis of the flow cytometry data was employed. Figure 36
illustrates dot plots of R1 gated cells as plotted by MHC-I PE fluorescence (x-
axis) and CD4 APC fluorescence (y-axis). A CD4 APC fluorescence-independent
cut-off, which selects only highly MHC-I PE fluorescing cells for analysis was
introduced and the percentages of gated cells that fall above this cut-off were
determined. As can be seen, the analysis of cells expressing high levels of
surface MHC-I exhibited a small, but discemable difference between Nef variants
in terms of the percentage of cells that fall within this region.
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Figure 35: Comparative plots of PE-fluorescing cell counts representing cell surface MHC-I expression in NefwT and Nef.
myl1)124LLAA-transfectedcells (outlined in light grey) versus cells transfected with empty pCMVKm2 vector (colour-filled
dark grey plots) .
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Figure 36: Determination of cell surface MHC-I expression. Forward and side scatter-gated 293 cells cotransfected with pcDNA-CD4
and Nef-expressing plasmids were plotted according to PE (x-axis) and APC (y-axis) fluorescence, indicating cell surface
MHC-I and CD4 expression, respectively. Highly MHC-I PE- fluorescing cells with a minimum cut-off exceeding 102
(falling to the right of the line and indicated by the arrows) were analysed. The percent gated cells falling into this region
are indicted in each dot plot.
These values are expressed for three independent experiments as a percentage
of high intensity PE fluorescing vector-transfected cells in Figure 37. As is
evident from comparing with vector-transfected cells, cotransfection with 11-'g
NefwT and NefoPT plasmid DNA per 35mm well effected a decrease in MHC-I PE
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fluorescence, as also seen on the dot plots in Figure 36, indicating Nef-mediated
MHC-I downregulation. Notably, MHC-I downregulation was stronger in cells
cotransfected with NefoPT compared to NefwT-transfected cells. In comparison,
cell surface MHC-I expression was restored to levels seen in vector-transfected
cells when cells were transfected with either of the Nef mutants Nef_myrD124or
NetmyrD124LLAA.
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Figure 37: Nel MHC-Idownregulation as expressed as percentage vector-translected 293 cells (set to 100%) exhibiting high-intensity
PE-Iluorescence. The values and maan lor three independent experiments are shown along with the standard deviation and
error, the latter ol which is represented by the error bars on the chart.
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CHAPTER 4: DISCUSSION
Tat, Rev and Nef make attractive vaccine components and have been
developed as single-standing HIV-1 vaccines (Tat) (Cafaro et a/., 2001;
Cafaro et a/., 2000; Pauza et a/., 2000; Cafaro et a/., 1999; Caselli et a/., 1999;
Gallo, 1999; Gringeri et a/., 1998) as well as components in combination with
structural genes (Boyer et a/., 2000; Hanke and McMichael, 1999; MacGregor
et a/., 1998; Boyer et a/., 1997a; Boyer et a/., 1997b; Wang et a/., 1995) or as
regulatory/accessory gene-cassette vaccines (Hel et a/., 2002; Calarota et a/.,
2001; Tahtinen et a/., 2001; Ayyavoo et a/., 2000; Calarota et a/., 1999;
Osterhaus et a/., 1999; Ayyavoo et a/., 1998; Calarota et a/., 1998; Kim et a/.,
1997b). Because these genes are expressed early in the viral life cycle and
expression of the structural genes is delayed until sufficient Rev is present for
RRE-coupled transcript export, processing of Tat, Rev and Nef via the MHC-I
pathway may lead to killing of the infected cell before the formation of new
virions (Hel et a/., 2002; Addo et a/., 2001; Mooij and Heeney, 2001; van
Baaien et a/., 1997). Numerous recent studies have highlighted the
immunogenicity of these proteins and it has been shown that cellular and
humoral immune responses to all three proteins inversely correlate with rapid
disease progression (Fiorelli et a/., 2002; Demirhan et a/., 1999; Zagury et a/.,
1998b; van Baaien et a/., 1997; Re et a/., 1995; Reiss et a/., 1990).
Immunisation with these proteins in the form of DNA vaccines or protein
immunogens has been shown to be effective and safe and a number of
vaccines incorporating Tat, Rev and/or Nef have entered human trials and
show promise (Hanke et a/., 2002; Calarota et a/., 2001; Boyer et a/., 2000;
Calarota et a/., 1999; Gringeri et a/., 1998; MacGregor et a/., 1998).
Immunisation with biologically active Tat protein has protected non-human
primates after pathogenic SHIV challenge over an extended period of time
and it has recently also been shown that the functional and immunogenic
regions in Tat from viruses representing a number of subtypes and geographic
origins were highly conserved (Butto et a/., 2002). In addition, it was shown
that Tat-specific antibody responses can be effectively cross-reactive against
infection with different HIV-1 subtypes (Fiorelli et a/., 2002). In a study in which
numerous novel CTL epitopes in African individuals who were infected with
HIV-1 subtype C were identified, a relatively equal density of CTL epitope
distribution was observed for subtype C Gag, Tat, Rev and Nef when these
were adjusted for protein size (Novitsky et a/., 2001). The study also identified
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a number of immunodominant epitopes in Tat and Nef and a large number of
subdominant epitopes in Tat, Rev and Nef and the authors propose that
inclusion of such subdominant epitopes may help in providing protection after
the emergence of escape variants. The development of Tat, Rev and Nef as
vaccine components may provide important advantages such as increased
breadth of immune responses with which Gag, Pol and Env immune
responses may be reinforced.
Characterisation of the tat, rev and nef genes of HIV-1 subtype C from
South Africa
This work was published recently as a sequence note in the journal AIDS
Research and Human Retroviruses and the manuscript is attached as
Appendix C. Phylogenetic analysis of the net and 5'LTR sequences of 14
HIV-1 isolates from Tygerberg Virology (TV) identified these genomic regions
as distinctly subtype C. This is supported by analysis of the deduced protein
sequences of Tat, Rev and Nef, which revealed characteristically subtype C
proteins (except Rev from TVOO5). When taken alongside the characterisation
of the env, gag (Engelbrecht et al., 2002) and accessory gene (Scriba et al.,
2002) sequences, the data support that the viral isolates are non-recombinant
HIV-1 subtype C.
Sequence analysis of the wild-type and consensus sequences
Consensus protein sequences (TV Cons) were drawn up from the fourteen
Tygerberg Virology (TV) Tat, Rev and Nef proteins and these were used as
template for codon-optimisation to synthesise the immunogens that were used
in this study. For comparative purposes, wild-type tat, rev and net genes from
those TV isolates that were least dissimilar in their deduced protein
sequences to the TV Cons were cloned to construct expression plasm ids
named TatwT (TV019), RevwT (TV010) and NefwT (TV002). Four additional
consensus sequences designated sA Cons (southem Africa i.e. South Africa
and Botswana), Compl Cons (all subtype C Tat, Rev and Nef protein
sequences used to draw up the phylogenetic trees), CONS C (the subtype C
consensus from the HIV sequence database) and India Cons (drawn up from
the subtype C isolates from India) were also included in the comparative
sequence analyses. The results revealed that the collective amino acid
distances of Tat, Rev and Nef of the consensus sequences were smallest
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between the TV Cons and sA Cons. This similarity was further supported by
the phylogenetic trees, which show that for the three proteins, the TV Cons
and sA Cons were very close and fell within the same monophyletic clusters.
Noteworthy was that again for all three proteins, the sA Cons was less
dissimilar to the TV Cons than the wild-type proteins, which were chosen on
the grounds of being the least dissimilar of the fourteen TV isolates. This was
also confirmed by the phylogenetic trees which showed that the sA Cons and
TV Cons were closer together and fell very close to the "backbones" of the
trees, indicating a higher degree of homology to the taxa of the individual viral
strains than virtually any individual viral strain. Moreover, similarity plots that
compared the amino acid distances of the three proteins when calculated
versus TV Cons or the wild-type TV isolates TV019 for Tat, TV010 for rev and
TV002 for Nef were done. These plots did not illustrate a striking difference in
amino acid distances due to step and window-size constraints of the Simplot
program when using short protein sequences such as Tat and Rev. Thus,
often 20-amino acid sequence steps would return the same distance output
and this made it difficult to distinguish distance between sequences as the Tat
sequences only generated four data points and the Rev sequences five data
points for their entire reading frames. Nonetheless, when observed closely,
distances were generally smaller between TV Cons and the TV isolates than
the wild-type TV sequences and the TV isolates. This was more clearly
evident when amino acid distances were expressed in stacked distance plots,
in which the sum of amino acid distances of the TV Cons versus the fourteen
TV isolates and each individual TV isolate versus the fourteen TV isolates
were compared. The TV Cons (and sA Cons) were clearly found to be more
similar to individual viral sequences than anyone of the individual TV isolate
sequences for Tat, Rev and Nef. Collectively, these results indicate that the
use of a consensus sequence such as TV Cons as a vaccine candidate may
contribute in reducing genetic variability between a vaccine strain and
circulating viruses as also shown for other consensus sequences (Novitsky et
al., 2002; Brander and Goulder, 2001). Our results thus correspond with those
described recently by Novitsky et al. (2002), who also showed more similarity
between a southern African subtype C consensus and individual sequences
than between an individual isolate sequence and a panel of individuals. Thus,
a less heterogeneous vaccine may have direct implications on specificity of
the vaccine induced immune responses and immunoreactivity with viruses in
an epidemic of highly diverse subtype C viruses such as southern Africa. The
fact that the TV Cons was only drawn up from fourteen viral strains rather than
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a much larger number of viruses was a concern as the consensus may not
have been representative of the actual population of circulating strains in
South Africa or southern Africa. This concern was alleviated by the very high
degree of similarity between the TV Cons and the sA Cons, the latter of which
was drawn up from approximately 70 sequences (depending on the protein)
from South Africa and Botswana. In terms of amino acid substitutions, the TV
Cons and sA Cons only differed by single residues for Tat (1%) and Nef
(0.5%) and four residues for Rev (3.7%). Thus, even though the TV Cons was
drawn up from fourteen HIV-1 subtype C viruses isolated at the Department of
Medical Virology, Tygerberg, Western Cape, these Tat, Rev and Nef
consensus sequences were representative of the circulating viral strains in
southern Africa. This also indicates the suitability of the TV Cons immunogens
being suitable as subtype C vaccine components for southem Africa and not
only South Africa. Taken together, these data demonstrate the suitability of
the TV Cons amino acid sequences for candidate HIV-1 subtype C Tat, Rev
and Nef vaccine immunogens.
Codon optimisation of the tat, rev and nef genes
In an attempt to increase the expression of proteins from the DNA plasmids
encoding the HIV-1 subtype C consensus Tat, Rev and Nef proteins, the
codon usage of these was changed to those of highly expressed human
genes as described (zur Megede J. et aI., 2000; Andre et aI., 1998; Haas et
aI., 1996b). The result was a marked increase in percentage GC content
across the entire reading frames of all three genes and overall increases of
approximately 20% per reading frame. Strong increases in expression levels
in 293 cells up to 900-fold were recorded for genes such as GFP and HIV-1
Env and Gag when they were codon-optimised in similar manners (zur
Megede J. et aI., 2000; Andre et aI., 1998; Haas et aI., 1996b). Although
apparently minute differences in expression level could be distinguished
between the wild-type and codon-optimised tat and nefplasmids, these results
were not distinct enough to be significant. However, the codon-optimised Rev
exhibited distinctly increased expression levels compared to that of the wild-
type Rev. It must be noted that immunoblotting is not an accurate quantitative
method with which protein levels can be determined and these results can
thus not be expressed quantitatively like those that may be obtained from for
example an ELISA with standard concentration curves. Nevertheless,
markedly increased expression was apparent for Rev and possibly to small
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degrees for Tat and Nef and these may result in increased immunogenicity,
when used in vivo as immunogens, as more protein can be processed via the
MHC-I antigen presentation pathways.
Biological characterisation of subtype C Tat proteins
The HIV-1 subtype C tat genes of viruses isolated at the Tygerberg
Department of Medical Virology were notably conserved and although some
length variation was observed, the deduced amino acid sequences showed
low levels of residue variation (see Appendix A). Upon discovery, the tat
gene was reported to encode a protein of 86 amino acid residues in length
with a relative electrophoretic mobility corresponding to approximately 14kDa
(Aldovini et a/., 1986; Wright et a/., 1986; Sodraski et a/., 1985a). This
shortened Tat, which was encoded by the subtype B virus LAIIIIIB/ARV (from
which HXB2 was derived) has been used for the majority of functionality
studies under the heading of "full length Tat" (Jeang, 1996). However, most
strains of HIV-1 encode a Tat protein that is 101 amino acid residues in length
(Kuiken et a/., 2000; Jeang, 1996). Interestingly, the viral isolates and
molecular clones used in these early studies incorporated a number of
truncated reading frames, including that of tat, which terminated prematurely
to express an 86 amino acid protein (Ratner et a/., 1985). Nevertheless, it was
found that only the first exon of Tat, which normally consists of 72 residues,
and more specifically the amino terminal 58 amino acids, were sufficient for
transactivation activity (Battaglia et a/., 1994; Kuppuswamy et a/., 1989;
Garcia et a/., 1988; Seigel et a/., 1986) and the C-terminal domain was
considered unimportant.
The results from the present study indicate that the wild-type subtype C Tat
protein derived from isolate TV019 as well as the codon-optimised consensus
Tat variants which encode proteins of 101 amino acids in length migrate at a
rate corresponding to approximately 18kDa on a denaturing SDS-PAGE gel.
The C22G and C37S mutations in the Tat mutants did not have an effect on
electrophoretic mobility. The subtype B Tat control protein, which was 86
amino acids in length, migrated at the expected 14kDa rate (Bohan et a/.,
1992). Two additional bands were immunoreactive in the lane containing this
Tat control protein, one of 25kDa and one of 10kDa. Although Aldovini et al.
reported a similar band at 25kDa while characterising the Tat protein, they
remarked that it was unlikely that a 25kDa dimer consisting of 14kDa subunits
would be detected on a gel that was electrophoresed under denaturing
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conditions (Aldovini et ai., 1986). Yet, it was shown later that the metal-linked
Tat dimer was stable under SOS conditions and migrated as a 25kOa protein
band on denaturing gels (Frankel et ai., 1988) and that such dimers form upon
oxidation to which biologically active Tat is highly sensitive (Ensoli et ai., 1990;
Viscidi et ai., 1989). The resuspension of the Iyophilised protein in PBS buffer
lacking reducing or chelating agents may have effected the oxidation and/or
degradation of the protein resulting in the appearance of smeared bands and
the additional 25kOa dimer and partial 10kOa products. Partial Tat fragments,
which form by oxidation on SOS gels, have also been previously reported
(Koken etai., 1994; Frankel etai., 1988).
Immunoblotting of Tat Iysates with polyclonal mouse serum showed
comparable reactivity of the polyclonal mouse serum for all subtype C Tat
proteins irrespective of mutations. The subtype B Tat control protein was also
immunoreactive, confirming the identity of the protein bands as indeed being
HIV-1 Tat. Furthermore, these results point out that the Tat proteins were
expressed and that Tatc22c37was able to elicit substantial humoral immune
responses in mice. It should be mentioned though that the dose of
immunogen was very high (two immunisations of 75IJgeach) and that this can
not be taken as indication of good immunogenicity.
Functional activity of the various Tat proteins was assessed by cotransfection
of the Tat variants with the reporter plasmid pl,TR-CAT, which was first
described by Peterlin et al. (1986) and used in a number of Tat transactivation
experiments, one of which first demonstrated the inactivity of Tat proteins
mutated in the cysteine-rich domain (Kuppuswamy et ai., 1989). Although
Kuppuswamy et al. performed these transactivation assays in Hela cells, a
comparison of the cotransfection assay in a number of cell lines was done to
determine whether corresponding results could be obtained. Hence a round of
preliminary experiments was performed in which a small number of Tat
variants were tested for transactivation activity in COS-7, RO, Hela and 293T
cells. Contrary to a substantial amount of published data, we found the
subtype C consensus Tat with a Cys22Gly substitution to be functionally
active in terms of being able to transactivate the HIV-1 l TR. These results
were subsequently confirmed in three independent experiments each in Hela
and 293T cells. However, in agreement with previously published reports, the
single mutant Tatc37 and the double mutant Tatc22C37were unable to
transactivate CAT expression from the l TR. The importance of the cysteine-
rich domain for the structure and function of Tat was shown soon after
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discovery of the protein (Viscidi et al., 1989; Frankel et al., 1988) and a
number of studies demonstrated that mutation of the cysteines at positions 22
and 37 as well as other positions rendered the Tat proteins unable to
transactivate l TR-directed gene expression (Rice and Carlotti, 1990;
Kuppuswamy et al., 1989; Ruben et al., 1989; Garcia et al., 1988). It was also
shown that a number of non-cysteine mutations in the cysteine-rich domain
(residues 22 through 37) reduced Tat activity (Rice and Carl otti , 1990) and a
study by Koken et al. indicated that the cysteines in this region are crucial for
the formation of intermolecular disulphide bonds, which confer correct protein
folding and functional activity (Koken et al., 1994). These Tat mutants were
subsequently analysed for additional functional effects and it was found that
when Tat22 was constitutively expressed in Jurkat T cells, it was able to act as
a transdominant negative mutant by inhibiting HIV-1 replication as well as
reactivation from latency (Caputo et al., 1996). This role was also
demonstrated in primary PBMCs and the authors suggested that it might be of
therapeutic value (Rossi et al., 1997). Additional studies revealed that the
C22, C37 and C22/C37 mutations did not affect cellular localisation and that
such mutant Tat proteins, when present extracellularly, were taken up and
localised within cells in a manner similar to that of wild-type Tat (Betti et al.,
2001). Due to these findings, the authors proposed that these substituted
cysteine residues do not drastically alter the conformation of Tat. However,
mutations in this region did bring about a decrease in receptor binding affinity
indicating a certain degree of conformational modification (Betti et al., 2001).
Interestingly, while TatwT and TatoPTdiffered by four amino acid substitutions,
both demonstrated virtually equal transactivation activity, showing that the
subtype C consensus Tat protein (TV Cons), which presumably does not
occur naturally, had full biological activity. It should be noted though that when
broken down into its putative functional domains (Jeang et a/., 1999), the
domains from Tat TV Cons were always identical to corresponding domains in
individual viral isolates and thus the consensus did not contain any unnatural
sequence combinations.
A possible reason for the finding that the subtype C consensus Tatc22 mutant
was capable of transactivating the HIV-1 l TR is not clear. Because the assays
used in this study were done as those described by Kuppuswamy et al.
(1989), who also used the same reporter plasmid and performed the
transactivation assays in Hela cells, the possibility of different methodology
can be excluded. The importance of cysteine residue conservation at position
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22 in Tat has been well established. Cys22 is highly conserved among HIV-1
and also a large number of HIV-2 and SIV viruses (Kuiken et ai., 2000) and
with the exception of our work, every previously published experiment has
shown mutation of this residue to abrogate transactivation (Betti et ai., 2001;
Caselli et ai., 1999; Rossi et ai., 1997; Caputo et ai., 1996; Balboni et ai.,
1993; Rice and Carlotti, 1990; Kuppuswamy et ai., 1989; Ruben et ai., 1989;
Garcia et ai., 1988). When dissected, only two disparities between these
previous experiments and the Tat transactivation work described in this study
can be recognized, and both implicate the Tat protein. Firstly, to my
knowledge, all studies that concern functional dissection, mutation or
structural analysis of Tat have been conducted on proteins encoded by HIV-1
subtype B viruses. While unlikely, the fact that the Tat proteins analysed here
are from subtype C viruses may be accompanied by suspicions that the
intrinsic structures and functions of Tat proteins from different HIV subtypes
can differ. Indeed, it is well known that the long terminal repeat as well as a
number of proteins including Rev, Vpu and the C-terminal of Pol are distinctly
different in subtype C viruses when compared to other subtypes (Rodenburg
et ai., 2001; Novitsky et ai., 1999; Gao et ai., 1998; Salminen et ai., 1996). It
would thus not be unreasonable to speculate about the unexplored subtype
factor in playing a possible role in a different structure or function of Tat. A
second distinction between the work completed in this study and again, to my
knowledge, all previous studies describing the Tat22 mutant is the factor of
protein length. As a result of the premature termination site in the tat reading
frame of the first laboratory HIV-1 strain, the majority of studies investigating
the function and structure of Tat22 (and many other studies) were conducted
on the 86 amino acid Tat protein and not the full-length 101 amino acid Tat
that is seen predominantly in viruses (HIV Sequence database). As described
before, early studies showed that the second exon was expendable for
transactivation activity (Seigel et ai., 1986). A number of recent studies
however, have demonstrated the second exon, which encompasses 29 amino
acids in most strains, to enhance viral replication (Neuveut and Jeang, 1996)
and pathogenesis (Jeang et ai., 2002) of HIV-1. The possibility exists that the
full length Tat proteins used in this study may have not been inactivated for
transactivation by mutation of C22 because of a counteracting function of the
C-terminal second exon. Interestingly, a Tat mutant (Y26A) which was
defective for transactivation activity and viral replication, regained activity
when a second-site suppressor mutation (Y47N) was acquired (Verhoef and
Berkhout, 1999). These data certainly provoke consideration of this concept,
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but it remains unlikely that mutation of such a critical residue in such a critical
domain of Tat can be suppressed by a longer C-terminal or a second-site
suppressor mutation. These questions will remain unanswered until they are
experimentally defined. Nonetheless, the aim of this study was to identify a
non-functional Tat protein that may act as potential vaccine immunogen and
this aim was most certainly achieved.
A note should be made about the experimental results obtained in the Tat
functionality assays. Although the experiments were repeated independently
in triplicate in both cell lines, a number of Tat protein variants were only
assayed twice while TatwT was only assayed once in 293T cells. The reason
for this is mostly due to the fact that the functionality assays were started
without the full complement of Tat variants and these were included as they
were constructed. SV40-Tat was only done in 293T cells as these assays
were completed at Chiron Corporation in the USA and because the assays in
Hela cells were done in South Africa, this plasmid was not available.
Nonetheless, the data obtained illustrates the feasibility of the assay in both
cell lines as well as the validity of the results. However, it should be mentioned
that for publication purposes, statistical significance can only be confirmed for
all Tat proteins if these assays are done in triplicate.
Tat's role as immunogen has been discussed in the context of this study. The
number of defined epitopes CTl epitopes in the HIV Immunology Database
(2000) is expanding every year. Although most epitopes have been identified
in HIV-1 subtype B infected individuals and some of these can be found in
proteins from other subtypes due to protein sequence conservation, new
studies are specifically targeting non-B subtypes for CTl mapping (Brander
and Goulder, 2001; Novitsky et al., 2001). Currently, only one subtype C-
specific CTl epitope has been identified and it is indicated on the TatoPT
protein sequence in Figure 38. It should be mentioned that a considerable
amount of CTl epitopes that were defined in subtype B Tat proteins vary by a
single residue and thus cannot be mapped on the subtype C consensus Tat
protein. It can be expected though, that at least a fraction of these residue
variations fall within non-anchor residue sites and that at least some of these
will thus be cross-reactive to subtype C proteins.
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Tat:
B*1503
TatOpt:
"' I IMEPVDPNLEPWNHPGSQPKT~CYCKHCSYHCLV~FQTKGLGISYGRKK
bl IC22 C37
TatOpt: RRQRRSAPPSSEDHQNPISKQPLPQTRGDPTGSEESKKKVESKTETDPFD*
Figure 38: Sequences ol the HIV-1 subtype C consensus (lV Cons) Tat immunogens constructed lor this study.
Amino acid substitutions in mutant proteins are indicated and named and the described subtype C-
specific CTL epitope ol known HLA restriction from the HIV Immunology Database (2000) is indicated.
Biological characterisation of subtype C Rev proteins
The molecular mass (Mr) of HIV-1 Rev is described quite inconsistently in the
literature. Emerman (1998), Pollard (1998), Malim et al. (1989a; 1988) and
Cochrane et al. (1989) report Rev to have a Mr of 18-19kDa, whereas it is
reported as a 13kDa protein by Hope (1999). Our results show the
recombinant subtype B Rev protein at the expected Mr of 18kDa, whereas the
codon-optimised, mutated RevM5M1omigrated to a distance calculated as
approximately 14.5kDa. The wild-type Revwt migrated slower than RevM5M1o,
albeit more rapidly than the protein control, to lie at around 16.5kDa. The
faster migration of the two subtype C Rev proteins relative to the subtype B
recombinant Rev (116 amino acids) may be attributed to the characteristic
Rev truncation (106 amino acids), which has also been reported in practically
all subtype C Rev proteins (Novitsky et aI., 2002; Scriba et aI., 2002;
Rodenburg et aI., 2001; van Harmelen et aI., 2001; Ndung'u et aI., 2000; Lole
et aI., 1999; Novitsky et aI., 1999; Gao et aI., 1998; Salminen et aI., 1996). In
addition, the increased migration of the codon-optimised, mutated RevM5M1o
relative to the wild-type Revwtwas not entirely surprising as minor variations in
the form of more rapid (Malim et aI., 1991; Mermer et aI., 1990; Malim et aI.,
1989a) as well as decreased (Malim et aI., 1991; Hope et aI., 1990b; Malim et
aI., 1989a) electrophoretic mobility have been reported for a number of Rev
mutants. The cause of this mobility shift remains to be clarified, as the
mutated proteins in these studies as well as the RevM5M1omutant described
here were of the same length in amino acids as the wild-type proteins. A
possible reason could be that mutation of the Rev protein may have effects on
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posttranslational protein modification, which may lead to variable
electrophoretic mobility. Rev is phosphorylated at one or more serine residues
when expressed in vivo (Hauber et ai., 1988) and when compared to the
sequence of RevM5M1o,the wild-type Rev has three substitutions in which
serine residues are lost while gaining a serine in one substitution (Appendix
A). This is unlikely to affect electrophoretic mobility however, as
posttranslational modification of Rev entails only phosphorylation and even
though the M5 mutation (M10 had no effect) has been shown to dramatically
reduce the level of phosphate incorporation into Rev, this effect was shown
not to affect electrophoretic mobility (Malim et ai., 1989a; Hauber et ai.,
1988). An additional possible cause could be variation in amino acid
composition, which is suggested as possible cause for variable electrophoretic
migration rates of Nef proteins (Kaminchik et ai., 1990). RevwT and RevM5M1o
differ by eleven amino acids (10%), a factor which may well affect migration
rates of the proteins. Nonetheless, similarly to a number of previous studies,
mutations in Rev effected a shift in mobility on SOS-PAGE gels, the basis of
which remains speculative.
Comparison of in vitro protein expression levels from the codon-optimised,
mutated and wild-type rev plasmids revealed a strong RevM5M1oprotein band
compared to a faint RevwT band on immunoblots, indicating higher expression
levels of the codon-optimised, consensus RevM5M1oprotein than the wild-type
RevwT. Such differences have been reported for other codon-optimised HIV-1
genes (zur Megede J. et ai., 2000; Andre et ai., 1998; Haas et ai., 1996b).
Although unlikely, it must be noted that the polyclonal mouse serum, which
was generated by immunisation with the mutant RevM5M1o,may display less
efficient immunoreactivity to the wild-type Rev protein due to potentially
altered structural conformations. If the reason that the two subtype C proteins
migrate at different rates on a denaturing SOS-PAGE gel is as a result of
possible differences in posttranslational modifications (Hope et al., 1990b) or
protein stability (Malim et ai., 1989a) this may also affect immunoreactivity.
Interestingly, although the subtype B control Rev protein was immunoreactive,
the subtype B Rev protein expressed by transfection of 293T cells (it showed
strong functional activity) with the pRSV-Rev plasmid was not detected by
immunoblotting with the subtype C-specific mouse serum.
Similarly to Tat, the immunoreactivity of the polyclonal mouse serum with the
subtype C and B Rev proteins demonstrated the identity of the protein bands
to be Rev and indicates protein expression and immunogenicity in mice.
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The cotransfection assay for Rev activity that was first described by Hope et
al. (1990b) and used extensively in other Rev functionality studies was altered
in this study. Whereas the initial assays were performed in COS7 or CV1
cells, in this study 293T cells were cotransfected to assess Rev function. 293T
cells, like the 293 cell line that they were derived from, strongly express
transfection-introduced genes (Graham et al., 1977) and although they may
not exhibit cellular conditions conducive to all functional and biochemical
studies, they have of late been increasingly used for studying such
parameters in proteins including HIV-1 accessory/regulatory proteins
(lundquist et el., 2002; Peng and Robert-Guroff, 2001; Craig et al., 1998).
Along these lines, the comparative preliminary Tat functionality assays, which
were performed in RD, COS-7, Hela and 293T cells, as well as the actual Tat
functionality assays, which were repeatedly performed in 293T and Hela
cells, showed no demonstrable difference between the cell lines in terms of
assay outcome or accuracy. In fact, due to the strong expression of the
proteins in the 293T cells, a more definable difference could be distinguished
between CAT levels exhibited. Although Rev functionality is distinct from that
of Tat, these criteria were reason enough to perform the assays in 293T cells.
Only basal CAT expression was observed in cells transfected with the reporter
plasmid pDM128 only while co-transfection with the pRSV-Rev plasmid
resulted in an 85-fold increase in CAT levels. This corresponds very well with
the results obtained by Hope et al., (1990) who recorded 75- to 100-fold
increases in CAT enzyme activity when CV1 cells were cotransfected with
pRSV-Rev and pDM128, further indicating the suitability of performing this
assay in 293T cells.
While the wild-type subtype C Rev protein RevwTinduced a marked 25-fold
increase in CAT levels, this was abolished for the mutated RevM5M1o.The
small error bars obtained from three independent experiments indicate the
repeatability and thus significance of these findings. The results indicate the
subtype C RevM5M1oprotein containing the M5 (RK 38,39 Dl; arginine-rich
NlS) and M10 (IE 78,79 Dl; NES) mutations to be unable to effect in vitro
nuclear export of unspliced RRE-coupled transcripts in 293T cells and thus
shows RevM5M1ot be functionally inactive. It should be noted that this
inactivity of RevM5M1owas recorded in the background of the apparently
stronger expressing, and thus more abundant RevM5M1oprotein compared to
the RevwTprotein. Possible explanations for the stronger activity of pRSV-Rev
compared to RevwTmay include abundance of Rev protein, a factor which
was not clarified as pRSV-Rev was not detectable on the subtype C-specific
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immunoblots (blots not shown). To my knowledge, no studies have
investigated the functional effects of the subtype C-specific truncation in Rev,
which truncates the protein by nine amino acids. However, two Rev mutants,
which contained residue substitutions in the C-terminal nine residues (termed
M13 and M14), were assessed for their ability to transactivate cytoplasmic
expression of unspliced viral transcripts. Although both mutants were reported
to have activity between 50% and 100% of wild-type Rev, M14 displayed less
than 80% wild-type activity while M13 displayed less than 70% (Malim et al.,
1989a). Unfortunately no additional experiments were done to assess these
mutants further and to attribute a decrease in Rev activity to these nine C-
terminal residues, a truncated Rev will have to be compared directly with its
wild-type form.
Further speculations could be made about the differences between the
interactions of a subtype Band C Rev with the subtype B Rev-responsive
element (RRE) present in the pDM128 plasmid. However, as these
discussions are purely speculative and reach beyond the scopes of this study,
these questions will remain unanswered.
The results obtained in this study are consistent with previous studies in which
the M5 and M10 mutations have individually been shown to be sufficient for
complete abrogation of functional Rev activity (Thomas et al., 1998; Madore et
al., 1994; Hope et al., 1992; Hope et al., 1990b; Malim et al., 1989a). Although
our experiments demonstrate the functionality of Rev in terms of ability to
transactivate cytoplasmic expression of unspliced pDM128 transcripts in
transfected 293T cells, the extent to which the M5 and M10 mutations have
been characterised reaches much further. M5 (also previously called MB2 by
Hope et al. (1990a)) was shown to cause defects in nuclear localisation (Hope
et al., 1990a; Hope et al., 1990b), phosphorylation of Rev (Malim et al.,
1989a) and multimerisation (Thomas et al., 1998; Madore et al., 1994) and
abrogated functional activity in terms of being able to rescue rev-defective
provirus and to transactivate cytoplasmic expression of unspliced HIV-1
transcripts (Malim et al., 1989a) or unspliced pDM128 transcripts (Hope et al.,
1990a; Hope et al., 1990b). Similarly, Rev proteins carrying the M10 mutation
displayed defective multimerisation (Thomas et al., 1998; Madore et al., 1994)
and were unable to rescue rev-defective provirus or transactivate cytoplasmic
expression of unspliced HIV-1 transcripts (Malim et al., 1989a) or unspliced
pDM128 transcripts (Hope et al., 1990b). In addition, cotransfection of M10
mutants with wild-type Rev was shown to inhibit wild-type Rev function in a
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transdominant manner (Hope et aI., 1990b; Malim et aI., 1989a) and to inhibit
HIV-1 replication through the RevM10-mediated prevention of functional Rev-
mediated nuclear export of unspliced viral transcripts and subsequent
inhibition of Gag-Pol and Env protein expression (Hope et aI., 1992). This
transdominant-negative Rev has since been developed for gene therapy in
HIV-1 infected individuals and was shown to be clinically safe in human trials
(Ranga et aI., 1998; Woffendin et aI., 1996). Moreover, RevM10-transducedT
cells were found to have prolonged survival and it was proposed that antiviral
gene therapy with this transdominant-negative Rev mutant may contribute to
the reconstitution of immune function in AIDS. More recent studies
demonstrated the emergence of RevM10-resistant HIV-1 variants and
selection of such mutated viruses in a T-Iymphoblastoid cell line constitutively
expressing RevM10 (Hamm et aI., 1999). However, novel HIV-1-based
retroviral vectors, which can transduce non-dividing cells were shown to
reduce the infectivity of inhibition-escape virions and confer protection against
HIV-1 replication to previously untransduced cells (Mautino et aI., 2001).
The inclusion of both M5 and M10 mutations into a potential HIV-1 subtype C
Rev immunogen such as pCMVKm2-RevM5M1oincorporates the collective
abrogation of all of the abovementioned functions and may also mediate the
transdominant inhibition of wild-type Rev function. These characteristics are
suggestive of a non-functional and thus potentially safe Rev immunogen,
which, in addition to possibly eliciting HIV-1 subtype C Rev-specific immunity,
may inhibit HIV-1 replication upon infection or lend a therapeutic value in HIV-
1 infected individuals through the competitive transdominant inhibition of
functional Rev. When compared to a protein like Nef, very few CTl and Th
epitopes have been described in HIV-1 Rev (HIV Immunology Database
(2000)) and those identified have been in individuals infected with
predominantly HIV-1 subtype B. Thus no epitopes that correspond to subtype
C Rev have been defined, although a study has identified subtype C Rev-
specific responses in individuals from Botswana (Novitsky et aI., 2001). This
makes it difficult to anticipate the immunological value of the pCMVKm2-
RevM5M1oas DNA immunogen. Yet as the sequences of the viruses from
Botswana studied by Novitsky et al. (2001; 2002) were shown to be very
similar to the ones from South Africa, the RevM5M1oimmunogen, which is
based on the South African consensus sequence (TV Cons) may elicit anti-
Rev responses similar to those detected in their study.
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Biological characterisation of subtype C Nef proteins
Genetic characterisation of the nef genes of fourteen HIV-1 subtype C isolates
from Tygerberg Virology (TV isolates) showed that these sequences did not
cluster distinctly in phylogenetic trees, but rather clustered with subtype C nef
sequences of global origin with the exception of nef sequences of Indian
origin. Since the deduced Nef protein from isolate TV002 showed the least
amino acid dissimilarity to the Nef TV Cons consensus sequence, which was
drawn up from the fourteen TV isolates, this isolate was chosen as template
for construction of the wild-type Nef construct. The NefwT and NefoPT as well
as both mutant Nef plasmid constructs encoded proteins of 208 amino acids in
length. However, the wild-type Nef protein, calculated to have a molecular
weight of 26kDa, migrated at a distinctly more rapid rate than the codon-
optimised Nef proteins, which migrated at a rate corresponding to 28kDa. The
unmutated Nef proteins NefwT and NefoPT differ in terms of amino acid
composition by nineteen residues, which accounts for 9% sequence
dissimilarity (Appendix A). While it has been reported that differential
posttranslational modification of proteins may account for variable
electrophoretic mobilities, the myristoylation of Nef has been shown not to
impact on mobility (Niederman et aI., 1993; Yu and Felsted, 1992; Kaminchik
et aI., 1991). Because they contain intact myristoylation signals it is
anticipated that both NefwT and NefoPT proteins will undergo myristoylation
while both Nef mutants have had their myristoylation signals mutated (G2A)
and will thus not be able to bind a myristic acid. The three codon-optimised
consensus Nef proteins comigrated at indistinguishable rates, a result that is
consistent with the previous results in that myristoylation did not affect
electrophoretic mobility. Moreover, since phosphorylation of Nef proteins do
not affect electrophoretic mobility (Coates et al., 1997), posttranslational
modification can be ruled out as basis for this phenomenon. A number of
studies have described the expression of two different sized Nef proteins,
usually 27kDa and 25kDa in size, from the same coding regions (Kaminchik et
al., 1991; Kaminchik et al., 1990; Guy et al., 1987; Franchini et al., 1986).
While Nef is cleaved by the viral protease (Chen et aI., 1998; Pandori et aI.,
1996; Welker et aI., 1996; Freund et aI., 1994), the cleavage product typically
comprises a molecular weight of 19kDa, eliminating proteolytic cleavage as
possible cause for the variable Nef product. Thus the particular event in which
the 27kDa and 25kDa Nef species were found was attributed to variable
translation form the normal initiation codon as well as an additional ATG that
occurs in a considerable fraction of nef reading frames around nucleotide
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position 60 (Ratner and Niederman, 1995; Kaminchik et al., 1991; Allan et al.,
1985). Since both the wild-type TV002 and the TV Cons consensus nef
reading frames do not include this second initiation codon (Appendix A), this
factor could also be eliminated as possible cause for such differential
migration rates. Ultimately the more rapid electrophoretic mobility of NefwT in
comparison to the native and mutated consensus Nef proteins may simply be
due to variation in amino acid composition. Such a variable electrophoretic
migration was previously observed for two subtype B Nef proteins from strains
BH10 (28 kDa) and LAV1 (26 kDa), which were of equal length and only
differed in amino acid composition (Kaminchik et al., 1990).
In vitro expression levels of the Nef proteins could also be determined from
the immunoblots. The four different Nef proteins were immunoreactive to anti-
Nef polyclonal mouse serum as well as a subtype B Nef-specific monoclonal
antibody, the latter confirming the identity of the proteins in the absence of a
Nef protein control. The immunoreactivity of the Nef serum, which was raised
by immunising mice with naked pCMVKm2-Nef.myr0124plasmid DNA, indicates
that this protein was expressed in mice and elicited a substantial humoral
immune response. While the codon-optlrnlsed, consensus Nef proteins were
expressed at indistinguishable levels, the wild-type Nef protein appeared to be
expressed at a somewhat lower level on both blots. Although not marked, this
difference in expression level may be indicative of higher levels of protein
expression due to codon-optimisation which is required for enhanced
immunogenicity of DNA vaccine immunogens (zur Megede et al., 2000; Andre
etaI., 1998).
The Nef protein from HIV-1, HIV-2 and SIV is expressed abundantly in the
early stages of viral gene expression and associates with host cellular
membranes through its N-terminal myristoylation (Kaminchik et al., 1991; Guy
et al., 1987). Along with a number of functions that contribute to the
enhancement of virion infectivity and disease pathogenesis, Nef
downregulates cell surface expression of MHC-I (Le Gall et al., 1997;
Schwartz et al., 1996) and CD4 (Aiken et al., 1994; Garcia and Miller, 1991;
Guy et al., 1987). Because these functional properties of Nef may raise safety
concerns and result in poor immune responses, two Nef mutants containing a
number of site-specific amino acid substitutions that have been shown to
abrogate some of these functions were constructed. The first mutant,
designated Nef.myrD124,had a G2A substitution in order to mutate the
myristoylation signal as well as a D124G substitution (described as D123G by
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Liu et al. (2000), which was shown to abolish oligomerisation, downregulation
of C04 and MHC-I and decrease viral infectivity (Liu et al., 2000).
Myristoylation of Nef has been shown to be essential for membrane
localisation (Niederman et al., 1993) and thus biological function including viral
pathogenicity (Aldrovandi et al., 1998), downregulation of C04 (Iafrate et al.,
1997; Goldsmith et al., 1995; Aiken et al., 1994) and MHC-I (Peng and
Robert-Guroff, 2001), enhancement of viral infectivity (Goldsmith et al., 1995)
and replication (Lundquist et al., 2002), activation of NFAT expression
(Manninen et al., 2001), disruption of T cell receptor (C03) signalling and
activation (Wang et al., 2000; Iafrate et al., 1997) and association with cellular
serine kinases (Sawai et al., 1995). Moreover, myristoylation of Nef has been
demonstrated to convey a cytotoxic function to Nef (Curtain et al., 1998;
Curtain et al., 1997).
The second mutant, designated Nef_myrD124LlAA,contained the same G2A and
0124G mutations as well as an additional, well described mutation in which
the dileucine motif at position 165 (LL 165AA) was substituted for alanines.
While having no effect on MHC-I downregulation (Mangasarian et al., 1999),
mutation of this motif has been shown to completely abrogate Nef-mediated
C04 downregulation (Lundquist et al., 2002; Swigut et al., 2001; Mangasarian
et al., 1999; Bresnahan et al., 1998; Craig et al., 1998). In addition, LL165AA
Nef mutants show defective viral replication (Lundquist et al., 2002) and
infectivity, disrupted Nef binding to the AP-1 clathrin adaptor (Bresnahan et
al., 1998) and C028 downregulation (Swigut et al., 2001).
The functional abilities of these Nef mutants as well as unmutated Nef
proteins to downregulate cell surface C04 and MHC-I were assessed in
assays described previously (Peng and Robert-Guroff, 2001; Goldsmith et al.,
1995). The results indicate that both unmutated HIV-1 subtype C Nef proteins,
NefwT and NefoPT, mediated downregulation of cell surface expression of C04
and MHC-I, indicating functional activity. Like those for Tat, these results
illustrate the biological activity of a consensus Nef protein, which does, in all
probability, not occur naturally. Both Nef mutants were defective at
downregulation of cell surface MHC-I expression, confirming that previously
published functional analysis results apply to subtype C Nef proteins.
However, in the background of cell surface C04 downregulation, mutant
Nef_myrD124LlAAdisplayed full abrogation of this function while mutant Nef_myrD124,
although not at full wild-type activity, showed C04 downregulation. These
results emphasize the importance of the dileucine motif for C04
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downregulation activity and demonstrate that the G2A and D123G mutations
were not individually sufficient for complete abrogation of this Nef function.
Furthermore, this finding corresponds with prior studies, which consistently
showed minor levels (below 25%) of CD4 downregulation in G2A Nef mutants
( Lundquist et aI., 2002; Goldsmith et aI., 1995).
It should be mentioned that while the Nef mutants displayed abrogated CD4
and MHC-I downregulation, the CD4 downregulation assay showed CD4
expression levels for Nef.myrD124LLAA-transfectedcells that exceeded vector-
transfected cells (100%) and similarly the MHC-I downregulation assay
showed MHC-I expression exceeding 100% for Nef.myrD124-and Nef.myrD124LLAA-
transfected cells. Similar cell-surface expression levels that exceed vector-
transfected cells, which are set as 100%, are reported in previously reported
transient cotransfection Nef functionality experiments and are not discussed
(Lundquist et aI., 2002; Manninen et aI., 2001; Peng and Robert-Guroff, 2001;
Liu et aI., 2000; Mangasarian et aI., 1999; Goldsmith et aI., 1995). This study
provides no possible explanation for such a phenomenon and ultimately the
most probable rationalization would be to attribute this to an artefact of the
transient cotransfection experiments.
With regard to the assay methodology that was employed to investigate Nef
functionality, a number of points should be made. Even though the CD4 and
MHC-I downregulation detected in this study were real, the methodology can
be enhanced to improve confidence of the significance of the data obtained. In
my opinion it is essential to include a control plasmid that expresses a protein
that can be detected by flow cytometry. Due to the strong expression of MHC-I
on the cell surfaces and the small percentage of cells that were transfected
with Nef, it was difficult to demonstrate MHC-I downregulation when looking at
the total cell population and only highly fluorescing cells showed the Nef-
mediated effect. With such an internal transfection control, it is possible to
analyse transfected cells only, a factor that may well have improved analysis
of MHC-I molecule downregulation. It would thus be ideal to use a GFP-
encoding plasmid for example, which constitutively expresses GFP in
transfected cells that may be detected in the FITC-channel during flow
cytometry. A second factor that can only improve the flow cytometric
methodology is the inclusion of antibody-matched isotype controls for AP and
APC in order to define the magnitude of background IgG binding to 293 cells.
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Nonetheless, the flow cytometric assays served to identify CD4 and MHC-I
down regulation in Nef transfected cells and also to identify mutant Nef
immunogens that are defective for these functions.
Nef has been identified to be frequently targeted by CTL and Th cellular
immune responses and a very extensive array of epitapes that are restricted
by all HLA types have and are being identified. Like Tat and Rev, Nef epitapes
have nearly exclusively been identified in HIV-1 subtype B infected individuals
and CTL epitapes elicited through vaccination have similarly been specific to
the predominantly subtype B vaccines. Nonetheless, in addition to a handful of
studies that have identified subtype C-Nef CTL epitapes, a considerable
number of epitapes are conserved across subtypes and those listed in the HIV
Immunology Database (2000) that are present in the TV Cons consensus Nef
sequence that was used for construction of the Nef immunogens are shown in
Figure 39. As can be seen, despite the mutations, which are indicated on the
consensus, a number of epitape clusters are present on the subtype C Nef
consensus sequence, a finding that was described recently for HIV-1 proteins
(Yusim et al., 2002). As most described CTL epitapes are specific for subtype
B sequences, it can be postulated that only a fraction of subtype C-specific
epitapes have been found to date either by experimental methods or
interpolation of subtype B epitapes onto subtype C sequences in conserved
regions. Thus, it is reasonable to expect that a significant number of subtype
C-specific Tat, Rev and Nef CTL epitapes are still to be identified. Even so,
Figure 39 demonstrates the potential value of the pCMVKm2-Nef.myrD124LLAA
plasmid as DNA immunogen.
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Nef: murine (HLA-
A201 transgen,c)
I
M~KWSKSSIVGWPAVRERIRRTEPAAEGVGAASQDLDKHGALTSSNTAA
-myr
NefOpt:
*0301
A2, 3,A3.1, 11
B*O 35 B*03 1
B*4001
B B*4002,B60/B61
i+'08"1' INefOpt: NNADCAWLEAQEEEEEVGFPVRPQVPLRPMTYKAAFDLSFFLKEKGGLEGL
A2
NefOpt: IYSKKRQEILDLWVYHTQGFFPbwQNYTPGPGVRYPLTFGWCFKLVPVD
ti\,.,
D124G
NefOpt: PREVEEANKGENNCI!HPMSQHGMEDEDREVLKWKFDSSLARRHMARELH
II
LL165AA
NefOpt: PEYYKDCA*
Figure 39: Sequences of the HIV·1 subtype C consensus (TV Cons) Nef immunogens constructed for this study. Amno acid
substitutions in mutant proteins are indicated and named and all described CTL epitopes of known HLA restriction from the
HIV Immunology Database (2000) are indicated.
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CHAPTER 5: CONCLUSION
The continued screening and characterisation of currently circulating viral
strains is of utmost importance, as an unnoticed change in circulating virus
populations in terms of prevalence of subtypes and emergence of inter-
subtype recombinant viruses may have detrimental consequences on vaccine
design. Moreover, such screening is important to evaluate the conservation of
genes that code for vaccine immunogens, providing breadth projections for
immune responses. Finally, continued sequencing of HIV-1 genomic regions
that are employed as immunogens in vaccine strategies will provide sequence
data for the calculation of consensus proteins, providing means with which
vaccine strains can be selected and with which the relevance of such selected
vaccine strains can be assessed over time.
The collective aim of this study was to design, construct and experimentally
identify plasmids that strongly express non-functional HIV-1 subtype C
consensus Tat, Rev and Nef proteins that may serve as DNA vaccine
immunogens. In fulfilment of the objectives, the plasmids pCMVKm2-Tatc22c37
and pCMVKm2-TatC37, pCMVKm2-RevM5M1oand pCMVKm2-NetmyrD124LLAA
were shown to strongly express proteins that were found to be completely
defective for their respective functional activities. Moreover, loss of activity
was achieved without disruption or deletion of portions of these proteins that
exceed two amino acid residues per site, a strategy employed to retain a
maximum amount of conserved protein sequences that may contain
immunodominant or subdominant CTL or Th epitapes. Consensus protein
sequences were used for construction of the candidate immunogens instead
of individual viral strains or isolates and this approach was justified by the
results that the consensus sequences for Tat, Rev and Nef displayed less
genetic distance to viral strains than did anyone of the fourteen subtype C
isolates. The use of these consensus immunogens would thus serve to reduce
genetic variation between vaccine-encoded immunogenic epitopes and those
present in circulating viral populations. These potential immunogens may thus
elicit broad immune responses specific for these early and abundantly
expressed accessory/regulatory proteins that can potentially effect cytotoxic
killing of HIV infected cells before the production and budding of new virions.
Additionally, when employed in combination with the structural protein
immunogens Gag, Pol and/or Env, the inclusion of these accessory gene
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immunogens may effectively broaden the array of immune responses to
achieve higher levels of viral suppression in several stages of viral replication.
The immunogenicity and thus potential value of these DNA vaccine constructs
remain speculative until immunological studies can cast more light on this
subject. It would be important to assess immune responses in mice that have
been immunised with the Tat, Rev and Nef plasm ids. Such a study will also
allow a comparison of immunogenicity between wild-type and consensus,
codon-optimised immunogens. Furthermore, these immunogens may be fused
to form a single TatRevNef polygene cassette that may be more practical in
terms of preparation and immunisation. The work contained in this study thus
lays the foundation for extensive immunological studies to elucidate whether
these Tat, Rev and Nef immunogens are of sufficient worth to warrant their
inclusion into a HIV-1 subtype C vaccine.
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APPENDICES
Appendix A: Plasmid construct sequences
tat constructs: DNA sequence
TatOpt
TatC22
TatC37
TatC22C37
Tatwt
TatOpt
TatC22
TatC37
TatC22C37
Tatwt
TatOpt
TatC22
TatC37
TatC22C37
Tatwt
TatOpt
TatC22
TatC37
TatC22C37
Tatwt
TatOpt
TatC22
TatC37
TatC22C37
Tatwt
TatOpt
TatC22
TatC37
TatC22C37
Tatwt
TatOpt
TatC22
TatC37
TatC22C37
Tatwt
SalI start 20 * 40 *
GTCGACGCCACCATGGAGCCCGTGGACCCCAACCTGGAGCCCTGGAACCA
.................... A ..A ..T ..T A .
60 * C22 * 100
CCCCGGCAGCCAGCCCAAGACCGCCTGCAACAAGTGCTACTGCAAGCACT
......................... G .
......................... G ..•.....................
T ..A ..A ..T .....T ..A ..T ..T ..T ..T .CA .....T ..T ..AA .A.
* C37 * 140 *
GCAGCTACCACTGCCTGGTGTGCTTCCAGACCAAGGGCCTGGGCATCAGC
.................... A .
.................... A .
·T T ..T ..A ..T T A ..A T .A TTC .
160 * 180 * 200
TACGGCCGCAAGAAGCGCCGCCAGCGCCGCAGCGCCCCCCCCAGCAGCGA
·.T A.G GA .A A ..A T ..T ..A T ..
* 220 * 240 *
GGACCACCAGAACCCCATCAGCAAGCAGCCCCTGCCCCAGACCCGCGGCG
·..T ..T ..A ..T ..T ..ATCA T.A AGA TA ..G.
260 * 280 * 300
ACCCCACCGGCAGCGAGGAGAGCAAGAAGAAGGTGGAGAGCAAGACCGAG
· G ..A TCA ATCG A .
* stop BeoRI
ACCGACCCCTTCGACTAAAGAATTC 325
325
325
325
324· .A .. T .. G - .
Tat protein sequence
TatOpt
TatC22
TatC37
TatC22C37
Tatwt
* 20 * 40 *
MEPVDPNLEPWNHPGSQPKTACNKCYCKHCSYHCLVCFQTKGLGISYGRK
•.•.................. G .
.................................... S .
..................... G S ......•......
....................... T K ...........•.........
50
50
50
50
50
100
100
100
100
100
150
150
150
150
150
200
200
200
200
200
250
250
250
250
250
300
300
300
300
300
50
50
50
50
50
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TatOpt
TatC22
TatC3?
TatC22C3?
Tatwt
60 * 80 * 100
KRRQRRSAPPSSEDHQNPISKQPLPQTRGDPTGSEESKKKVESKTETDPFD*
......................... R.L .
101
101
101
101
101
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rev constructs: DNA sequence
RevOpt
RevM5M10
Revwt
RevOpt
RevM5M10
Revwt
RevOpt
RevM5M10
Revwt
RevOpt
RevM5M10
Revwt
RevOpt
RevM5M10
Revwt
RevOpt
RevM5M10
Revwt
RevOpt
RevM5M10
Revwt
SalI start * 40 *
GTCGACGCCACCATGGCCGGCCGCAGCGGCGACAGCGACGAGGCCCTGCT
· A ..AA.A A A A ..G ..T ..
60 * 80 * 100
GCAGGCCGTGCGCATCATCAAGATCCTGTACCAGAGCAACCCCTACCCCA
C ..A ..A ..AA.G A A A .
* 120 M5 140 *
AGCCCGAGGGCACCCGCCAGGCCCGGAAGAACCGCCGCCGCCGCTGGCGC
....................... <lACeT .
· T A T ..AA.AA.AA.G A.A
160 * 180 * 200
GCCCGCCAGCGCCAGATCCACAGCATCAGCGAGCGCATCCTGAGCACCTG
·.AA.A A .A T .AG ..T ..T G ..T ..T T ..
* 220 * 240 MlO
CCTGGGCCGCCCCGCCGAGCCCGTGCCCTTCCAGCTGCCCCCCATCGAGC
........................................... GA.CT ..
·.....A ..AT.T.AG .....T .....T ..T.T ...A ..A ..G ..T ...A
260 * 280 * 300
GCCTGCACATCGACTGCAGCGAGAGCAGCGGCACCAGCGGCACCCAGCAG
·A ..T ..T ..T ..T TG .T ..A ..TTCT ..G ..G .
* 320 * stop BeoRI
AGCCAGGGCACCACCGAGGGCGTGGGCAGCGCCTAAAGGAATTC 344
344
344TCT G ..T ..A G A C .T .
50
50
50
100
100
100
150
150
150
200
200
200
250
250
250
300
300
300
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Rev protein sequence
RevOpt
RevM5M10
Revwt
RevOpt
RevM5M10
Revwt
RevOpt
RevM5M10
Revwt
* 20 * MS *
MAGRSGDSDEALLQAVRIIKILYQSNPYPKPEGTRQARKNRRRRWRARQR
..................................... DL .
....... N .
50
50
50
60 * MlO * 100
QIHSISERILSTCLGRPAEPVPFQLPPIERLHIDCSESSGTSGTQQSQGT : 100
........................... DL : 100
...K SE L G. .......... : 100
TEGVGSA* 107
107
107...... P.
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nef constructs: DNA sequence
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
-myr
SalI start I * 40
GTCGACGCCACCATGGGCGGCAAGTGGAGCAAGAGCAGCATCGTGGGCTG
................ C .
................ C .
· G TCA ..A T ..AA .T ..A ..
60 * 80 * 100
GCCCGCCGTGCGCGAGCGCATCCGCCGCACCGAGCCCGCCGCCGAGGGCG
·..T .AA..AA.A ..AA.A ...A.A ..A ..TAG.T.A ..A ..A .....A.
* 120 * 140 *
TGGGCGCCGCCAGCCAGGACCTGGACAAGCACGGCGCCCTGACCAGCAGC
·A ..AT .A ..GTCT ..A ...T .A ..T ..A.GT ..G ..A ..T ..A.C ....
160 * 180 * 200
AACACCGCCGCCAACAACGCCGACTGCGCCTGGCTGGAGGCCCAGGAGGA
· A CA ..G T ..T ..T A .A ..G ..A .
* 220 * 240 *
GGAGGAGGAGGTGGGCTTCCCCGTGCGCCCCCAGGTGCCCCTGCGCCCCA
·..A ..A ..A ..A .....T ..A ..CA .A ..T .....A ..TT.AA .A ..A .
260 * 280 * 300
TGACCTACAAGGCCGCCTTCGACCTGAGCTTCTTCCTGAAGGAGAAGGGC
· T ..T ..A ..A ..AA.A ..T ..C TT .A..A ..A G
* 320 * 340 *
GGCCTGGAGGGCCTGATCTACAGCAAGAAGCGCCAGGAGATCCTGGACCT
·.A A ..GT .A ..T TC AA .G ..A .G T ..TT .
360 * D124G * 400
GTGGGTGTACCACACCCAGGGCTTCTTCCCCGACTGGCAGAACTACACCC
................................ G .
................................ G .
· T ..TA A ..A T ..T A A.
* 420 * 440 *
CCGGCCCCGGCGTGCGCTACCCCCTGACCTTCGGCTGGTGCTTCAAGCTG
·G ..A ..A ..G ..CA.A.TT ..A T ..A A
460 * 480 * 500
GTGCCCGTGGACCCCCGCGAGGTGGAGGAGGCCAACAAGGGCGAGAACAA
*
50
50
50
50
100
100
100
100
150
150
150
150
200
200
200
200
250
250
250
250
300
300
300
300
350
350
350
350
400
400
400
400
450
450
450
450
500
500
500
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Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
·A A ..C A.AG ..A ..A ..A TG .A..A ..A .
LL16SAA 520 * 540 *
CTGCCTGCTGCACCCCATGAGCCAGCACGGCATGGAGGACGAGGACCGCG
.... GC.GC .
·..TT .A..A T T ..A T ..A A.A.
560 * 580 * 600
AGGTGCTGAAGTGGAAGTTCGACAGCAGCCTGGCCCGCCGCCACATGGCC
·A ..AT .A.GA T T.TG ..A ..A A.A .
* 620 * stop EcoRI
CGCGAGCTGCACCCCGAGTACTACAAGGACTGCGCCTAAAGAATTC
........ A .. T .. G T A .
500
550
550
550
550
600
600
600
600
646
646
646
646
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Nef protein sequence
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
NefOpt
-myrD124
-myrD124LLAA
Nefwt
-m,yr * 20 * 40 *
MGGKWSKSS IVGWPAVRERIRRTEPAAEGVGAASQDLDKHGALT SSNTAA
.A .
.A .
.......... I E RS S R T H
60 * BO * 100
NNADCAWLEAQEEEEEVGFPVRPQVPLRPMTYKAAFDLSFFLKEKGGLEG
S K 1 .
* D124G * 140 *
LIYSKKRQEILDLWVYHTQGFFPDWQNYTPGPGVRYPLTFGWCFKLVPVD
....................... G .
....................... G .
........ G N F E .
160 LL165AA lBO * 200
PREVEEANKGENNCLLHPMSQHGMEDEDREVLKWKFDSSLARRHMARELH
.............. AA .
.Q E R M .
NefOpt PEYYKDCA* 20B
-myrD124 ......... 20B
-myrD124LLAA ......... 20B
Nefwt ......... 20B
50
50
50
50
100
100
100
100
150
150
150
150
200
200
200
200
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Appendix B: Raw data for p-galactosidase internal control and normalisation of CAT enzyme levels for Tat and
Rev functionality assays.
Normalisationof CAT enzyme levels with the internal transfection control ~-Galactosidase for three Tat functionality experiments done in Hela cells. The raw CAT enzyme readings were multiplied with a
normalisationfactor, calculated from ~-Galactosidaseenzymelevels, to control for Iransfectionefficiency.
experiment 1 experiment 2 experiment 3
CAT raw normal CAT raw normal CAT normal
data ~-Gal factor .CAT data ~-Gal factor . CAT raw ~-Gal factor .CAT
data
Mock 5.0 0.92 1.00 5.0 0.0 1.12 1.00 0.0 0.0 1.17 1.00 0.0
pLTR-CAT 4.7 0.87 1.06 5.0 0.0 1.16 0.96 0.0 0.0 1.27 0.93 0.0
Tatwr 712.9 1.07 0.86 613.0 203.6 1.09 1.03 210.2 537.0 1.17 1.00 538.4
TatoPT 826.1 1.25 0.74 608.0 213.8 1.01 1.11 237.6 340.5 1.10 1.07 363.1
Tab2 399.1 0.90 1.02 408.0 196.1 0.94 1.20 234.4 202.0 1.02 1.15 231.4
Tatc22c37 5.1 0.94 0.98 5.0 0.0 0.98 1.15 0.0 0.0 1.06 1.11 0.0
Tab7 0.0 1.20 0.77 0.0 0.0 1.08 1.04 0.0 0.0 1.15 1.02 0.0
~-Gal, ~-Galactosidase reading; factor, normalisation factor calculated from ~-Galactosidase reading, mock was set as 1; normal. CAT, normalised CAT level.
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Normalisationof CATenzymelevelswith the internal transfectioncontrol ~·Galactosidasefor three Rev functionalityexperimentsdone in 293Tcells.The raw CATenzymereadingswere multipliedwith a
normalisationfactor,calculatedfrom~-Galactosidaseenzymelevels,to controlfor transfectionefficiency.
experiment 1 experiment 2 experiment 3
CAT raw normal CAT raw normal
CAT normal
data ~-Gal factor .CAT data ~-Gal
factor .CAT raw ~-Gal factor .CATdata
Mock 5.0 1.50 1.00 5.0 8.5 1.76 1.00 8.5 0.0 1.15 1.00 0.0
pOM128 6.4 1.91 0.79 5.0 25.0 1.87 0.94 23.5 0.0 1.26 0.91 0.0
pRSV-Rev 1119.0 1.87 0.80 897.6 NO NO NO NO 731.2 1.20 1.05 767.7
RevWT 395.3 1.80 0.83 329.4 110.2 1.66 1.06 116.8 278.2 1.22 0.98 273.7
RevM5Ml0 5.8 1.74 0.86 5.0 13.2 1.72 1.02 13.5 0.0 1.33 0.92 0.0
~.Gal, ~.Galactosidase reading; factor, normalisation factor calculated from ~-Galactosidase reading, mock was set as 1; normal. CAT, normalised CAT level; NO, not done.
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Appendix C: Characterisation of the South African HIV-1 subtype C complete 5' LTR,
nef and regulatory genes
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Sequence Note
Characterization of the South African HIV Type 1 Subtype C
Complete 5' Long Terminal Repeat,
nef, and Regulatory Genes
THOMAS 1. SCRIBA,I TANIA DE VILLIERS,I FLORETTE K. TREURNICHT,I JAN ZUR MEGEDE,2
SUSAN W. BARNETT,2SUSAN ENGELBRECHT, I and ESTRELITA JANSE VAN RENSBURGI
ABSTRACT
Human immunodeficiency virus type 1 (HIV-I) subtype C has become the major etiological agent in the global
and especially African epidemic. To gain better understanding of the genetic diversity and rapid transmis-
sion ofHIV-l subtype C, we have characterized the complete 5' long terminal repeat (LTR) region along with
the regulatory genes tat and rev as well as the accessory gene nef of 14 South African HIV-I subtype C iso-
lates. Phylogenetic analysis revealed a subtype C 5' LTR cluster, as well as subclustering of our nefsequences
with various subtype C strains separate from the India and China subclusters. At least 3 NF-KBsites were
present in the 5' LTR of most isolates and 13 isolates had the subtype C-specific Rev truncation. Some length
variation in exon 2 and the absence of a critical cysteine were found in Tat. Residue variation in the myrls-
toylation signal and motifs involved in CD4 and MHC-I downregulation was recorded in our nef gene se-
quences.
THE HUMAN IMMUNODEFICIENCY VIRUS type I (HIV-I) sub-type C epidemic is responsible for most HIV -I infections
worldwide and close to half of the HIV -I infections in sub-Sa-
haran Africa.' This epidemic has attained a rapid global distri-
bution and, whereas transmission of other subtypes such as B
seems to be on the decline, HIV -I subtype C is spreading at
alarming rates.I? To date, the majority of genetic characteriza-
tion studies of South African HIV -1 strains have been focused
on the env and the gag genes, and thus little is known about
the regulatory regions and genes of local subtype C strains.
Specifically, the 5' long terminal repeat (LTR) region as well
as the tat and rev genes of South African subtype C strains re-
main to be comprehensively characterized. Thus analysis
thereof may provide more data about the diversification of this
efficiently transmitted subtype. In this study we sequenced and
phylogenetically analyzed the tat, rev, and nef genes as well as
the 5' LTR of 14 previously described HIV-I subtype C iso-
lates from South Africa.ê-"
The three genomic regions containing tat and rev exons I
and 2 as well as nef were amplified in a nested polymerase
chain reaction (PCR) from a 9-kb, nearly full-length fragment
as described previously.ê-" The 5' LTR was amplified by sin-
gle-step PCR from DNA prepared from primary isolates. Primer
pairs NefF (5'-CCTAGAAGAATAAGACAGGGCTI-3')
and NefR (5'-CCTGGAACGCCCCAGTGG-3'); NewS I_IT/
NewS I_IC (5'-GCAGGACGTCAAGCTIGGAAGGGTI A-
ATTIACTC[T/C]AAGAA-3') and SI_65INot (5'-CCT-
TGGCCAGCGGCCGCCCCTGTTCGGGCGCCACTGCTA-
GAGA-3'); TatXIF (5'-AATIGGGTGCCAGCATAGC-3')
and NACD (5'-CCATAATAGACTGTGA-CCCACAA-3');
and RevX2F (5'-TGCTGTGCTCTCTATAGTRA-3') and.
RevX2R (5'-TCCTATCTGTICCTTCAGCTA-3') were used
for the amplification of the -660-bp fragment containing the
nef gene, the -640-bp 5' -LTR region, the -570-bp fragment
containing the tat/rev exon 1, and the -350-bp fragment con-
taining the tat/rev exon 2, respectively. 5'-LTR amplicons of
'Department of Medical Virology, University of Stellenbosch, Tygerberg 7505, South Africa.
2Chiron Corporation, Emeryville, California 94608.
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FIG. 1. Rooted trees depicting the evolutionary relationships among the 5' LTR region (A) as well as the nef (B) nucleotide
sequences from South African HIV -I subtype C isolates. The Kimura two-parameter distance matrix and neighbor-joining method
were used in the phylogeny calculations. The distance scale indicates 0.1 nucleotide replacements per site. Horizontal branch
lengths are drawn to scale and the validity of the branching orders was estimated with 500 bootstrap replicates. The significant
(above 85%) bootstrap values are indicated at the respective branch bases.
three isolates (TVOOI, TVOO4, and TVa 12) were cloned into
the pGEM-llZf( +) vector (Promega, Madison, WI) according
to the manufacturer protocol and can be identified by their clone
numbers. Sequencing reactions were carried out by using the
ABI Prism BigDye terminator cycle sequencing protocol and
sequencing was performed on a 310 genetic analyzer (PE Ap-
plied Biosystems, Foster City, CA). The PCR primers were used
as direct sequencing primers with the addition of the LTRFor
(5'-ACAAAGACTGCTGACACA-3') and LTRRev (5'-TGT-
GTCAGCAGTCTITGT-3') primers for the 5' LTR region. Se-
quences were verified manually and sequence assembly, mul-
tiple alignments, and translation into predicted amino acid se-
quences were performed as described.ê-" Calculation of distance
matrices, phylogeny inference, and construction of trees were
performed with the PHYLIP software packages SEQBOOT,
DNADIST, NEIGHBOR, and CONSENSE. Rooting and ma-
nipulation of the trees were done in TREEVIEW.
The phylogenetic tree constructed with all full-length 5' LTR
7""1
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FIG. 1. Continued.
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sequences from the Los Alamos database (Fig. IA) shows a
clustering of our isolates with the only available subtype C full-
length 5' LTR from Botswana (isolate 96BW06.F20). The tree
constructed with all available subtype C nef coding sequences
(approximately 625 bp in length) (Fig. lB) shows the South
African isolates including the recently described 97ZAOI2.!
(AF286227) from Durban.ê subcluster with isolates from
Botswana, Ethiopia, Brazil, Tanzania, and Zambia as well as
one Israeli and two Indian isolates. This monophyletic subtype
C clade is distinctly separate from the Chinese and Indian
clades, as supported by statistically significant bootstrap val-
ues. These data thus display a lesser degree of diversity for the
South African strains than was reported for the gag and env
genes" as well as the genomic fragment encompassing the viJ,
vpr, and vpu genes.! In contrast with the nef sequence results,
these previous studies showed a diversity within the South
African isolates that virtually matches the diversity of the global
C subtypes studied to date as a whole. However, this finding is
expected because nef is a smaller, highly conserved coding re-
gion. Interestingly, two Indian sequences fall among the main
monophyletic clade. Considering the distinct subclustering of
the Indian isolates, which indicates that they share a common
ancestor, this suggests that these two isolates may have origi-
nated in sub-Saharan Africa and migrated to or been transmit-
ted in India through the frequent movement of people.
Nucleotide alignments of the full-length 5' LTR sequences
confirm the presence of all potential transcription factor-bind-
ing sites, with the third NF-KB site reported for HIV-l subtype
C sequences (Fig. 25a).6-8 All three sites in most of our isolates
conform to the reported NF-KB sequence." while NF-KB-like
sites have been identified in TV008 [GGGGCGG_TCCj,
TVOl2c2 [GGAACTITCCj, and TVOl9 [GGGACTTTCI1.
The ClOT substitution seen in TVOl9 has previously been iden-
tified in another South African isolate, 98ZA445ZA.8 In their
previous report, Rodenburg et al.5 described frequent deletions
or mutations in the third NF-KB site, questioning the causal role
of the third site in the explosive subtype C epidemic. In con-
trast, 12 of our isolates have 3 NF-KB sites and only TV008
and TVOl2 have two sites, with a third NF-KB-like site. Our
data thus indicate that in the majority of South African isolates
analyzed in this study, the presence of the three NF-KB sites
may well confer a stronger promoter activity resulting in more
rapid transmission. The Sp I-I, Sp I-II, and Sp I-III sites in the
core promoter are conserved, with Sp I-III being the most vari-
able and SpI-II the most conserved. This contrasts with a re-
port stating that Spl-I is the more conserved element."? The
guanine residue at position 4 of the Sp 1 sites, imperative for
maximizing Sp factor recruitment, is conserved for all our se-
quences.'? A fourth Sp 1 site (positions -433 to -441) dis-
covered to be essential for negative-sense transcription in the
HXB2 sequence (5' -TGGGAGTGA-3') has up to three substi-
tutions in our sequences.'! The NF-AT sites show little diver-
gence among our isolates, but differ substantially from the
HXB2 sequence. A reported subtype C consensus in the core
region of the NRE (CGCARACA YVTK) was almost perfectly
conserved in all our sequences. i2 Johansson et al. i3 reported
that the GIA CAGA motif within the above-mentioned sequence
is diagnostic for subtype C strains. All but three of our isolates
possess this motif: TV003 displays a G4C, TVOIO a C2T, and
TVO19 a G4A substitution. The alanines at positions 5 and 9,
SCRIBA ET AL.
as well as the guanine at position 10, of the TCF-la site are
conserved across our isolates and the reference strains. with the
exception of subtype B and group O. TVO 19 has a C-to- T sub-
stitution in the bulge of the TAR region, which has been iden-
tified in subtype G, circulating recombinant forms, as well as
SIV strains. The T-to-C nucleotide change at position 2 of the
loop structure in the TAR element occurs in eight of our iso-
lates.
The deduced Nef amino acid sequences (Fig. 3A) show pre-
viously described length variations, especially in the reported
N-terminal variable region. Thirteen South African isolates
have seemingly intact Nef open reading frames. The premature
stop in the N-terminal of the protein sequence of isolate TV006
suggests that this isolate would start translation at the second
initiation site.14.15 This protein would lack the myristoylation
signal and would thus, because of unsuccessful myristoylation,
most probably not fold correctly or be directed to the mem-
brane.!? All isolates with the exception of TV005, TV006,
TVOI2, and TVOl3 as well as reference strain 96BW12-1O from
Botswana have conserved GGXXS motifs in their myristoyla-
tion signals. It has been described that GSXXS mutations are
possibly associated with slow disease progression!" and that
deletion or substitution of the glycine residues, to which the
myristylic acid is linked, prohibits myristoylation.!" Other stud-
ies and sequences in the Los Alamos sequence database sug-
gest sequence diversity is not uncommon among myristoyla-
tion signals.'? Residue and length variations observed in our
Nef proteins correlate with those in the other subtype C strains,
suggesting relatedness. Most of the significant domains such as
those involved in CD4 and MHC-I downregulation as well as
altering of cell signaling are found to be well conserved in all
sequences and variations correlate with results obtained in pre-
vious studies.17.19-22 Furthermore, considering the presence of
intact WL57 motifs, which allow for proteolytic cleavage, post-
translational modification of Nef seems to be intact. None of
the gene deletions associated with non progression or slow pro-
gression of HIV -I disease have been found to be present in our
isolates and, in fact, the disease progression of the 14 patients
is not in any way abnormal.' However, some of the amino acid
variations reported to be more frequent in progressors as op-
posed to nonprogressors-" were present in our sequences as well
as some subtype C reference sequences. Specifically, the AI5,
C 163, and Q 170 variations were found in most subtype C se-
quences. In addition, the N51 amino acid variation found to be
more frequent in nonprogressors was predominant in subtype
c.20
Whereas most South African isolates have Tat amino acid
sequences of lOl residues in length, some length variation was
found in 5 isolates (Fig. 3B). TVOOI lacks the orthodox stop at
position 102 and is terminated at the next position. whereas
TV004, TVOIO, TVOI2, and TVOl8 terminate prematurely at
position 100. Yet, all 14 isolates show intact open reading
frames and, interestingly, this two-residue truncation in Tat has
been identified in HIV-I subtypes D, F, H, J, and K. Notably,
the basic domain GRKKRRQRR (residues 48-56) as well as
the highly conserved ESKKKVE motif are 100% conserved
among all subtype C sequences except in TVO12, which con-
tains an EPKKKVE motif. The critical cysteine residues at po-
sitions 22, 25, 27, 30, 34, and 37 of all sequences are found to
be 100% conserved. Yet at position 31, all isolates except
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FIG.2. Graphical representation of the nucleotide sequence alignment of the 5' LTR from South African subtype C isolates along with the available subtype C strain from
Botswana and HXB2. Regulatory elements are represented as blocks for clarity. For a detailed review of these elements refer to Pereira et al.5u -VI~
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TV004, TVOIO, and TVOl4 have a putative serine residue in-
stead of the prevalently conserved cysteine. Similarly to Tat,
Rev shows well-conserved amino acid sequences with some
variation in the C-terminal region and intact reading frames in
all isolates (Fig. 3C). The truncation in exon 2 of Rev at posi-
tion 108, which seems to be exclusive to HIV-I subtype C
strains, is found in our isolates. Notably, isolate TV005 does
not have this subtype C-specific Rev truncation and thus has
an Rev protein 126 amino acids in length. Isolates TVOl4 and
TVOl9 have a seven-residue deletion directly following the nu-
clear export signal (NES), which is also present in one subtype
C reference strain. In correlation with Tat and Nef, residue vari-
ations within both exons of Rev in our isolates are similar to
those seen in the other subtype C strains.
As reported in the study of the env genes of these isolates,"
no significant or prominent sequence variations in the Rev re-
sponsive element that may have implications on interaction with
the Rev protein have been detected.
The rapid transmission of HIV -I, and in particular HIV-l
subtype C, has been the topic of extensive research to fathom
the mechanisms involved. Yet, limited data concerning the sub-
type C epidemic in southern Africa make this a daunting task.
Reports have suggested that the more rapid transmission of sub-
type C in relation to the other subtypes could be due to higher
levels of LTR promoter activity resulting in upregulation of vi-
ral transcription.v-" This could be attributed to either the extra
NF-KB-binding site and/or the distinctly different NRE se-
quence in the LTR of subtype C strains. The upregulation of
transcription should thus be apparent in the isolates that show
a conserved subtype C NRE region, especially TVO19, which
has three NF-KB sites as well as an additional Nf-xfs-like site.
Gene expression should be efficient in all our isolates, as a re-
sult of the TAT A box being well conserved. Moreover, stronger
C-strain transcription may possibly be the combined effect of
these unique features in the LTR along with the differences
found in the cysteine-rich domain of subtype C Tat. Being the
trans-activator of HIV -1 gene expression, mutations in the func-
tional domains of Tat may well have significant effects on in-
teraction with the promoter regions in the LTR. However, in
their study, Jeang et 01.24 found that although a C3l E substitu-
tion results in decreased trans-activation activity of Tat, a C31S
substitution has no significant effect. In addition to the missing
critical cysteines, the two-residue truncation in exon 2 of Tat
in some isolates could possibly also contribute to variable in-
teraction with the LTR. If the truncation of Rev confers en-
hancing effects on !he efficiency of Rev-dependent transcript
export and thus expression of late viral mRNAs and their pro-
teins, this may point to a coevolution of the subtype C LTR,
Rev, and Tat to constitute a transcriptional regulation pathway
that functions at higher levels. Alternatively, the rapid trans-
mission of subtype C could be a result of non virological fac-
tors and further studies will have to be performed to investi-
gate the validity of these hypotheses. The local subtype C isolate
that did not contain the signature truncation in Rev at position
108 (TV005) was the only isolate that was able to utilize the
co receptors CXCR4, CCR2b, CCR3, and CCR4 in addition to
CCR5 in HOS-CD4 coreceptor transfectants. However, it was
still nonsyncytium inducing in MT-2 cells and no changes in
charge associated with the syncytium-inducing phenotype were
present in the V3 loop area of the envelope protein.P
SCRIBA ET AL.
When taken alongside the characterization of the env, gag,
and accessory gene sequences, these data show that the 14 iso-
lates from Tygerberg Hospital are nonrecombinant subtype C
isolates representative of the South African HIV-I subtype C
epidemic.
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Appendix 0: Plasmid vectors
1. pCR3.1 (Invitrogen, CA, USA)
2. pcDNA3.1 (Invitrogen, CA, USA)
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Eukaryotic TA Expression Kit
Bidirectional
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Catalog nos. K3000-01, K3000-40
A Limited Label License covers this product (see Purchaser Notification). By use of this
product, you accept the terms and conditions of the Limited Label License.
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Overview
Purpose
How Eukaryotic
TACloning®
Works
Diagram
Advantages
gNote
Introduction
The Eukaryotic TA Expression Kit from Invitrogen provides a quick, one-step system to
directly ligate a Taq polymerase-amplified PCR product into a mammalian expression
vector. Once cloned, analyzed, and transfected, the PCR product can be directly tested
for expression in mammalian cell lines.
Taq polymerase has a nontemplate-dependent activity that adds a single deoxyadenosine
(A) to the 3' ends of duplex molecules. The linearized vector supplied in this kit has
single 3' deoxythymidine (T) residues. This allows PCR inserts to ligate efficiently with
the vector.
The diagram below shows the concept behind TA Cloning'[.
3'
Using the Eukaryotic TA Expression Kit...
• Eliminates any enzymatic modifications of the PCR product.
• Does not require the use ofPCR primers that contain restriction sites .
• Allows direct expression in mammalian cell lines without additional subcloning.
Thermostable polymerases containing extensive 3'- to 5'-exonuclease activity, such as
Vent" and Plu, do not leave 3' A-overhangs. PCR products created using these enzymes
can be cloned efficiently into TA Cloning" vectors after incubation with Taq
polymerase (see page 15). Incubation with Taq polymerase adds 3' A-overhanls to
blunt ends to allow efficient cloning of blunt PCR products using TA Cloning vectors.
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The pCR®3.1 Vector
Figure of pCR®3.1 The figure below shows the map of pCR®3.1. Restriction sites are labeled to indicate the
actual cleavage site. The arrow indicates the start ofT7 transcription. The complete
sequence can be downloaded from our Web site (www.invitrogen.com) or requested
from Technical Service (see page 24). Note that pCR®3.! is supplied linearized at the
TA Cloning" site.
638
Nhs I PmsI Hjm III Kpn I BamHI
I I I I ITAATACGACT CACTATAGGG AGACCCAAGC TGGCTAGCGT TTAAACTTAA GCTTGGTACC GAGCTCGGAT
ATTATGCTGA GTGATATCCC TCTGGGTTCG ACCGATCGCA AATTTGAATT CGAACCATGG CTCGAGCCTA
708
BsfX I EcoR I EcoR I Pst I EcoR V
I I I I I
CCACTAGTCC AGTGTGGTGG AATTCGGC_T •••••• 'AGCCG AATTCTGCAG ATATCCAGCA
GGTGATCAGG TCACACCACC TTAAGCCG ' TTCGGC TTAAGACGTC TATAGGTCGT
763
BsF I Ncr I XhlO I x~a I APia I Pre I BGH reversepriming
CAGTGGCGGC CGCTCGAGTC TAGAGGGCCC GTTTAAACCC GCTGATCA C CTCGACTGTG CCTTCTA
GTCACCGCCG GCGAGCTCAG ATCTCCCGGG CAAATTTGGG CGACTAGT G GAGCTGACAC GGAAGAT
Comments for pCR®3.1
5060 nucleotides
pCR®3.1
5060 bp
CMV promoter: bases 1-596
Putative transcriptional start: bases 620-625
T7 promoter/priming site: bases 638-657
Multiple cloning site: bases 670-801
TA Cloning® site: 737-738
BGH reverse priming site: bases 813-831
BGH polyadenylation site: bases 812-1026
pUC origin: bases 1116-1789
SV40 promoter and origin: bases 3194-3532 (complement)
Neomycin/kanamycin resistance gene (ORF): bases 2371-3159 (complement)
Thymidine kinase polyadenylation site: bases 1926-2196 (complement)
Ampicillin resistance gene (ORF): bases 3611-4471 (complement)
f1 origin: bases 4602-5058
Continued on next page
2
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The pCR®3.1 Vector, continued
Features The table below describes the features ofpCR®3.1 (5060 bp)
Feature Function
Cytomegalovirus (CMV) immediate- High-level expression of cloned gene
early promoter
T7 promoter and priming site In vivo or in vitro transcription of sense RNA
Sequencing of insert
TA Cloning" site Insertion of Taq polymerase-generated PCR
product
Polylinker Unique restriction sites allow excision of
PCR product, if desired
BGH reverse priming site Sequencing of insert
Bovine growth hormone mRNA stability and effective termination
polyadenylation signal
SV40 early promoter Expression of the kanamycin gene for G418
selection in mammalian cells
SV40 origin Episomal replication in cells containing
SV40 large T antigen
Neomycinlkanamycin resistance gene Selection and generation of stable
mammalian cell lines
Selection and maintenance in E. coli
Note: pCR®3.l confers resistance to
kanamycin by means of a cryptic promoter.
The bacterial kan promoter was not
subeloned into the vector.
Ampicillin resistance gene Selection and maintenance in E. coli
pUC origin Replication, maintenance, and high copy
number in E. coli
fl origin Rescue of sense strand for mutagenesis and
single-strand sequencing
3
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Methods
Experimental Outline
Description
Experimental
Process
4
In order to clone into peR®3.1, it is necessary to first generate the peR product desired.
Once your peR product is synthesized, it is ligated into peR®3.1 and transformed into
One Shot" (TOPIOF') competent cells. The peR product generated can ligate into the
vector in either orientation. Individual recombinant plasmids need to be analyzed by
restriction mapping for orientation. The recombinant plasmid with the correct orientation
is purified for transfection into mammalian cell lines.
You should already have a mammalian cell line of choice and a protocol for transfection.
References for transfection of mammalian cell lines are found in the Reference section
(see page 29).
The table below describes the general steps needed to clone your peR product into
peR®3.1.
Step Action Page
1 Design your peR primers to clone the DNA of interest 5
2 Amplify your peR product 5
3 Ligate the peR product into peR®3.1 7
4 Transform the ligation mixture into TOPIOF' cells 9
5 Select transformants and analyze for insert and orientation 10
6 Isolate clean plasmid DNA for transfection into mammalian cells Il
7 Assay for expression of the peR product 12
When using the Eukaryotic Expression Kit for the first time, it is recommended that you
complete the control reactions for peR, ligation, and transformation along with your
sample. This will help you analyze any possible problems with your experiment.
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Producing peR Products
Design of PCR
Primers
Kozak Sequence
Guidelines for
PCR
Amplifying Your
Product
Desi~n of the peR primers is critical for expression of the desired gene of interest.
peR 3.1 is a nonfusion expression vector that does not contain an ATG initiation
codon. If there is no initiating ATG codon or optimal sequences for translation initiation
(Kozak sequences) in the DNA to be amplified, then these features need to be
incorporated into your forward primer.
In general, we recommend that you include a Kozak translation initiation sequence for
proper initiation of translation in mammalian cells. An example ofa Kozak consensus
sequence is provided below. Note that other sequences are possible, but the A or G at
position -3 and the G at position +4 are the most critical for function (shown in bold).
The ATG initiation codon is shown underlined.
AlGNNATGG
Generally, 10-100 ng of DNA is sufficient to use as a template for peR. If amplifying a
pool of cDNA, the amount needed depends on the relative abundance of the message of
interest in your mRNA population. For optimal ligation efficiencies, We recommend
using no more than 30 cycles of amplification.
1. Set up the amplification reaction in a 50 JlI volume as follows. For the DNA
template, use 10 ng if you are using plasmid DNA and 100 ng if you are using
genomic DNA.
DNA template 10-100 ng
lOX peR buffer 5 ul
dNTP Mix 0.5 f.ll
Primers 1 f.lM each
Taq DNA polymerase (1 unit/nl) 1 f.ll
Sterile water bring volume to 50 ui
Total Volume 50 f.ll
2. Overlay the reaction with 70 ul of mineral oil.
3. Perform 20-30 amplification cycles with a final 7-10 minute extension step. The
final 7-10 minute extension step is necessary to make sure all DNA is double-
stranded with 3' A-overhangs.
4. Remove 10 ul from each amplification reaction and analyze by gel electrophoresis
in a 0.8-1.5% agarose gel. You should see a discrete band. If you do not see a
discrete band, see the next page. Keep the amplification reaction on ice or store at
-20°e.
5. Quantify the amount of DNA (ug/ml) by measuring against a known standard run
on the same gel. Proceed to Cloning into pCR®3.1.
Continued on next page
5
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Producing peR Products, continued
~Nore
Smearing or multiple banding of product may necessitate gel purification. Gel
purification may decrease ligation efficiency. It is recommended that your PCR
reactions be optimized to avoid gel purification. Innis, et al. provides suggestions to
optimize your PCR reaction. Invitrogen also offers the PCR Optimizer™ Kit (Catalog
no. KI220-OI) that incorporates some of the recommendations found in this reference.
6
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Cloning into pCR®3.1
Before Starting
~Nore
Cloning into
pCR®3.1
You should have a fresh solution of your PCR product that gives a discrete band on an
agarose gel. There is usually no need to clean or purify the PCR product after the final
amplification cycle.
Since there is no blue-white screening for the presence of inserts, individual
recombinant plasmids need to be analyzed by restriction analysis for the presence and
orientation of insert. The T7 Forward and BGH Reverse primers can be used to
sequence across an insert in the multiple cloning site to also confirm orientation.
For optimal ligation efficiencies, Invitrogen recommends using fresh (less than I day
old) PCR products because the single 3' A-overhangs on the PCR products may degrade
over time, reducing ligation efficiency.
The pCR®3.1 vector is stable for 6 months from date of purchase if it has not been
subjected to freeze-thaw cycles. Care must be taken when handling the linearized vector
as loss of the 3' T-overhangs will cause a blunt-end self-ligation of the vector and
subsequent decrease in ligation efficiency with your product.
1. Centrifuge one vial ofpCR®3.1 briefly to collect all the liquid in the bottom of the
vial.
2. Mark the date of first use on the vial, and ifthere is any vector remaining after the
experiment, store at -20°C or -70°C.
3. Use the formula below to estimate the amount ofPCR product needed to ligate with
60 ng (20 frnoles) ofpCR®3.1 vector:
X ng PCR product = (Y bp PCR product) (60 ng pCR®3.1 vector)
(size in bp of the pCR®3.l vector: 5060)
"X" ng is the amount of PCR product of "Y" base pairs to be ligated for a I: I
(vector:insert) molar ratio. However, it is recommended that a 1:2 (vector:insert)
ratio be used, so multiply "X" by 2 to get the amount needed for ligation.
4. Using the concentration previously determined for your PCR reaction, calculate the
volume needed to give the amount determined in step 3. Use sterile water to dilute
your PCR reaction if necessary.
5. For example, set up the ligation reaction as follows:
Fresh PCR product
10X Ligation Buffer
pCR®3.1 vector (30 ng/J.11)
T4 DNA Ligase (4 units/ul)
Sterile water
X III
1 III
2111
1 III
to a final volume of 10 III
6. Incubate the ligation reaction at 15°C for a minimum of 4 hours (preferably
overnight). Proceed to Transformation, page 9.
7. If you are unable to transform immediately, you can store your DNA at -20°C until
ready for transformation.
Continued on next page
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Cloning into pCR®3.1, continued
~Nore
In general, 0.5 to 1.0 ul of a typical PCR reaction with an average insert length will give
a ratio of 1:2 (vector:insert). The ratio of 1:2 (vector:insert) gives the best efficiency of
ligation. You may wish to do a second ligation reaction at a ratio of 1:3 (vector:insert)
or I: I (vector:insert), if you are concerned about the accuracy of your DNA
concentrations.
Ligation at higher or lower temperatures than 15°C may reduce the ligation efficiency.
8
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Transformation
Before Starting
Using Competent
Cells
For Users of
pCR®2.1
Preliminary Steps
At this point you should have a ligation reaction with your insert ligated into pCR®3.1,
and you are ready to transform into One Shot" cells (TOP IOF').
Competent cells are highly sensitive to changes in temperature or mechanical lysis
caused by pipetting. Therefore, be extremely gentle when working with competent cells.
Transformation should be started immediately following the thawing of the cells on ice.
Stir gently with a pipette tip to mix reagents; do not pipette up and down. Do not hold
the bottom of the tube in your fingertips as this warms the cells.
Remember to use sterile technique when handling and plating your transformations.
Use kanamycin to select transformants when PCR products are amplified from
ampicillin-resistant plasmids. For example, the lacZ product amplified from the pUCI8
Control DNA template included in the kit is a PCR product from an ampicillin-resistant
plasmid. Selecting with kanamycin will prevent contamination of the transformation
reaction by the original ampicillin-resistant plasmid (pUC 18).
DO NOT use One Shot" INVaF' competent cells as a substitute if you have these in
your laboratory. Transformation efficiencies are 100-1000 fold less on kanamycin than
TOPIOF'. Also do not use TOPIOF' with pCR®2.1 unless you use IPTG along with
X-Gal for blue-white screening.
I. Equilibrate a water bath to 42°C. Thaw the vial of SOC medium and bring to room
temperature.
2. Place an appropriate number of 10 em diameter LB agar plates with either
25 ug/ml kanamycin or 50 ug/rnl ampicillin in a 37°C incubator to remove excess
moisture. Use two plates for each ligation/transformation.
Continued on next page
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Transformation, continued
Procedure for
Transformation
Restriction
Analysis
Troubleshooting
10
1. Centrifuge the vials containing the ligation reactions briefly and place them on ice.
2. Thaw on ice one 50!l1 vial offrozen One Shot" TOPIOF' competent cells for each
ligation/transformation.
3. Pipette 2 ul of each ligation reaction directly into the competent cells and mix by
stirring gently with the pipette tip. Do not pipette up and down.
4. Incubate the vials on ice for 30 minutes. Store the remaining ligation mixtures at
-20°e.
5. Heat shock for exactly 30 seconds in the 42°C water bath. Do not mix or shake.
6. Remove the vials from the 42°C water bath and immediately place on ice.
7. Add 250 JLI of SOC medium (at room temperature) to each tube.
8. Shake the vials at 37°C for 1 hour at 225 rpm in a shaking incubator.
9. Spread 10-50 ul from each transformation vial on separate, labeled LB agar plates
containing either 25 ug/ml kanamycin or 50 ug/ml ampicillin. Make sure all the
liquid is absorbed, then invert the plates and place them in a 37°C incubator
overnight. Note: Plate two different volumes to ensure that at least one plate has
well-spaced colonies. When plating small volumes « 20 ul), add 20 ul SOC to
ensure even spreading.
10. You should obtain 100-400 colonies per plate depending on the volume plated.
I. Pick at least 10 colonies and inoculate into LB containing 50 ug/ml ampicillin or
25 ug/ml kanamycin.
2. Isolate plasmid DNA and analyze by restriction mapping or sequencing for the
presence and orientation of the insert. The T7 Forward and BGH Reverse primers
are included for this purpose. Resuspend primers in deionized water to the
concentration desired. Note that not all T7 primers have the same sequence, so if
you substitute primers, check the sequence carefully.
3. Once you have confirmed that you have the correct clone, be sure to prepare a
glycerol stock for long-term storage and then proceed to Transfeetion, next page.
If you have problems obtaining a clone with the appropriate insert, review the control
reactions described on pages 16-19. Perform the control reactions prior to contacting
Technical Service (page 24).
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Transfection
Introduction
Plasmid
Preparation
Methods of
Transfection
Positive Control
Assay for CAT
Activity
Once you have confirmed that your insert is in the correct orientation for expression,
you are ready to transfect your cell line of choice. We recommend that you include the
positive control vector (pCR®3. JlCAT) and a mock transfection to evaluate your results.
Plasmid DNA for transfection into eukaryotic cells must be very clean and free from
phenol and sodium chloride. Contaminants will kill the cells, and salt will interfere with
lipid complexing, decreasing transfection efficiency. We recommend isolating plasmid
DNA using the S.N.A.P.'" MiniPrep Kit (10-15 ug DNA, Catalog no. KI900-01), the
S.N.A.P."" MidiPrep Kit (10-200 ug, Catalog no. KI9IO-OI), or CsCI gradient
centrifugation.
For established cell lines (e.g. HeLa), consult original references or the supplier of your
cell line for the optimal method oftransfection. We recommend that you follow exactly
the protocol for your cell line. Pay particular attention to medium requirements, when to
pass the cells, and at what dilution to split the cells.
Methods for transfection include calcium, lipid-mediated, and electroporation. Invitrogen
offers the Calcium Phosphate Transfection Kit for mammalian cell transfection and
Lipofectamine" 2000 Reagent to optimize lipid-mediated transfection.
Catalog No. Description
K2780-01 Calcium Phosphate Transfection Kit
11668-027 Lipofectamine™ 2000 Reagent
pCR®3.lICAT is provided as a positive control vector for mammalian cell transfection
and expression and may be used to optimize transfection conditions for your cell line
(see page 20). A successful transfection will result in CAT expression that can be easily
assayed (see below).
Note: Resuspend the lyophilized plasmid in water and transform into TOPIOF' cells as
described on page 10. Isolate plasmid DNA as described above.
You may assay for CAT expression by a number of methods. A simple, one-vial
procedure utilizing [14C] or CH]acetyl CoA has been reported (Neumann et al., 1987).
For your convenience, Invitrogen offers the CAT Antiserum (Catalog no. R902-25).
Other commercial kits are available for assaying CAT expression.
Continued on next page
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Transfection, continued
Assay for
Function
After you have transfected your peR®3.l construct into mammalian cells you need to
assay for transient expression of your peR product. After confirming expression using
the method appropriate for your cell line and peR product, you may elect to create
stable cell lines.
Stable Cell Lines peR®3.1 confers resistance to the antibiotic G418. In general, we recommend that you
perform a kill curve to determine the concentration of G4l8 that kills your host cell line.
If you already know the concentration, you may proceed with transfection and selection,
us ing your method of choice.
12
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pcDNA3.1 (+)
pcDNA3.1(-)
Catalog nos. V790-20 and V795-20, respectively
Version I
081401
28-0104
•-I Invitrogen'"
life technologies
www.invitrogen.com
tech_ service@lnvitrogen.com
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Overview
Introduction
Experimental
Outline
Methods
pcDNA3.1(+) and pcDNA3.1(-) are 5.4 kb vectors derived from pcDNA3 and designed
for high-level stable and transient expression in mammalian hosts. High-level stable and
non-replicative transient expression can be carried out in most mammalian cells. The
vectors contain the following elements:
• Human cytomegalovirus immediate-early (CMV) promoter for high-level expression
ina wide range of mammalian cells
• Multiple cloning sites in the forward (+) and reverse (-) orientations to facilitate
cloning
• Neomycin resistance gene for selection of stable cell lines
• Episomal replication in cells lines that are latently infected with SV40 or that express
the SV40 large T antigen (e.g. COS-I, COS- 7)
The control plasmid, pcDNA3.lICAT, is included for use as a positive control for
transfection and expression in the cell line of choice.
Use the following outline to clone and express your gene of interest in pcDNA3.1.
I. Consult the multiple cloning sites described on pages 3-4 to design a strategy to clone
your gene into pcDNA3.1.
2. Ligate your insert into the appropriate vector and transform into E. coli. Select
transformants on LB plates containing 50 to 100 ug/ml ampicillin.
3. Analyze your transformants for the presence ofinsert by restriction digestion.
4. Select a transformant with the correct restriction pattern and use sequencing to
confirm that your gene is cloned in the proper orientation.
5. Transfect your construct into the mammalian cell line of interest using your own
method of choice. Generate a stable cell line, if desired.
6. Test for expression of your recombinant gene by western blot analysis or functional
assay.
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E. coli Strain
Transformation
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pcDNA3.1
Cloning
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Diagrams are provided on pages 3-4 to help you design a cloning strategy for ligating your
gene of interest into pcDNA3.1. General considerations for cloning and transformation are
listed below.
For help with DNA ligations, E. coli transformations, restriction enzyme analysis,
purification of single-stranded DNA, DNA sequencing, and DNA biochemistry, please
refer to Molecular Cloning: A Laboratory Manual (Sambrook et al., 1989) or Current
Protocols in Molecular Biology (Ausubel et al., 1994).
Many E. coli strains are suitable for the propagation of this vector including TOPIOF',
DH5aT"_TlR, and TOPlO. We recommend that you propagate vectors containing inserts in
E. coli strains that are recombination deficient (recA) and endonuclease A-deficient
(endA).
For your convenience, TOPIOF' is available as chemically competent or electrocornpetent
cells from Invitrogen.
Item Quantity Catalog no.
One Shot® TOPIOF' (chemically competent cells) 21x50JlI C3030-03
Electrocornp" TOPIOF' 5 x 80 JlI C665-55
Ultracomp'" TOPIOF' (chemically competent cells) 5 x 300 JlI C665-03
You may use any method of your choice for transformation. Chemical transformation is
the most convenient for most researchers. Electroporation is the most efficient and the
method of choice for large plasmids.
To propagate and maintain pcDNA3.1, we recommend resuspending the vector in 20 JlI
sterile water to make a I Jlg/JlI stock solution. Store the stock solution at -20°C.
Use this stock solution to transform arecA, endA E. coli strain like TOPIOF', DH5aT"-
TIR, TOPlO, or equivalent. Select transformants on LB plates containing 50 to
100 ug/ml ampicillin. Be sure to prepare a glycerol stock of your plasmid-containing
E. coli strain for long-term storage (see page 5).
pcDNA3.1(+) and pcDNA3.1(-) are nonfusion vectors. Your insert must contain a Kozak
translation initiation sequence and an ATG start codon for proper initiation of translation
(Kozak, 1987; Kozak, 1991; Kozak, 1990). An example ofa Kozak consensus sequence
is provided below. Please note that other sequences are possible (see references above),
but the G or A at position -3 and the G at position +4 are the most critical for function
(shown in bold). The ATG initiation codon is shown underlined.
(G/A)NNATGG
Your insert must also contain a stop codon for proper termination of your gene. Please
note that the Xba I site contains an internal stop codon (TCTAGA).
continued on next page
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Cloning into pcDNA3.1, continued
Multiple Cloning
Site of
pcDNA3.1(+)
Below is the multiple cloning site for pcDNA3.1(+). Restriction sites are labeled to
indicate the cleavage site. The Xba I site contains an internal stop codon (TeTAGA). The
multiple cloning site has been confirmed by sequencing and functional testing. The
complete sequence of pcDNA3.1(+) is available for downloading from our web site
(www.invitrogen.com) or from Technical Service (see page 13). For a map and a
description of the features ofpcDNA3.1(+), please refer to the Appendix, pages 10-11.
689
enhancer region (3' end)
CATTGACGTC AATGGGAGTT TGTTTTGGCA CCAAAATCAA CGGGACTTTC CAAAATGTCG
~ ~
TAACAACTCC GCCCCATTGA CGCAAATGGG CGGTAGGCGT GTACGGTGGG AGGTCTATAT
3' end ofhCMV •~ I putative transcriptional start
AAGCAGAGCT CTCTGGCTAA CTAGAGAACC CACTGCTTAC TGGCTTATCG AAATTAATAC
749
809
869
T7 promoter/primer binding site Nhe I Pme I Ajl II Hind III A~p718 I Kpn I
I I I I I IGACTCACTAT AGGGAGACCC AAGCTGGCTA GCGTTTAAAC TTAAGCTTGG TACCGAGCTC
929
BamH I BstX 1* EcoR I EcoR V BstX 1* Not I Xho I
I I I I I I IGGATCCACTA GTCCAGTGTG GTGGAATTCT GCAGATATCC AGCACAGTGG CGGCCGCTCG
989
Xba I Apa I Pme I pcDNA3.I1BGH reverse priming site
I I IAGTCTAGAGG GCCCGTTTAA ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC
1049 CATCTGTTGT TTGCCCCTCC CCCGTGCCTT CCTTGACCCT GGAAGGTGCC ACTCCCACTG
1109
BGH poly (A) site
TCCTTTCCTA ATAAAATGAG GAAATTGCAT
·Please note that there are two BstX I sites in the polylinker.
continued on next page
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Cloning into pcDNA3.1, continued
Multiple Cloning
Site of
pcDNA3.1(-)
Below is the multiple cloning site for pcDNA3.l(-). Restriction sites are labeled to
indicate the cleavage site. The Xba I site contains an internal stop codon (TeTAGA). The
multiple cloning site has been confirmed by sequencing and functional testing. The
complete sequence ofpcDNA3.l(-) is available for downloading from our web site
(www.invitrogen.com) or from Technical Service (see page 13). For a map and a
description of the features ofpcDNA3.1(-), please see the Appendix, pages lO-II.
enhancer region (3' end)
689 CATTGACGTC AATGGGAGTT TGTTTTGGCA CCAAAATCAA CGGGACTTTC CAAAATGTCG
CAAT ,TATA,,----,
749 TAACAACTCC GCCCCATTGA CGCAAATGGG CGGTAGGCGT GTACGGTGGG AGGTCTATAT
3' end ofhCMV •
~ I putative transcriptional start
809 AAGCAGAGCT CTCTGGCTAA CTAGAGAACC CACTGCTTAC TGGCTTATCG AAATTAATAC
T7 promoter/primer binding site Nhe I Pme I Apa IXba I }(ho I Not I
1 1 ,.-'"869 GACTCACTAT AGGGAGACCC AAGCTGGCTA GCGTTTAAAC GGGCCCTCTA GACTCGAGCG
BstX 1* EcoR V EcoR I BsIX 1* BamH I
'I .-' , .-'929 GCCGCCACTG TGCTGGATAT CTGCAGAATT CCACCACACT GGACTAGTGG ATCCGAGCTC
Asp718 I Kpn I Hind III Afl II Pme I pcDNA3.1IBGH reverse priming site
II.-'r--' 1 1 ,989 GGTACCAAGC TTAAGTTTAA ACCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC
1049 ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT
1109 CCTTTCCTAA TAAAATGAGG AAATTGCATC
'Please note that there are two BstX I sites in the polylinker.
continued on next page
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Cloning into pcDNA3.1, continued
E.coli
Transformation
Preparing a
Glycerol Stock
Transform your ligation mixtures into a competent recA, endA E. coli strain (e.g. TOPIOF',
DH5a™ -Tl R, TOPID) and select transformants on LB plates containing 50 to 100 ug/ml
ampicillin. Select 10-20 clones and analyze for the presence and orientation of your insert.
We recommend that you sequence your construct with the T7 Promoter and BGH Reverse
primers (Catalog nos. N560-02 and N575-02, respectively) to confirm that your gene is in the
correct orientation for expression and contains an ATG and a stop codon. Please refer to the
diagrams on pages 3-4 for the sequences and location of the priming sites. The primers are
available separately from Invitrogen in 2 ug aliquots.
Once you have identified the correct clone, purify the colony and make a glycerol stock for
long-term storage. You should keep a DNA stock of your plasmid at -20°C.
• Streak the original colony out on an LB plate containing 50 ug/ml ampicillin. Incubate
the plate at 37°C overnight.
• Isolate a single colony and inoculate into 1-2 ml ofLB containing 50 ug/ml ampicillin.
• Grow the culture to mid-log phase (OD6oo = 0.5-0.7).
• Mix 0.85 ml of culture with 0.15 ml of sterile glycerol and transfer to a cryovial.
• Store at -80°C.
5
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Once you have verified that your gene is cloned in the correct orientation and contains an
initiation ATG and a stop codon, you are ready to transfect your cell line of choice. We
recommend that you include the positive control vector and a mock transfection (negative
control) to evaluate your results.
Plasmid DNA for transfection into eukaryotic cells must be clean and free from phenol
and sodium chloride. Contaminants will kill the cells, and salt will interfere with lipids
decreasing transfection efficiency. We recommend isolating plasmid DNA using the
S.N.A.P.™ MiniPrep Kit (1O-15!lg DNA, Catalog no. KI900-01), the S.N.A.P. TM
MidiPrep Kit (l0-200 ug DNA, Catalog no. K191O-0 I), or CsCI gradient centrifugation.
For established cell lines (e.g. HeLa), please consult original references or the supplier of
your cell line for the optimal method oftransfection. We recommend that you follow
exactly the protocol for your cell line. Pay particular attention to medium requirements,
when to pass the cells, and at what dilution to split the cells. Further information is
provided in Current Protocols in Molecular Biology (Ausubel et al., 1994).
Methods for transfection include calcium phosphate (Chen and Okayama, 1987; Wigier et
al., 1977), lipid-mediated (Feigner et al., 1989; Feigner and Ringold, 1989) and
electroporation (Chu et al., 1987; Shigekawa and Dower, 1988). Invitrogen offers the
Calcium Phosphate Transfection Kit (Catalog no. K2780-01) and a large selection of
reagents for transfection. For more information, please refer to our World Wide Web site
(www.invitrogen.com) or call Technical Service (see page 13).
pcDNA3.lICAT is provided as a positive control vector for mammalian transfection and
expression (see page 12) and may be used to optimize transfection conditions for your
cell line. The gene encoding chloramphenicol acetyl transferase (CAT) is expressed in
mammalian cells under the control of the CMV promoter. A successful transfection will
result in CAT expression that can be easily assayed (see below).
You may assay for CAT expression by ELISA assay, western blot analysis, fluorometric
assay, or radioactive assay (Ausubel et al., 1994; Neumann et al., 1987). If you wish to
detect CAT protein using western blot analysis, you may use the Anti-CAT Antiserum
(Catalog no. R902-25) available from Invitrogen. Other kits to assay for CAT protein
using ELISA assay are available from Roche Molecular Biochemicals (Catalog no. 1 363
727) and Molecular Probes (Catalog no. F-2900).
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Creation of Stable Cell Lines
Introduction
Geneticln®
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Antibiotic
Geneticin®
Selection
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Determination of
Antibiotic
Sensitivity
The pcDNA3.1(+) and pcDNA3.1(-) vectors contain the neomycin resistance gene for
selection of stable cell lines using neomycin (Geneticin"), We recommend that you test
the sensitivity of your mammalian host cell to Geneticin" as natural resistance varies
among cell lines. General information and guidelines are provided in this section for your
convenience.
Geneticin® Selective Antibiotic blocks protein synthesis in mammalian cells by interfering
with ribosomal function. It is an aminoglycoside, similar in structure to neomycin,
gentamycin, and kanamycin. Expression of the bacterial aminoglycoside phosphotransferase
gene (APH), derived from Tn5, in mammalian cells results in detoxification of Geneticin"
(Southern and Berg, 1982).
Geneticin® Selective Antibiotic is available from Invitrogen (Catalog no. 10486-025).
Use as follows:
• Prepare Geneticin" in a buffered solution (e.g. 100 mM HEPES, pH 7.3).
• Use 100 to 800 ug/ml of'Geneticin" in complete medium.
• Calculate concentration based on the amount of active drug (check the lot label).
• Test varying concentrations of Geneticin® on your cell line to determine the
concentration that kills your cells (see below). Cells differ in their susceptibility to
Geneticin",
Cells will divide once or twice in the presence ofIethal doses of Geneticin", so the effects
of the drug take several days to become apparent. Complete selection can take up to 3
weeks of growth in selective media.
Tos uccessfully generate a stable cell line expressing your gene of interest from
pcDNA3.1, you need to determine the minimum concentration of Geneticin" required to
kill your untransfected host cell line. We recommend that you test a range of
concentrations to ensure that you determine the minimum concentration necessary for your
host cell line.
1. Plate or split a confluent plate so the cells will be approximately 25% confluent.
Prepare a set of 7 plates. Allow cells to adhere overnight.
2. The next day, substitute culture medium with medium containing varying
concentrations of Geneticin" (0,50,100,200,400,600, 800 ug/ml Geneticin'").
3. Replenish the selective media every 3-4 days, and observe the percentage of surviving
cells,
4. Count the number of viable cells at regular intervals to determine the appropriate
concentration of Geneticin" that prevents growth within 2-3 weeks after addition of
Geneticin",
continued on next page
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Creation of Stable Cell Lines, continued
Possible Sites for
Linearization of
pcDNA3.1(+)
Prior to transfection, we recommend that you linearize the pcDNA3.1(+) vector.
Linea rizing pcDNA3.1 (+) will decrease the likelihood of the vector integrating into the
genome in a way that disrupts the gene of interest or other elements required for expression
in mammalian cells. The table below lists unique restriction sites that may be used to
linearize your construct prior to transfection. Other unique restriction sites are possible.
Be sure that your insert does not contain the restriction enzyme site you wish to use to
linearize your vector.
Enzyme Restriction Site (bp) Location Supplier
BglII 12 Upstream of CMV promoter Invitrogen, Catalog no. 15213-028
MleI 161 Upstream of CMV promoter New England Biolabs
Bstll07 I 3236 End ofSV40 polyA AGS', Fermentas, Takara, Roche
Mol. Biochemicals
Eamll05 I 4505 Ampicillin gene AGS', Fermentas, Takara
PvuI 4875 Ampicillin gene Invitrogen, Catalog no. 25420-019
Sea I 4985 Ampicillin gene Invitrogen, Catalog no. 15436-017
Ssp I 5309 bla promoter Invitrogen, Catalog no. 15458-011
• Angewandte Gentechnologie Systeme
Possible Sites for
Linearization of
pcDNA3.1(-)
The table below lists unique restriction sites that may be used to linearize your
peON A3.1 (-) construct prior to transfection. Other unique restriction sites are possible.
Be sure that your insert does not contain the restriction enzyme site you wish to use to
Iineari ze your vector.
Enzyme Restriction Site (bp) Location Supplier
BgllI 12 Upstream of CMV promoter Invitrogen, Catalog no. 15213-028
MleI 161 Upstream of CMV promoter New England Biolabs
Bstll07 I 3235 End of SV40 polyA AGS', Fermentas, Takara, Roche
Mol. Biochemicals
Eamll05 I 4504 Ampicillin gene AGS', Fermentas, Takara
PvuI 4874 Ampicillin gene Invitrogen, Catalog no. 25420-019
Sea I 4984 Ampicillin gene Invitrogen, Catalog no. 15436-017
Ssp I 5308 bla promoter Invitrogen, Catalog no. 15458-0 II
• Angcwundte Gentechnologie Systeme
continued on next page
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Creation of Stable Cell Lines, continued
Selection of Stable
Integrants
Once you have determined the appropriate Geneticin'" concentration to use for selection in
your host cell line, you can generate a stable cell line expressing your gene of interest.
1. Transfect your mammalian host cell line with your pcDNA3.1 construct using the
desired protocol. Remember to include a plate ofuntransfected cells as a negative
control and the pcDNA3.1/CAT plasmid as a positive control.
2. 24 hours after transfection, wash the cells and add fresh medium to the cells.
3. 48 hours after transfection, split the cells into fresh medium containing Geneticin® at
the pre-determined concentration required for your cell line. Split the cells such that
they are no more than 25% confluent.
4. Feed the cells with selective medium every 3-4 days until Geneticinf-resistant foci can
be identified.
5. Pick and expand colonies in 96- or 48-well plates.
9
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Rapid DNA Ligation Kit
Cat. No. 1 635 379
Kit for 40 ligation reactions
For life science research only. Not for use in diagnostic procedures.
FOR IN VITRO USE ONLY.
Version 2. May 2002
Store at -15 to -250 C
1. Kit contents
2 Product overview
3. Procedures and required materials
3.1 Standard ligation reaction for DNA
3.2 Electroporation of E. coli cells after recirculatrisation
3.3 Ligation reaction for insertion into phage-vectors
(including linker ligation)
4. Results
5. Appendix
5.1 References
5.2 Related products
1. Kit contents
Bottlel Label Content CaL No.
Cap (if available
separately)
1 T4 DNA Liga- 0.5 ml
tion Buffer.
2x conc.
2 DNA Dilution 0.5 ml
Buffer.
sx cone.
3 T4DNA . 40~1 799009
Ligase . [5 U/~I]
2. Product overview
Kit description The Rapid DNA Ligation Kit enables ligation of sticky-
end or blunt-end DNA fragments in just 5 min at 15-
25° C. Depending on DNA concentration. either circu-
lar (low DNA concentration) or concatemeric (high
DNA concentration) ligation products are formed. All
necessary reagents required for ligation are provided.
There is no need to prepare buffers or to add ATP or
Mg2+.
Application The Rapid DNA Ligation Kit can be used for:
• cloning in plasmid vectors.
• cloning in phage vectors.
• linker ligation.
• recircularization of linear DNA
Nl1lJl;. Electroporation can be performed after ligation
in combination with the High Pure Purification Kit.
Sample material Dephosphorylated blunt- or sticky-end DNA
Ligation time 5 min
Number of 40 ligation reactions (standard assay: 50 ng linearized
ligation reactions and dephosphorylated vector DNA and 150 ng insert
DNA).
0502.1837l1li8(7)
Quality control
ligation and
recutting
Kit storage!
stability
Each lot of the Rapid DNA Ligation Kit is tested under
the above described procedures and the following
results are guaranteed per ~g vector DNA. Results are
depending on the DNA purity. Purification by caesium
chloride gradient is recommended:
Recircularization pUC19/Sma I pUC19/Hindlll
Yield of trans- > lxl06 > lxl06
formed colonies
Insertion of an pUC19/Sma I pUC19/Hindlli
insert in plasmid + +
vectors 2100 bp insert 2300 bp insert
Yield of white colo- > lxl05 >6xl05
nies after transfor -
mation into
competent E. coli
JMB3 cells
Insertion of DNA into phage vectors lambda gt 11
arms + insert!
feoRI
Yield of white plaques >lxl07
1 ~g pUC19 DNA. digested with Hind III. is dephospho-
rylated with alkaline phosphatase and ligated with 1 ~g
of DNA molecular weight marker II' according to the
standard protocol. After ethanol precipitation the liga-
tion products are redigested with Hind III. Only the
original digestion pattern was observed after separa-
tion on an agarose gel.
The unopened kit is stable at -15 to -25°C through the
expiration date printed on the label.
~ Repeated freezing and thawing should be
avoided.
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3. Procedures and required material
3.1 Standard ligation reaction for DNA
Before you begin In order to achieve optimal results, please consider the
following:
Purification The DNA to be ligated should be purified by phenol
extraction and ethanol precipitation or use the Agarose
Gel DNA Extraction Kit" (Cat. NO.1 696505)
Dephosphoryla- For insertion of DNA into plasmid vectors the vector DNA
tion should be dephosphorytated (except for recircularization)
with alkaline phophatase" (Cat No. 713 023)
Reaction volume · Dissolve the DNA to be ligated in 1x conc. DNA dilu-tion buffer (vial 2), in a total volume of 10 ul,· Ifthe total volume of DNA solution in 1x DNA dilutionbuffer is greater than lO ).l.I,then the volume of all the
other reagents in the reaction should be increased
accordingly and the ligation reaction should be for 30
min.
Molar ratio · The molar ratio of vector DNA to insert DNA in a total
volume of 10).l.1should be 1+3 (e. g. as described in
the standard assay with approximately equal length of
vector DNA and insert DNA. 50 ng linearized dephos-
phorylated vector DNA and 150 ng insert DNA).· When the vector DNA and insert DNA are not similarin lengths, other molar ratios 1+ 1. 1+2 are possible.· A molar ratio of 1+5 can be used for sticky-end liga-tions.
!iJll!:;. For blunt-ended DNA however, a decrease of trans-
formed colonies was observed when a molar ratio of 1+5
was used.
Transformation To avoid an inhibition by a surplus of DNA a maximum of
1'10 of the volume of the ligation reaction mixture should
be used for the transformation assay.
Maximum The maximum amount of DNA to be ligated in 5 min
amount of DNA should not exceed 200 ng.
T4 DNA Ligase T4 DNA ligase can be completely inactivated by a lO min
inactivation incubation at 65° C. This step should only be done if the
ligation reaction mixture is used in experiments other than
transformation assays.
fJJlII:;. Heat inactivation of the ligation reaction mixture
before transformation leads to a drastic decrease
ï> factor 20) of transformed colonies.
Preparation of kit Mix the sx conc. DNA dilution buffer (viaI2) thoroughly
working solutions and dilute with double dist water to a final concentra-
tion of 1x.
Procedure In the following table the standard protocol for the
ligation reaction is described.
Step Action
1 Dissolve vector DNA and insert DNA in thor-
oughly mixed and diluted 1 x COlIC. DNA Dilu-
tion Buffer to a final volume of 10).l.1in a sterile
reaction vial.
2 · Mix thoroughly T4 DNA Ligation Buffer(vial 1).
I:IJJlJ:;.lt is absolutely necessary to mix the con-
tents of viall directly prior to use.· Add 10).l.1T4 DNA Ligation Buffer (viall)to the reaction vial.· Mix thoroughly.
3 · Add 1 ).l.1T4 DNA Ligase (vial 3).· Mix thoroughly.
4 Incubate for 5 min at 15-25°C.
5 The ligation reaction mixture can be used
directly for the transformation of competent
cells. or can be stored without heat inactivation
at - 15 to -25°C.
!:/.Qlff. Heat inactivation of the T4 DNA ligase
drastically decreases the transformation effi-
ciency.
6 The ligated DNA can be analyzed by agarose gel
electrophoresis.
3.2 Electroporation of E.coli cells after recircularization
Additional
required material
and equipment
• High Pure PCR Product Purification Kit
(Cat. NO.1 732 668)
• Electroporation unit. e.g. BioRad pulsar unit
• Electrocompetent cells
Preparation of From the High Pure peR Product Purification Kit:
working solutions Make sure that 40 ml for the 50 purification pack size
and 200 ml ethanol p.a. for the 250 purification pack
size have been added to the Wash Buffer (blue cap)
prior to first use.
Caution The Binding Buffer (green cap) contains guanidine-
HCI, which is an irritant. Wear gloves and follow usual
safety precautions when handling.
Procedure Modified protocol for the purification of ligated DNA
from the standard ligation reaction for use of the DNA
in electroporation.
I:IJJlJ:;. The use of the High Pure PCR Product Purifica-
tion Kit adds an additional 10- 15 min to the overall time
required to prepare electrocompetent reactions.
Step Action
1 Add 100 ).l.1Binding Buffer to the 20 ul liqation,
2 Pipet the sample into the upper reservoir of a
combined Filter Tube-Collection Tube assembly.
3 Centrifuge 1 min at max. speed in a standard
table top centrifuge.
4 · Discard the flowthrough.· Combine again the filter tube and the collec-tion tube.
5 · Add 500 iJlWash Buffer (blue cap) to theupper reservoir.· Centrifuge 1 min at max. speed.t!!llJ:i Make sure that the filter tube has no con-
tact with the surface of the Wash Buffer
f1owthrough.
6 · Discard the flowthrough.· Combine again the filter tube and the collec-tion tube.· Add 200 iJlWash Buffer (blue cap) to theupper reservoir.
· Centrifuge 1 min at max. speed (13000 rpm).
7 · Discard the flowthrough.· Combine again the filter tube and the collec-tion tube.· Centrifuge 1 min at max. speed to removeresidual Wash Buffer.
8 · Discard the collection tube.· Insert the filter tube in a clean 1.5 ml reactiontube.
9 · Add 100 iJl sterile double dlst, water to theupper reservoir, (pH approx. Z4).· Centrifuge 1 min at max. speed
10 Recovered final volume is about 100 ).l.I.
10).l.1which represents 1'10 of the ligation reac-
tion is used for electroporation.
Electroporation • Electroporate 1110 volume of the ligation reaction
into electrocompetent cells using the BioRad pulsar
unit and 0.2 cm cuvettes under the following condi-
tions:
2.5 kV. 25 MF. 200 ohm.
(The specific electroporation conditions have to be
evaluated for each strain.)
• Plate out a 1120 volume of the electroporated cells.
!J!lllJl;. Colonies arising on each plate represent 0.5 ng
of DNA.
2 Roche Applied Science
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3.3 Ligation reaction for insertion into phage-vectors (including linker
ligation)
Before you begin In order to achieve optimal results, please consider the
following:
Purification The DNA to be ligated should be puri-
fied by phenol extraction and ethanol
precipitation or use the Agarase Gel
DNA Extraction Kit'.
Dephosphory- For insertion of DNA in phage-vectors,
lation the arms of the vector DNA should be
dephosphorylated with alkaline phos-
phatase.
Reaction If the total volume of DNA solution in
volume 1 x DNA dilution buffer is greater than
10 Ill, then the volume of all the other
reagents in the reaction should be
increased accordingly and the ligation
reaction should be incubated for 30
min.
Ratio of vector The ratio of vector arms to insert DNA
arms to DNA should be approx. 8+ 1 in a total volume
of 10 III (e. g. 1000 ng DNA. lambda gt
11, Eco RI arms, dephosphorylated and
120 ng insert DNA).
T4DNA T4 DNA ligase can be completely inac-
Ligase tivated by a 10 min incubation at 65·C.
inactivation This step should only be done if the
ligation reaction mixture is used in
experiments other than packaging
assays.
~ Heat inactivation of the ligation
reaction mixture before packaging
leads to a drastic decrease of plaques.
Procedure Protocol for the ligation reaction for insertion into
phage vectors.
NIllJ:;_lf an adaptor is necessary for the cloning strat-
egy, add the required quantity to the DNA in a total
volume of 10 Ill.
Step ActIon
1 Dissolve DNA (vector arms + insert + adaptor, if
necessary) in 1 x cone. DNA Dilution Buffer
to a final volume of 10 III in a sterile vial.
2 0 Add 10 III T4 DNA Ligation Buffer (2 x
con c.) (vial 1).
~ It is absolutely necessary to thoroughly
mix the contents of viall directly prior to use.
0 Mix thoroughly.
3 0 Add 1 III T4 DNA Ligase (vial 3).
0 Mix thoroughly.
4 Incubate for 5 min at 15-25·C.
5 For each packaging reaction 4111of the product
from the ligation reaction should be used. The
ligation reaction mixture can be stored without
heat inactivation at -15 to -25·C.
~ Heat inactivation of the T4 DNA ligase
drastically decreases the packaging efficiency
4. Results
Analysis of results The products from the DNA ligation reaction can be
analyzed by agarase gel electrophoresis (1/2 of the
ligation product for plasmid cloning experiments or 1/4
of the ligation product for phage cloning experiments),
by the addition of 1/5 volume of gel loading buffer
given below, e. g. 10 III ligation product and 2111gel
loading buffer.
Gel loading buffer.
1% SDS (w/v), 50 mM EDTA. 0,02% bromophenol
blue (w/v), 500/0glycerol (v/v), pH 7.5.
~ For analysis of circular DNA on an agarase gel, a
sufficient amou nt of DNA should be used for the DNA
ligation reaction. The DNA concentration in the ligation
reaction however, should never be more than 200 ng
DNA in 20 III ligation reaction mixture. (Raise the reac-
tion volume, if necessary).
Recircularization 50 ng pUC19 DNA, digested with Sma I or Hind III
respectively, were religated according to the standard
protocol and transformed into competent [Hanahan
method (3)] E. coli JM83 cells.
Yield of transformed colonies per mg of DNA:
pUC19 DNA pUC19/Sma I pUC19/Hindlll
undigested digest digest
2 x 107 7 X 106 8 X 106
Cloning of an
insert into
plasmid vectors
50 ng pUC19 DNA, digested with Sma I or Hind III,
respectively, and dephosphorylated with alkaline phos-
phatase, were ligated with 150 ng blunt- or sticky-end
insert DNA, respectively, according to the standard
protocol. The inserts were purified by electrophoresis
and isolated from the agarase gel by aqarase" diges-
tion.
Yield of white colonies per mg of vector DNA after
transformation into competent E. coli JM83 cells.
pUC19 DNA pUC19/Sma I pUC19/Hindlll
undigested digest + 2100 bp digest + 2300 bp
insert DNA insert DNA
2 x107 6 x105 1.3 x106
Cloning of an
insert into
phage-vectors
1 Ilg of DNA, lambda gt 11, Eco RI arms, dephosphory-
lated, was ligated to 120 ng linearized pUC19 DNA.
digested with either Sma I or Eeo RI as insert (for the
ligation of blunt ends, 20 ng of adaptor were added).
After packaging into phages, E.coli Yl 090 - cells were
infected and plated onto agar plates.
Yield of white plaques:
lambda gt 11 lambda gt 11 lambda gt 11
vector control arms+ arms+
insert! Sma I + insert! Eeo RI
adaptor
1.6 x109 4.9 x104 1.2 x108
5. Appendix
5.1 References
1 Hayashi, K et al. (1986) Nucleic Acids Res. 14,7617-7631.
2 Sambrook. J ..,Fritsch, E. F. & Maniatis. T (1989) Molecular Ooning. A Laboratory
Manual, Cold Spring Harbor Laboratory, (NY): 1989. 2nd ed ..Voll,2 and 3,p 561-563.
3 Hanahan, D. (1983) J. Mol. Bioi. 166, 557-580.
3 Roche Applied Science
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5.2 Related products
Kits
Product Pack Size Cat. No.
Agarose Gel DNA 1 kit 1 696505
Extraction Kit (max.100
reactions)
eDNA Synthesis Kit 1 kit 1 117831
(for 25 j..I.g
RNA)
1 kit 1013882
(for 50 j..I.g
RNA)
First Strand eDNA Syn- 1 kit 1 483188
thesis Kit for RT-PCR
(AMV)
High Pure PCR Product 50 purif. 1 732668
Purification Kit 250 purif. 1 732676
Single reagents
Product Pack Size Cat. No.
5-Bromo-4 chloro-3- 100 mg 1 680293
indolyl-b-D-galactopyra- 250 mg 651 745
noside (X-gal) 1 g 745 740
2.5 g 703729
Agarase 100 U 1417215
500 U 1 417223
Agarose MP 100 g 1388983
500 g 1388991
Alkaline Phosphatase 1000 U 713023
(1 U/j..I.l) 1097075
1000 U
(20 U/j..I.l)
Alkaline Phosphatase 1000 U 1758250
Shrimp
DNAMWMII 50 j..I.g 236250
(1 ~60 unit)
Isopropyl-b-D-thiogalac- 1 g 724815
tosid e 0PTG) 5g 1411446
Klenow Enzyme. 100U 1 008404
labeling grade 500 U 1 008412
Pwo DNA Polymerase 100U 1644947
2x 250 U 1 644955
T4 DNA Ligase 100U 481 220
[1 U/j..I.l]
500 U 716359
[1 Ulj..I.l]
500 U 799009
[5 U/j..I.l]
T4 RNA Ligase 500 U 1449478
Taq DNA Polymerase. 250 U 1 647679
1 unit/ml 4x 250 U 1 647687
Taq DNA Polymerase. 100U 1 146165
5 units/ml 500 U 1146173
4x 250 U 1 418432
lOx 250 U 1596594
20x 250 U 1435094
• available from Roche Applied Science (see also section 5.3)
How to contact Roche Applied Science
www.roche-applied-science.com
• to place you r order
find product information
for answers to technical queries. or.
contact your local sales representative.
www.roche-applled-science.com/pack-insert/1635379a.pdf
Roche Diagnostics GmbH
Roche Applied Science
Sandhofer Strasse 116
0-68305 Mannheim
Germany
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Appendix F: QIAprep Spin Miniprep Kit (Qiagen)
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Plasmid Mini Purification Protocol
This protocol is for Mini (up to 20 ~g) preparations of high-copy plasmid DNA from
cultures of E. coli. For cosmid and low-copy-number plasmid purification see
recommendations on page 13. For purification of BACs, PACs, Pl s, and purification of
double-stranded M 13 replicative form see recommendations on page 14.
Important notes before starting
• New usersare strongly recommended to read Appendix A (page 21) at the end of
this handbook before starting the procedure.
• To ensure high yields of pure DNA, use no more than 3 ml LBculture for high-copy-
number plasmids (e.g., pUC, pêluescrlpt'"]. For low-copy-number plasmids
(e.g., pBR322), useno more than 10 ml LBculture and refer to the recommendations
on page 13. We do not recommend the use of rich media such as TB or 2x YT for
culture. When low-copy-number plasmids containing the ColE1 replication origin are
prepared, the yield can be improved by amplification in the presence of chloram-
phenicol (34 mg/ml). They should then be treated as high-copy-number plasmids.
• Add the provided RNase A solution to Buffer Pl before use (spin down RNase A
briefly before use).BufferPl should then be stored at 2-8°C and is stable for 6 months.
• Check Buffer P2 for SDSprecipitation due to low storage temperatures. If necessary,
dissolve the SDS by warming to 37°C.
• Chill Buffer P3 at 4°C.
• Optional: To confirm purification or to identify a problem, samples may be taken at
specific steps for analysis on an agarose gel. Appropriate samples and
volumes are indicated in the protocol below.
Procedure
1. Resuspend the bacterial pellet in 0.3 ml of Buffer Pl.
Ensure that RNase A has been added to Buffer Pl. The bacteria should be
resuspended completely, leaving no cell clumps.
2. Add 0.3 ml of BufferP2, mix gently, and incubate at room temperature for 5 min.
After addition of Buffer P2, the solution should be mixed gently, but thoroughly, by
inverting the tube 4-6 times. Do not vortex, as this will result in shearing of genomic
DNA. The lysate should appear viscous. Do not allow the lysis reaction to proceed
for more than 5 min. After use, the bottle containing Buffer P2 should be closed
immediately to avoid any reaction between the NaOH and CO2 in the air. If the
buffer is leftopen for any lengthof time, it should be prepared freshfrom stocksolutions.
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3. Add 0.3 ml of chilled Buffer P3, mix immediately but gently, and incubate on ice for
5 min.
Precipitation is enhanced by usingchilled BufferP3and incubating on ice. After addition
of Buffer P3, the solution becomes cloudy and very viscous. To avoid localized
potassium dodecyl sulfate precipitation, mix the solution gently, but thoroughly,
immediately after addition of Buffer P3. Mix by inverting the tube 4-6 times.
4. Centrifuge at maximum speed in a microcentrifuge for 10min. Remove supernatant
promptfy.
Before loading the centrifuge, the sample should be mixed again. Centrifugation
should be performed at maximum speed in 1.5 ml or 2 ml microcentrifuge
tubes (e.g., 10,000-13,000 rpm in a microcentrifuge). Maximum speed
corresponds to 14,000-18,000 x 9 for most microcentrifuges. After centrifugation,
the supernatant should be clear. If the supernatant is not clear, a second, shorter
centrifugation should be carried out to avoid applying any suspended or particulate
material to the column. Suspended material (which causes the sample to appear
turbid) will clog the column and reduce or eliminate flow.
• Remove a 50 IJlsample from the cleared lysate and save it for an analytical gel
(sample 1).
5. Equilibrate a QIAGEN-tip 20 by applying 1 ml Buffer QBT, and allow the column to
empty by gravity flow.
Place QIAGEN-tips into a QIArack over the waste tray or use the tip holders
provided with each kit (see "Setup of QIAGEN-tips" page 9). Flow of buffer will
begin automatically by reduction in surface tension due to the presence of detergent
in the equilibration buffer. Allow the QIAGEN-tip to drain completely. The resin bed
will retain some buffer and will not readily dry out. QIAGEN-tips can therefore be
left unattended. Do not force out the remaining buffer.
6. Apply the supernatant from step 4 to the QIAGEN-tip 20 and allow it to enter the
resin by gravity flow.
The supernatant should be loaded onto the QIAGEN-tip promptly. If it is left too long
and becomes cloudy due to further precipitation of protein, it must be recentrifuged
before loading to prevent clogging of the QIAGEN-tip.
• Removea 50 IJlsample of the flow-through and save for an analytical gel sample 2).
7. Wash the QIAGEN-tip 20 with 4 x 1 ml Buffer QC.
Allow Buffer QC to move through the QIAGEN-tip by gravity flow. The first 2 ml is
sufficient to remove all contaminants in the majority of plasmid DNA preparations.
The second 2 ml ensures complete removal of contaminants, and will also ensure
consistent results in sequencing. (Thesecond 2 ml is particularly necessarywhen large
culturevolumesor bacterial strainsproducing large amountsof carbohydrate are used.)
It is particularly important not to force out residual wash buffers. Traces of wash buffer
will not affect the elution step.
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• Remove a 50 fJlsample of the combined wash fractions and save for an analytical gel
(sample 3).
8. Elute DNAwith 0.8 ml BufferQF.
Place the upper part of a QIArack over the lower rack fitted with clean 1.5 ml or
2 ml microcentrifuge tubes and collect the samples in the tubes. Alternatively, use the
tip holders provided. Flow begins when Buffer QF is added. Drain the QIAGEN-tip
by allowing it to empty by gravity flow.
• Remove a 50 fJl sample of the eluate and save for an analytical gel (sample 4).
9. Precipitate DNA with 0.7 volumes (0.56 ml per 0.8 ml of elution volume) of
room-temperature isopropanol. Centrifuge immediately at ~10,000 rpm for 30 min
in a microcentrifuge, and carefully decant the supernatant.
Precipitation of DNA with isopropanol should be carried out with all solutions
equilibrated to room temperature in order to minimize salt precipitation. Isopropanol
pellets have a glassy appearance and may be more difficult to see than the fluffy,
salt-containing pellets that result from ethanol precipitation. Marking the outside of
the tube before centrifugation allows the pellet to be easily located.
10. Wash DNAwith 1 ml of 70% ethanol, air-dry for 5 min, and redissolve in a suitable
volume of buffer.
The DNA pellet should be washed briefly in 70% ethanol, and then recentrifuged.
The 70% ethanol serves to remove precipitated salt, as well as to replace isopropanol
with the more volatile ethanol, making the DNA easier to redissolve. A second wash
with room-temperature 70% ethanol may improve results in more sensitive applications,
such as transfection. After careful and complete removal of ethanol, the pellet should
be air-dried briefly (approximately 5 min) before redissolving in an appropriate
volume of TE buffer. Overdrying the pellet will make the DNA difficult to redissolve.
Resuspend the DNA pellet by rinsing the walls to recover all the DNA. Pipetting the
DNA up and down to promote resuspension may cause shearing, and should be
avoided. DNA dissolves best under slightly alkaline conditions; it does not easily
dissolve in acidic buffers.
Determination of yield
To determine the yield, DNA concentration should be determined by both UV spectro-
photometry and quantitative analysis on an agarose gel.
Analytical gel (optional): to analyze the purification procedure as shown in Figure 2
(Appendix A, page 27), precipitate samples 1-4 (from steps 4-8) with 35 fJl of
isopropanol. Rinse the pellets with 70% ethanol, drain well, air-dry, and resuspend in
10 fJl of TE, pH 8.0. Use 2 fJl of each for analysis on a 1% agarose gel (1).
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EndoFree Plasmid Mega and Giga Protocol
This protocol is designed for preparation of up to 2.5 mg of high- or low-copy plasmid
and cosmid DNA using the EndoFree Plasmid Mega Kit, or up to 10 mg of high-copy
plasmid DNA using the EndoFree Plasmid Giga Kit. Endotoxin-free DNA will improve
transfection into sensitive eukaryotic cells and is essential for gene therapy research. For
background information on endotoxins, see pages 68-70. (Please note: the EndoFree
Plasmid Giga Kit is not recommended for low-copy plasm ids or cosmids).
Low-copy plasm ids which have been amplified in the presence of chloramphenicol
should be treated as high-copy plasm ids when choosing the appropriate culture volume.
Maximum recommended culture volumes"
EndoFreeMega EndoFree Giga
Hiqh-copy number
plasmids
Low-copy number
plasm ids
500 ml LB culture
(1.5 g pellet wet weightp
2.5 liters LB culture
(7.5 g pellet wet weightjt
2.5 liters LB culture
(7.5 g pellet wet weightp
Not recommended for low-
copy plasm ids or cosrnids'
* For high-copy plasm ids, expected yields are 1.5-2.5 mg for the EndoFree Plasmid Mega Kit and 7.5-10 mg
for the EndoFree Plasmid Giga Kit. For low-copy plasmids, expected yields are 0.5-2.5 mg for the EndoFree
Plasmid Mega Kit. The EndoFree Plasmid Giga Kit is not recommended for low-copy plasmid preparations.
t On average, a healthy 1-liter shaker culture yields a pellet with a wet weight of approximately 3 g. When
working with fermentation cultures, however, the pellet wet weight may be significantly higher. Therefore, when
using fermentation cultures please refer to the pellet wet weight instead of the recommended culture volumes.
I Due to the large culture volume required for preparation of low-copy plasmid and cosmid DNA and the limited
capacity of the QIAfilter Mega-Giga Cartridge, the EndoFree Plasmid Mega Kit is a better choice than the
EndoFree Plasmid Giga Kit for purification of low-copy plasmids and cosmids.
Important notes before starting
• New users are strongly advised to read the "General Considerations for Optimal
Results" section on pages 60-70 before starting the procedure.
• Use endotoxin-free or pyrogen-free plastic pipet tips and tubes for elution and
subsequent steps (step 15 onwards). Endotoxin-free or pyrogen-free plasticware can
be obtained from many common vendors. Please check with your current supplier to
obtain recommendations. Alternatively, glass tubes may be used if they are baked
overnight at 180°C to destroy endotoxins.
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• The QIAfilter Mega-Giga Cartridge is designed for use with a 1 liter, 45 mm-neck,
vacuum-resistant glass bottle (e.g., Schott, cat. no. 2181054 or Corning, cat. no.
1395-1L). Note: Bottles are not included in the kit and must be supplied by the user.
The cartridge operates with any vacuum source (e.g., a house vacuum, vacuum pump,
or water aspirator) that generates vacuum pressures between -200 and --600 millibars
(-150 and -450 mm Hg). The vacuum pressure is measured as differential pressure
between the inside of the bottle and the atmosphere (1013 millibars or 760 mm Hg).
Vacuum recommendations are given in negative units to indicate the required
reduction in pressure with respect to the atmosphere.
• To avoid the possibility of implosion do not use plastic/glass bottles or any other
vessels that are not designed for use with a vacuum. Do not use plastic/glass bottles
or any other vessels that are cracked or scratched. Wear safety glasses when
working near a bottle under vacuum.
• Add the provided RNase A solution to Buffer Pl before use. Use one vial of RNase A
(spin briefly before use) per bottle of Buffer Pl, to give a final concentration of
100 jJg/ml.
• To prepare endotoxin-free 70% ethanol, add 40 ml of 96-100% ethanol to the
endotoxin-free H20 supplied with the kit.
• Check Buffer P2 for SDS precipitation due to low storage temperatures and, if
necessary, dissolve the SDS by warming to 3rc.
• Pre-chill Buffer P3 to 4°C.
• In contrast to the standard protocol, the lysate is not incubated on ice after addition
of Buffer P3.
• Optional: remove samples at the steps indicated with the symbol ~ in order to
monitor the procedure on an analytical gel.
Procedure
1. Pick a single colony from a selective plate and inoculate a starter culture of 5-10 ml
LB medium containing the appropriate selective agent. Grow for ...8 h at 37°C with
vigorous shaking (...300 rpm).
Use a flask with a volume of at least 4 times the volume of the culture.
2. Dilute the starter culture 1/500 to 1/1000 into selective LBmedium. For high-copy
plasm ids inoculate 500 ml or 2.5 liters medium. For low-copy plasm ids, inoculate
2.5 liters medium. Grow at 37°C for 12-16 h with vigorous shaking (...300 rpm).
Use a flask or vessel with a volume of at least 4 times the volume of the culture. The
culture should reach a cell density of 3-4 x 109 cells per ml, which typically corresponds
to a pellet wet weight of approximately 3 g/liter medium (see page 65).
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J. Harvest the bacterial cells by centrifugation at 6000 x g for 15 min at 4°C.
6000 x g correspondsto 6000 rpm in Sorvall GSA or GS3 or Beckman®JA-l 0 rotors.
Remove all traces of supernatant by inverting the open centrifuge bottle until all
medium has been drained.
® If you wish to stop the protocol and continue later, freeze the cell pellets at -20°C.
4. Screw the QIAfilter Mega-Giga Cartridge onto a 45 mm-neck glass bottle and
connect it to a vacuum source.
Do not overtighten the QIAfilter Cartridge on the bottle neck, because the QIAfilter
Cartridge plastic may crack.
5. Resuspend the bacterial pellet in 50 ml or 125 ml Buffer Pl.
Note: For efficient lysis it is important to use a vessel that is large enough to allow
complete mixing of the lysis buffers. We recommend a 500 ml bottle for Mega
preparations and a 1000 ml bottle for Giga preparations. Ensurethat the RNase A
has been added to Buffer Pl. The bacteria should be resuspended completely by
vortexing or pipetting up and down until no cell clumps remain.
6. Add 50 ml or 125 ml Buffer P2, mix gently but thoroughly by inverting 4-6 times,
and incubate at room temperature for 5 min.
Do not vortex, as this will result in shearing of genomic DNA. The lysate should
appear viscous. Do not allow the lysis reaction to proceed for more than 5 min.
After use, the bottle containing Buffer P2 should be closed immediately to avoid
acidification from CO2 in the air.
7. Add 50 ml or 125 ml chilled Buffer PJ, and mix immediately and thoroughly by
inverting 4-6 times. Mixwell until a white fluffymaterial has formed and the lysate
is no longer viscous. Proceed directly to step 8. Do not incubate on ice.
Precipitation is enhanced by using chilled Buffer P3. After addition of Buffer P3, a
fluffy white precipitate containing genomic DNA, proteins, cell debris, and SDS
becomes visible. The lysate should be mixed well to reduce the viscosity and
prevent clogging of the QIAfilter Cartridge.
8. Pour the lysate into the QIAfilter Mega-Giga Cartridge and incubate at room
temperature for 10min.
Important: This 10 min incubation at room temperature is essential for optimal
performance of the QIAfilter Mega-Giga Cartridge. Do not agitate the QIAfilter
Cartridge during this time. A precipitate containing proteins, genomic DNA, and
detergent will float and form a layer on top of the solution. This ensures convenient
filtration without clogging.
9. Switch on the vacuum source. After all liquid has been pulled through, switch off
the vacuum source. Leave the QlAfilter Cartridge attached.
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10. Add 50 ml (Mega and Giga) Buffer FWB to the QIAfilter Cartridge and gently stir
the precipitate using a sterile spatula. Switch on the vacuum source until the liquid
has been pulled through completely.
Gentle stirring of the precipitate enhances the flow of liquid through the filter unit.
Take care not to disperse the precipitate, as this may result in carryover of cell
debris and SDS, which will affect flow and binding characteristics of the QIAGEN
column. The filtered lysate in the bottle contains the plasmid DNA.
1& Remove a 120 fJlor 75 fJlsample from the cleared lysate and save for an analytical
gel (sample 1) to determine whether growth and lysis conditions were optimal.
11. Add 12.5 ml or 30 ml Buffer ER to the filtered lysate, mix by inverting the bottle
approximately 10 times, and incubate on ice for 30 min.
After addition of Buffer ER the lysate appears turbid, but will become clear again
during the incubation on ice.
12. Equilibrate a QIAGEN-tip 2500 or QIAGEN-tip 10000 by applying 35 ml or 75 ml
Buffer QBT and allow the column to empty by gravity flow.
Flow of buffer will begin automatically by reduction in surface tension due to the
presence of detergent in the equilibration buffer. Allow the QIAGEN-tip to drain
completely. QIAGEN-tips can be left unattended, since the flow of buffer will stop
when the meniscus reaches the upper frit in the column.
13. Apply the filtered lysate from step 11 onto the QIAGEN-tip and allow it to enter the
resin by gravity flow.
Due to the presence of Buffer ER the lysate may become turbid again, however this
does not affect the performance of the procedure.
1& Remove a 120 fJlor 75 fJlsample of the flow-through and save for an analytical gel
(sample 2) in order to determine the efficiency of DNA binding to the QIAGEN Resin.
14. Wash the QIAGEN-tip with a total of 200 ml or a total of 600 ml Buffer QC.
Allow Buffer QC to move through the QIAGEN-tip by gravity flow. The first half of the
volume of wash buffer is enough to remove all contaminants in the majority of plasmid
DNA preparations. The second half is particularly necessary when large culture
volumes or bacterial strains producing large amounts of carbohydrates are used.
1& Remove a 160 fJl or 120 fJl sample of the eluate and save for an analytical gel
(sample 3).
Important: For all subsequent steps use endotoxin-free or pyrogen-free plasticware
(e.g. new polypropylene centrifuge tubes) or pre-treated glassware.
15. Elute DNA with 35 ml or 75 ml Buffer QN.
Drain the QIAGEN-tip by allowing it to empty by gravity flow. Use of polycarbonate
centrifuge tubes for collection is not recommended as polycarbonate is not resistant
to the alcohol used in subsequent steps.
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~ Remove a 22 IJl or 15 IJl sample of the eluate and save for an analytical gel
(sample 4).
® If you wish to stop the protocol and continue later, store the eluate at 4°(.
Storage periods longer than overnight are not recommended.
16. Precipitate DNA by adding 24.5 ml or 52.5 ml room-temperature isopropanol
(0.7 volumes) to the eluted DNA. Mix, and centrifuge immediately at ~ 15,000 x g
for 30 min at 4°C. Carefully decant the supernatant.
All solutions should be at room temperature in order to minimize salt precipitation,
although centrifugation is carried out at 4°C to prevent overheating of the sample.
A centrifugal force of 15,000 x g corresponds to 9,500 rpm in a BeckmanJS-13 rotor
and 11,000 rpm in a Sorvall SS-34 rotor. Alternatively, disposable conical bottom
centrifuge tubes can be used for centrifugation at 5,000 x g for 60 min at 4°(.
Isopropanol DNA pellets have a glassy appearance and may be more difficult to see
than the fluffy, salt-containingpelletsthat resultfrom ethanol precipitation. Marking the
outside of the tube before centrifugation allows the pellet to be easily located.
Isopropanol DNA pellets are also more loosely attached to the side of the tube, and
care shouldbe takenwhen removingthe supernatant.
17. Wash DNA pellet with 7 ml or 10 ml of endotoxin-free room-temperature 70%
ethanol (add 40 ml of 96-100% ethanol to the endotoxin-free H20 supplied with
the kit) and centrifuge at ~ 15,000 x g for 10min. Carefully decant the supernatant
without disturbing the pellet.
Alternatively, disposable conical bottom centrifuge tubescan be used for centrifugation
at 5,000 x g for 60 minat4°(.The70% ethanol removesprecipitated saltand replaces
isopropanol with the more volatile ethanol, making the DNA easier to redissolve.
18. Air-dry the pellet for approximately 10-20 min, and redissolve the DNA in a
suitable volume of endotoxin-free Buffer TE.
Redissolve the DNA pellet by rinsing the walls to recover all the DNA, especially if
glass tubes have been used. Pipetting the DNA up and down to promote
resuspension may cause shearing, and should be avoided. Overdrying the pellet
will make the DNA difficult to redissolve. DNA dissolves best under slightly alkaline
conditions; it does not dissolve easily in acidic buffers.
Determination of yield
To determine the yield, DNA concentration should be determined by both
UV spectrophotometry and quantitative analysis on an agarose gel.
Agarose gel analysis
We recommend removing and saving aliquots during the purification procedure
(samples 1-4). If the plasmid DNA is of low yield or quality, the samples can be
analyzed by agarose gel electrophoresis to determine at what stage of the purification
procedure the problem occurred (see page 50).
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QIAfilter Plasmid Midi and Maxi Protocol
This protocol is designed for preparation of up to 100 ~g of high- or low-copy plasmid
or cosmid DNA using the QIAfilter Plasmid Midi Kit, or up to 500 ~g using the QIAfilter
Plasmid Maxi Kit. In this protocol, QIAfilter Cartridges are used instead of conventional
centrifugation to clear bacterial Iysates. For purification of double-stranded M 13
replicative-form DNA, we recommend using the protocol on page 49.
Low-copy plasmids which have been amplified in the presence of chloramphenicol
should be treated as high-copy plasmids when choosing the appropriate culture volume.
Maximum recommended culture volumes"
QIAfilter Midi QIAfilter Maxi
High-copy plasmids
Low-copy plosrnids'
25 ml
50 ml
100 ml
250 ml
* For high-copy plasm ids, expected yields are 75-1 00 ~g for the QlAfilter Plasmid Midi Kit and 300-500 ~g
for the QIAfilter Plasmid Maxi Kit. For low-copy plasm ids, expected yields are 10-50 ~g for the QIAfilter
Plasmid Midi Kit and 50-250 ~g for the QIAfilter Plasmid Maxi Kit using these culture volumes.
t The maximum recommended culture volumes apply to the capacity of the QIAfilter Midi and Maxi Cartridges.
If higher yields of low-copy plasm ids yields are desired, the Iysates from two QIAfilter Midi Cartridges can be
loaded onto one QIAGEN-tip 100, or the Iysates from two QIAfilter Maxi Cartridges can be loaded onto one
QIAGEN-tip 500.
Important notes before starting
• New users are strongly advised to read "General Considerations for Optimal
Results" provided on pages 60-70 before starting the procedure.
• Add the provided RNaseA solution to Buffer P1 before use. Useone vial of RNase A
(spin down briefly before use) per bottle of Buffer Pl, to give a final concentration
of 100 ~g/ml.
• Check Buffer P2 for SDSprecipitation due to low storage temperatures. If necessary,
dissolve the SDS by warming to 37°C.
• Pre-chili Buffer P3 to 4°C.
• In contrast to the standard protocol, the lysate is not incubated on ice after addition
of Buffer P3.
• Optional: remove samples at the steps indicated with the symbol 1& in order to
monitor the procedure on an analytical gel.
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Procedure
1. Pick a single colony from a freshly streaked selective plate and inoculate a starter
culture of 2-5 ml LB medium containing the appropriate selective antibiotic.
Incubate for ....8 h at 37°C with vigorous shaking (....300 rpm).
Use a tube or flask with a volume of at least 4 times the volume of the culture.
2. Dilute the starter culture 1/500 to 1/1000 into selective LBmedium. For high-copy
plasmids inoculate 25 ml or 100 ml medium. For low-copy plasm ids, inoculate 50 ml
or 250 ml medium. Grow at 37°C for 12-16 h with vigorous shaking (....300 rpm).
Usea flaskor vesselwith a volumeof at least4 timesthevolumeof the culture.Theculture
should reach a cell density of approximately 3-4 x l09 cells per ml, which typically
corresponds to a pellet wet weight of approximately 3 g/Iiter medium (see
page 65).
3. Harvest the bacterial cells by centrifugation at 6000 x g for 15 min at 4°C.
6000 x g corresponds to 6000 rpm in Sorvall GSA or GS3 or BeckmanJAl 0 rotors.
Remove all traces of supernatant by inverting the open centrifuge tube until all
medium has been drained.
® If you wish to stop the protocol and continue later, freeze the cell pellets at -20°C.
4. Resuspend the bacterial pellet in 4 ml or 10 ml Buffer Pl.
For efficient lysis it is important to use a vessel that is large enough to allow
complete mixing of the lysisbuffers. Ensurethat RNaseA has been added to BufferPl.
The bacteria should be resuspended completely by vortexing or pipetting up and
down until no cell clumps remain.
5. Add 4 ml or 10 ml Buffer P2, mix gently but thoroughly by inverting 4-6 times, and
incubate at room temperature for 5 min.
Do not vortex, as this will result in shearing of genomic DNA. The lysate should
appear viscous. Do not allow the lysis reaction to proceed for more than 5 min.
After use, the bottle containing Buffer P2 should be closed immediately to avoid
acidification from CO2 in the air.
During the incubation prepare the QIAfilter Cartridge:
Screw the cap onto the outlet nozzle of the QIAfilter Midi or QIAfilter Maxi
Cartridge. Place the QIAfilter Cartridge in a convenient tube.
6. Add 4 ml or 10 ml chilled Buffer P3 to the lysate, and mix immediately but gently
by inverting 4-6 times. Proceed directly to step 7. Do not incubate the lysate on ice.
Precipitation is enhanced by using chilled Buffer P3. After addition of Buffer P3, a
fluffy white precipitate containing genomic DNA, proteins, cell debris, and SDS
becomes visible. The buffers must be mixed completely. If the mixture still appears
viscous and brownish, more mixing is required to completely neutralize the
solution. It is important to transfer the lysate into the QIAfilter Cartridge immediately
in order to prevent later disruption of the precipitate layer.
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7. Pour the lysate into the barrel of the QlAfilter Cartridge. Incubate at room
temperature for 10min. Do not insert the plunger!
Important: This 10 min incubation at room temperature is essential for optimal
performance of the QIAfilter Midi or QIAfilter Maxi Cartridge. Do not agitate the
QIAfilter Cartridge during this time. A precipitate containing proteins, genomic
DNA, and detergent will float and form a layer on top of the solution. This ensures
convenient filtration without clogging. If, after the 10 min incubation, the precipitate
has not floated to the top of the solution, carefully run a sterile pipet tip around the
walls of the cartridge to dislodge it.
8. Equilibratea QIAGEN-tip 100 or QIAGEN-tip 500 by applying 4 ml or 10 ml BufferQBT
and allow the column to empty by gravity flow.
Flow of buffer will begin automatically by reduction in surface tension due to the
presence of detergent in the equilibration buffer. Allow the QIAGEN-tip to drain
completely. QIAGEN-tips can be left unattended, since the flow of buffer will stop
when the meniscus reaches the upper frit in the column.
9. Remove the cap from the QlAfilter outlet nozzle. Gently insert the plunger into the
QIAfilter Midi or QIAfilter Maxi Cartridge and filter the cell lysate into the
previously equilibrated QIAGEN-tip.
Filter until all of the lysate has passed through the QIAfilter Cartridge, but do not
apply extreme force. Approximately 10 ml and 25 ml of the lysate are generally
recovered after filtration.
!TE Remove a 240 ~I or 120 ~I sample of the filtered lysate and save for an
analytical gel (sample 1) in order to determine whether growth and lysis
conditions were optimal.
10. Allow the cleared lysate to enter the resin by gravity flow.
!TE Remove a 240 ~I or 120 ~I sample of the flow-through and save for an
analytical gel (sample 2) in order to the efficiency of DNA binding to the
QIAGEN Resin.
11. Wash the QIAGEN-tip with 2 x 10 ml or 2 x 30 ml Buffer QC.
Allow Buffer QC to move through the QIAGEN-tip by gravity flow. The first wash
is sufficient to remove all contaminants in the majority of plasmid preparations. The
second wash is particularly necessary when large culture volumes or bacterial
strains producing large amounts of carbohydrates are used.
!TE Remove a 400 jJl or 240 ~I sample of the combined wash fractions and save
for an analytical gel (sample 3).
12. Elute DNA with 5 ml or 15 ml Buffer QF.
Collect the eluate in alO ml or 30 ml tube. Use of polycarbonate centrifuge tubes
for collection is not recommended as polycarbonate is not resistant to the alcohol
used in subsequent steps.
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lIE Remove a 100 jJl or 60 jJl sample of the eluate and save for an analytical gel
(sample 4).
® If you wish to stop the protocol and continue later, store the eluate at 4°C.
Storage periods longer than overnight are not recommended.
13. Precipitate DNA by adding 3.5 ml or 10.5 ml (0.7 volumes) room-temperature
isopropanol to the eluted DNA.Mix and centrifuge immediately at ~15,000 x g for
30 min at 4°C. Carefully decant the supernatant.
All solutions should be at room temperature in order to minimize salt precipitation,
although centrifugation is carried out at 4°( to prevent overheating of the sample.
A centrifugal force of 15,000 x g corresponds to 9,500 rpm in a BeckmanJS-13 rotor
and 11,000 rpm in a Sorvall SS-34 rotor. Alternatively, disposable conical bottom
centrifuge tubes can be used for centrifugation at 5,000 x g for 60 min at 4°C.
Isopropanol pellets have a glassy appearance and may be more difficult to see
than the fluffy, salt-containing pellets that result from ethanol precipitation. Marking
the outside of the tube before centrifugation allows the pellet to be more easily
located. Isopropanol pellets are also more loosely attached to the side of the tube,
and care should be taken when removing the supernatant.
14. Wash DNA pellet with 2 ml or 5 ml of room-temperature 70% ethanol and
centrifuge at ~15,000 x g for 10 min. Carefully decant the supernatant without
disturbing the pellet.
Alternatively, disposable conical bottom centrifuge tubescan be used for centrifugation
at 5,000 x g for 60 min at 4°C. The 70% ethanol removes precipitated salt and
replaces isopropanol with the more volatile ethanol, making the DNA easier to
redissolve.
15. Air-dry the pellet for 5-10 min, and redissolve the DNA in a suitable volume of
buffer (e.g., TE,pH 8.0, or 10 mM Tris·CI,pH 8.5).
Redissolve the DNA pellet by rinsing the walls to recover all the DNA, especially if
glass tubes have been used. Pipetting the DNA up and down to promote
resuspension may cause shearing and should be avoided. Overdrying the pellet
will make the DNA difficult to redissolve. DNA dissolves best under alkaline
conditions; it does not easily dissolve in acidic buffers.
Determination of yield
To determine the yield, DNA concentration should be determined by both
UV spectrophotometry and quantitative analysis on an agarose gel.
Agarose gel analysis
We recommend removing and saving aliquots during the purification procedure
(samples 1-4). If the plasmid DNA is of low yield or quality, the samples can be
analyzed by agarose gel electrophoresis to determine at what stage of the purification
procedure the problem occurred (see page 50).
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3.2 Sample preparation
Cell lysis Preparing the cell extracts using the lysis buffer offers the advantage that
• very mild conditions are used
• adherent cells do not need to be scraped from the culture dish
• samples are processed very rapidly
• thereby markedly facilitating CAT determinations in large scale experiments.
Another advantage ofthe lysis buffer is, that it is fully compatible with the J3-Gal ELISA
and the enzymatic reporter gene assays for luciferase and J3-galactosidase (see related
products). Therefore, the CAT ELISA could be combined with the a.m. determination
methods in co-transfection experiments.
Additional buffers For the preparation of cells Phosphate-buffered saline (PBS), pre-cooled to 2-BoC is
required required.
Preparation of Please refer to the following table
suspension eells
Step Action
1 Pellet the suspension cells at 250 x g for 10 min in a refrigerated centrifuge at
2-BoC.
2 Discard the supernatant
3 Resuspend the cell pellet and wash the cells with 5 ml of pre-cooled PBS (2-
BOC).
" Repeat the centrifugation and wash steps two more times.
Preparation of Carefully remove culture medium and wash cells with 5 ml of pre-cooled PBS three
adherent eells times.
Preparation of Please refer to the following table.
cell extracts
Step Action
1 After the last washing step, carefully remove PBS.
2 Add 1 ml of Lysisbuffer (solution B) to the cells to stand for 30 min at 15 to
25°C.
N!1l!:.: 1 ml Lysis buffer is sufficient for the lysis of approx. 2 x 106 cells grown
in suspension or for adherent cells grown in a 6 cm culture dish.
3 Cell extracts should be used immediately for the CAT ELISA or stored at
-70°C.
We recommend that the cell extracts be frozen in dry ice/ethanol before trans-
ferring the cell extracts for storage at -70°C. This rapid freezing by the dry
ice/ethanol step avoids the degradation of CAT.
!!!:Ill:;. Prolonged storage at 2-BoC should be avoided. In order to stabilize the
cell extracts protease inhibitors may be added.
continued on next page
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3.2 Sample preparation, continued
General
comments
All cytoplasmic and nucleoplasmic components, including CAT, will be extracted by the
lysis buffer.
IF you use... THEN ...
adherent cells, nuclei, Transfer 1 ml of cell extract (i.e. the supernatant) to
including DNA packed in chro- a microfuge tube. The cell extract contains soluble
matin, will remain attached to components of the cell including the CAT enzyme.
the vessel surface (16). · Spin the cell extract in a microfuge at maximum
speed for 10 min to remove any cellular debris.
Centrifugation at 2- BOCis recommended.
suspension cells the extract · We recommend spinning suspension cells using aalso contains nuclei and other microfuge at maximum speed for 15 min. Alterna-
cellular structures that remain tively, centrifuge cell extracts for 10 min at approx.
attached to the vessel surface 15 000 x g in a refrigerated centrifuge.
with adherent cells. · Remove the supernatant and take an aliquot of thesupernatant for protein determination (see 3.3).
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3.3 Protein detennination
Introduction Results have to be normalized with respect to protein concentration or cell number.
For protein determination use Roche Molecular Diagnostic's Protein Assay ESL or other
copper-based protein assays e.g. according to Lowry (17).
Be aware that higher detergent concentrations may interfere with determination
method. Therefore, check for interference or correct the calibration curve by addition
of an equal amount of detergent lysis buffer.
Protein determination should be performed in the linear range of the calibration
curve. If absorbance in the sample is in the nonlinear range, we recommend
repeating the protein determination to obtain reliable results .
• Volumes of samples should be adjusted so that the absorbance of the sample falls
within the linear range. Do not dilute the cell extracts before performing the protein
determination.
Alternatively different methods for determination of cell numbers can be used for
normalization e.g. measurement of metabolic activity by cleavage of the tetrazolium salt
WST-1·.
Additional WST-1, Cell proliferation Reagent (Cal NO.1 644 807)
reagents required
How to use Please refer to the following table.
WST -1 assay:
Step Action
1 Perform cell culturing and transfection according to your standard protocol.
2 30-150 min before cell lysis, add 10% WST-1 reagent to the cell medium.
3 Quantify conversion ofWST-1 directly from an aliquot. using an ELISA reader.
4 Withdraw reagent/medium and lyse cells for reporter gene assay.
5 Normalize reporter results according to the absorbance of the WST-1 assay.
Further information: http://biochem.roche.comltechserv/ttip0598.htm
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3.4 Measurement of CAT
General • The amount of sample material required in the assay depends on the level of expres-
recommendations sion. The type of promoter, type of expression (stable versus transient) and cell type
all affect the amount of CAT produced. In general, it is recommended to start with
50 j.Lg or 1 x 103 cells.
• Most of the available ELISA plate readers reach their absorbance maximum at
approx. 2 to 2.5 absorbance units. Measurement of supernatants with high CAT
concentrations therefore requires further dilution of the cell extracts with Sample
buffer (solution 7).
Weak
CAT expression
When testing vectors with weak CAT expression, incubate the microplate with the CAT-
containing cell extract for 2 h at 3rC. This results in an increase in sensitivity by a factor
of 1.5 to 2. Alternatively, the protein concentration used per well can be increased (e.g.
from 50 j.Lg/well to 150 j.Lg/well).
Substrate
enhancer
The use of the substrate enhancer with POD substrate ABTS (solution 5) approximately
doubles the sensitivity of the assay and can be used following the regular ABTS (SOlu-
tion 4).
Step Action
1 Removal of the POD substrate ABTS without substrate enhancer (solution 4),
when the test is first performed under non-optimal conditions.
2 Washing of each well two times with Washing buffer (solution 6).
3 Incubate with POD substrate ABTS with Substrate enhancer (solution 5).
4 Using the same procedure, an incubation with any of the substrate buffers
may be followed by an incubation with another POD substrate solution to
adapt the sensitivity.
N!d&;, In any case, an additional substrate reaction can only be performed
when the preceding incubation step has not been stopped, e.g. using H:zS04.
Non-linear
calibration
curves
Prolonged incubation of the samples with the peroxidase substrate ABTS (e.g. overnight
at 2-BOC) can produce a non-linear calibration curve and is therefore only recom-
mended for qualitative analysis of CAT expression.
Since the POD substrates (solutions 4, 5) are slightly colored, leave one well free in
order to determine the blank (baseline) value. Add POD substrate to this well for use as
a reference when measuring the MP modules in the ELISA reader. Most readers can be
programmed to automatically subtract the reference (blank) value from the values of
the other samples.
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3.5 Preparation of CAT enzyme standards
Preparation of
CAT enzyme
working dilution
Handling
instructions
Procedure
Add 40 j.ll CAT enzyme stock solution (solution 1) to 3.96 ml Sample buffer (solution 7)
to obtain a CAT enzyme working dilution (final concentration approx. 1 ng/ml), sufficient
to produce a calibration curve in duplicate.
• The CAT enzyme standard dilutions should be prepared freshly before use and
should not be stored.
• Prepare the standard dilution series in reaction tubes in 1:2 dilution steps as
described in the table below.
• To obtain a calibration curve, we recommend using the five concentrations listed.
• 200 j.ll of each dilution is needed per well.
• To ensure that the measurements and the calibration curve are accurate, we recom-
mend preparing two samples of each concentration for measurement.
• To avoid carryover of the higher cone. solution to the lower cone. samples, use a
fresh pipette tip for each dilution step.
Each dilution must be measured in duplicate.
Preparation of CAT enzyme standards are used to produce a calibration curve for the
CAT enzyme.
Step CATenzyme working Add Sample buffer Approximate CAT enzyme
dilution (approx. 1 (solution 7) conc. (ng/ml)
ng/ml)
0 0 1000 j.ll 0
1 1000 j.ll 0 1.0
2 500 j.ll of step 1 500 j.ll 0.5
3 500 j.ll of step 2 500 j.ll 0.25
4 500 j.ll of step 3 500 j.ll 0.125
Pipetting scheme Please refer to the following table.
for the microplate
1 2 3 4 5 6 7 8 9 10 11 12
A BI BI P1 P1
B SO so
C Sl Sl
0 S2 S2
E S3 S3
F S4 S4
G P1 P1
H P2 P2 P39 P39
legend:
BI = blank (= POD substrate, solution 4 or 5)
SO-54 = CAT standard dilutions
Pl-P39 = samples 1-39
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3.6 EUSAASSAY
Handling
instructions
Procedure
Use only the microplate (MP) modules required for the particular experiment and place
them in the frame in the correct orientation. (Correct fitting ensures a tight support of
the MP modules), The MP modules are ready-to-use and need not to be rehydrated
prior to addition of the samples.
Important: Reagents should be fully equilibrated to room temperature (20-23°C)
before starting the test Reagents from kits with different lot numbers must not be used
in one test series.
Step Action
1 Pipette 200 ILl of CAT standard. working dilutions or 200 ILl cell extracts
per well.
2 Cover the MP modules with a cover foil.
Incubate for 1 h at 37°C.
3 Remove the solution.
Rinse wells 5 times with 250 ILl of Washing buffer (solution 6) for 30 s each
and remove Washing buffer carefully.
4 Pipette 200 ILl of Anti-CAT-DIG working dilution (solution 2a) per well
Cover the MP modules with the cover foil.
Incubate for 1 h at 3rC.
5 Remove the solution.
Rinse wells 5 times with 250 ILl of Washing buffer (solution 6) for 30 s each
and remove washing buffer carefully.
6 Pipette 200 ILl of Anti-DIG-POD working dilution (solution 3a) per well.
Cover the MP modules with the cover foil
Incubate for 1 h at 3rC.
7 Remove the solution.
Rinse wells 5 times with 250 ILl of Washing buffer (solution 6) for 30 s each
and remove washing buffer carefully.
B Pipette 200 ILl of POD substrate without (solution 4) or POD substrate
with substrate enhancer (solution 5) into each well.
!/QJ!:;, Use the substrate enhancer only if the CAT concentration is lowl
Incubate at 15 to 25°C until color development (green COlor) is sufficient for
photometric detection (10-40 min).
Shaking of microplates at 250 rpm during incubation with substrate solution
can be employed to shorten the incubation period. but is not essential. If
shaking is not carried out. gently tap on the side of the microplate before
measuring absorbance to ensure a homogeneous distribution of the colored
reaction product
9 Measure the absorbance of the samples at 405 nm (reference wavelength:
approx. 490 nm) using a microplate (ELISA) reader (e.g. EAR 340 AnC. SLT
Lab Instruments).
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3.6 EUSA ASSAY, continued
Interpretation of • Upon completion of the experimental procedure, calculate the exact CAT eoncentra-
results tion (ng/ml) of the calibration standards. Plot the absorbance values obtained on the
y-axis against the lot specific standard concentrations on the x-axis, This results in a
linear calibration curve (for an example, see fig. 2).
CAT concentration of unknown samples can then be determined by plotting the
observed absorbance values also on the y-axls, extrapolating to meet the calibration
curve and reading the CAT enzyme concentration from the x-axls. To obtain reliable
results. the absorbance values of the unknown sample should lie within the linear
portion of the calibration curve.
!Jm!:.: A separate calibration curve must be established for each series. We recommend
that one experimental series be performed on one microplate. When more than one
microplate is used in one series. a calibration must be carried out on each plate.
3
1
'1
J
I 2
o
o 500
CAT enzyme [pg/ml]
1000
Fig. 2: A typical calibration curve using ABTS with (0) or without (e) substrate enhancer as peroxidase
substrate.
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Product specification
EeL Plus Western blotting reagent pack
RPN 2124
Before using this product, please read the instructions below
for safe handling, storage and disposal.
Safety warnings and precautions
Warning: For research use only. Not recommended or intended for diagnosis of disease in humans
or animals. Do not use internally or externally in humans or animals.
We recommend that this product and components are handled only by those persons who have been
trained in laboratory techniques and that it used in accordance with the principles of good
laboratory practice. As all chemicals should be considered as potentially hazardous, it is advisable
when handling chemical reagents to wear suitable protective clothing, such as laboratory overalls,
safety glasses and gloves. Care should be taken to avoid contact with the skin or eyes. In the case of
contact with skin or eyes, wash immediately with water.
Description
This kit contains reagents for membrane blocking and secondary detection of
membrane-bound mouse and rabbit primary antibodies. Detection reagents are
not included, but the system is optimized for use with ECL Plus™ (1,2)
Contents of kit
Anti mouse IgG, peroxidase linked whole antibody (from sheep) 100,.u
Anti rabbit IgG, peroxidase linked whole antibody (from donkey) 100fll
ECL™ Membrane blocking agent Sg
Detection of membrane bound primary antibodies
Prepare samples according to experimental requirements, following usual gel
electrophoresis and western blotting techniques. We recommend use of
Hybond™ ECL membrane (RPN2020D) or Hybond P PVDF membrane (RPN
2020P) for maximum sensitivity. To avoid membrane contamination or
damage, always use forceps and wear gloves when handling membranes.
f)
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Protocol
1) Block the membrane
Non-specific binding sites are blocked by immersing the membrane in a
5%(w/v) solution of the blocking agent in PBSor TBSTweenTM (0.1% is
usually sufficient) for 1 hour at room temperature on an orbital shaker.
2) Washing
PBSor TBSTween (0.1%) is recommended as the wash buffer. Briefly rinse the
membrane twice, then wash 3 times, once for 15 minutes and twice for 5
minutes at room temperature with fresh changes of wash buffer on an orbital
shaker.
3) Dilution of the primary antibody
During the washing step, dilute the primary antibody. Incubate the washed
membrane in the diluted antibody. 1 hour at room temperature is often
sufficient, but this should be optimized for each antibody.
4) Washing
Wash the membrane as detailed above.
5) Incubation with the species specific peroxidase linked second
antibody
These dilution factors are meant as a guide only, and are indicated as suitable
for the system in which they were used. Users should optimize their own
system to determine the dilution factors required. It is likely that when using
EeL Plus, dilution factors may need to be greater than previously used with
other detection systems.
• For detection with EeL Plus when using Hybond EeL membrane
We have found in our laboratories that dilutions of 1:25000 of the peroxidase
linked anti mouse antibody is suitable to detect 3ng of actin protein with an
exposure time of 5 minutes. We have also found that a dilution factor of
1:100000 of the peroxidase linked anti rabbit antibody is suitable for the
detection of 6ng of beta galactosidase with an exposure time of 5 minutes.
• For detection with EeL Plus when using Hybond PVDF membrane
We have found in our laboratories that dilutions of 1:50000 of the peroxidase
linked anti mouse antibody is suitable to detect 3ng of actin protein with an
exposure time of 5 minutes. We have also found that a dilution factor of
1:200000 of the peroxidase linked anti rabbit antibody is suitable for the
detection of 6ng of beta galactosidase with an exposure time of 5 minutes.
6) Washing
Wash the membrane as detailed above.
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7) Detection
Follow the detection procedures as outlined in the protocol booklet provided
with the detection reagents.
Notes
1) It is essential to optimize both primary and secondary antibodies for results
with high signal and low background due to the extreme sensitivity of the
detection system when using ECL and ECL Plus.
2) As a general rule, as large a volume of washing buffer as possible should be
used each time. It may be necessary to adjust the blocking conditions for
certain applications.
3) Do not use azide as a preservative for buffers to be used in immunodetection
as it is an inhibitor of horseradish peroxidase.
Additional information
Reagent specifications
• Peroxidase labelled anti species antibodies
Horseradish peroxidase conjugated antibody is supplied in phosphate buffered
saline (sodium phosphate O.lM,NaCI O.lM) pH7.5, containing 1%(w/v)
bovine serum albumin and an anti microbial agent.
Store at 2-8°C, do not freeze. Under these conditions, the reagent is stable for 6
months.
• ECL blocking reagent
This reagent has been selected to give effective blocking of membranes in
virtually all blotting contexts, if used as directed. Caution: Moisture will affect
the solubility properties of the powder. Store the container at room
temperature, ensuring that the lid is tightly closed.
References
(1) AKHAVEN-TAFTI, H. et al., Clin. Chem., 41, pp.1368-1369, 1995.
(2) AKHAVEN-TAFTI, H. et al., Biolum. and Chemilum. Fundamentals and
Applied Aspects, pp.199-202, Chichester, 1994.
Stellenbosch University http://scholar.sun.ac.za
Related products
EeL Plus Western blotting detection reagents
- sufficient for 3000cm2 membrane
- sufficient for 1000cm2 membrane
EeL Western blotting detection reagents
sufficient for 6000cm2 membrane
- sufficient for 4000cm2 membrane
sufficient for 2000cm2 membrane
sufficient for 1000cm2 membrane
RPN 2133
RPN 2132
EeL Western blotting analysis system
For the detection of either mouse or rabbit membrane bound primary antibodies with EeL
detection reagents. Sufficient for 1000cm2 membrane
EeL streptavidin-HRP and blocking reagent
Mouse IgG, horseradish peroxidase linked whole antibody (from sheep)
Rabbit IgG, horseradish peroxidase linked whole antibody (from donkey)
Rat IgG, horseradish peroxidase linked whole antibody (from sheep)
Human IgG, horseradish peroxidase linked whole antibody (from sheep)
Mouse IgG, horseradish peroxidase linked F(Ab'h fragment (from sheep)
Rabbit IgG, horseradish peroxidase linked F(Ab'h fragment (from donkey)
Rat IgG, horseradish peroxidase linked F(Ab'h fragment (from sheep)
Human IgG, horseradish peroxidase linked F(Ab'h fragment (from sheep)
Streptavidin horseradish peroxidase conjugate
Streptavidin biotinylated horseradish peroxidase complex
EeL protein molecular weight markers
RainbowlM coloured protein molecular weight markers
(molecular weight range 2350 - 46000)
Rainbow coloured protein molecular weight markers
(molecular weight range 14300 - 200000)
Full Range Rainbow recombinant protein molecular weight markers
(molecular weight range 10000 - 250000)
Hybond EeL nitrocellulose membrane
Hybond PVDFmembrane
HyperfilmlM-EeL
RPN 2134
RPN 2106
RPN 2209
RPN 2109
RPN 2108
RPN 2195
NA 931
NA934
NA932
NA 933
NA 9310
NA 9340
NA 9320
NA 9330
RPN 1231
RPN 1051
RPN 2107
RPN 755
RPN 756
RPN 800
RPN 2020D
RPN 2020P
RPN 2103
For details of sizes, availability and ordering information, please contact your
local sales office.
EeL, Eel device, ECLPlus, Rainbow, Hybond and Hyperfilm are trademarks of Amersham Pharmacia Biotech Limited or its subsidiaries
Amersham is a trademark of Nycomed Amersham pic
Pharmacia and Drop Design are trademarks of Pharmacia & Upjohn Inc
Tween is a trademark of 10 Americas Inc
<eAmershamPharmacia Biotech UK limited 1999 - All righrs reserved
All goods and services are sold subject to the terms and conditions of sale of the company within the Amersham Pharmacia Biotech group which
supplies them. A copy of these terms and conditions is available on request.
http://www.apbiorech.com
Amenham Pharmacia Biotech UK Limited Amersham Place
Little Chalfont Buckinghamshire England HP7 9NA
Amenham Pharmacia Biotech AB 5&751 84 Uppsala Sweden
Amersham Pharmacia Biotech Inc 800 Centennial Avenue PO Box 1327 Piscataway NJ08855 USA
Amersham Pharmacia Biotech Europe GmbH Munzinger Srrasse 9 D-79111 Freiburg Germany RPN2124PSlAB
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oCD It is important
to read the absorbance
immediately after
addition of 1M Sodium
Carbonate (3).
~ Do not incubate
reactions overnight.
IV. [3-Galactosidase Assays
A. Standard Assay
Preparation of a standard curve is optional. If a standard curve is desired,
please see Section V.
1. Thaw the system components and mix each component well before use.
Place the Assay 2X Buffer on ice. See Note 1.
2. It may be necessary to dilute the ceillysates in 1X Reporter Lysis Buffer.A
2:1 dilution of lysate to 1X Reporter Lysis Buffer (100~1of lysate plus 50~1of
1X Reporter Lysis Buffer) is a good starting dilution, but up to 150~1of cell
lysate can be used per reaction. As a negative control, prepare the same
dilution of a cell lysate made from cells that have not been transfected with
the [3-galactosidasegene.
3. Pipet 150~1of the appropriately diluted (or undiluted) ceillysates into
labeled tubes.
4. Add 150~1of Assay 2X Buffer to each of the tubes.
5. Mix all samples by vortexing briefly.
6. Incubate the reactions at 3rC for 30 minutes or until a faint yellow color has
developed. Color development continues for approximately 3 hours. If
enzyme activity is low, samples may be incubated overnight if the reaction
tubes are tightly capped.
7. Stop the reactions by adding 500~1of 1M Sodium Carbonate. Mix by
vortexing briefly.
8. Read the absorbance at 420nm.
B. 96-Well Plate Assay
This protocol is useful for testing numerous samples. The modified assay is
performed directly in 96-well plates, and the absorbance of each sample is read
using a plate reader. Preparation of a standard curve is optional. If a standard
curve is desired, please see Section V.
1. Thaw the system components and mix each component well. Place the
Assay 2X Buffer on ice. See Note 1.
2. It may be necessary to dilute the ceillysates in 1X Reporter Lysis Buffer.
Mix 30~1of lysate with 20~1of 1X Reporter Lysis Buffer as a starting
dilution, but up to 50~1of cell lysate can be used per reaction. As a negative
control, prepare the same dilution of a cell lysate made from cells that have
not been transfected with the [3-galactosidasegene.
3. Pipet 50~1of the appropriately diluted (or undiluted) ceillysates into labeled
wells of a 96-well plate.
4. Add 50~1of Assay 2X Buffer to each well of the 96-well plate.
5. Mix all samples by pipetting the well contents. Place a cover on the plate.
6. Incubate the plate at 37°C (an incubator works well) for 30 minutes or until a
faint yellow color has developed. Color development continues for
approximately 3 hours. Due to the small sample volume, we do not
recommend incubating the reactions overnight.
Promega Corporation· 2800'Woods Hollow Road· Madison, WI 53711·5399 USA. Toll Freein USA800-356-9526· Telephone608·274-4330· Fax608·277·2516· www.promega.com
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7. Stop the reaction by adding 1501J1of 1M Sodium Carbonate. Mix by pipetting
the contents of each well. Avoid producing bubbles, which may interfere with
absorbance readings; if present, bubbles may be removed by piercing with a
fine gauge needle.
8. Read the absorbance of the samples at 420nm in a plate reader (see Note 5).
Notes:
1. If crystals are present in the 1M Sodium Carbonate, warm the solution to
3rC to dissolve the crystals and then leave it at room temperature. If a
precipitate is present in the Assay 2X Buffer, warm briefly in a 3rC water
bath to dissolve and then place the solution on ice.
2. The 96-well plate assay is configured for a plate that has a maximum well
volume of approximately 3001J1.For plates with different maximum well
volumes, the reaction may be scaled up or down proportionally.
3. Plate readers generally perform best using plates that have flat-bottomed,
optically clear wells.
4. The coatings applied to some 96-well plates may inhibit the f3-galactosidase
reaction. To test for this, perform identical reactions in a 96-well plate and in
microcentrifuge tubes. Stop the reactions, pipet the tube reactions into the
plate wells and read all samples in a plate reader. The absorbance values
should be the same for both types of samples.
5. Some plate readers are limited in the number of wavelengths at which they
can read. Although the peak absorbance of the reaction product is near
420nm, other wavelengths close to 420nm may be used to monitor the
reaction. The greatest sensitivity is obtained with wavelengths of 410-430nm.
V. Standard Curves
A. Preparation of Standard Curve for Standard Assays
If a standard curve is desired, use standards between 0 and 6.0 x 10-3 units of
[3-Galactosidase. Prepare the following dilution series in 1X Reporter Lysis Buffer
immediately before use. Add 1OIJI of 1u/IJI f3-Galactosidase to 9901JI of 1X Reporter
Lysis Buffer and mix. Then add 101J1of this 1:100 dilution to 9901J1of 1X Reporter
Lysis Buffer and mix it to make a 1:10,000 stock solution. Using this stock, prepare
1501J1of each [3-Galactosidase standard per tube as described below.
~Galactosidase
Standard (milliunlts)
Volume of
1:10,000 Stock
Volume of 1X
Reporter Lysis Buffer
o
1.0
2.0
3.0
4.0
5.0
6.0
1501J1
1401J1
1301J1
1201J1
1101J1
1001J1
901J1
OIJI
101J1
201J1
301J1
401J1
501J1
601J1
1. Follow the protocol described in Section IV.A, Steps 4-8.
2. Plot the absorbance at 420nm versus concentration of f3-Galactosidase
standards. An example of a standard curve prepared by the standard assay
method is shown in Figure 1.
o
CD n is important
to read the absorbance
immediately after
addition of 1M Sodium
Carbonate (3).
CD Ifa
standard curve is
used, prepare fresh
enzyme dilutions
each time the assay
is performed.
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Milliunils ~-Galaclosidase
Figure 1. A sample standard curve for the standard assay. This standard curve was
prepared as described in Section VA Samples were incubated for 30 minutes at 37°e.
B. Preparation of Standard Curve for 96-Well Plate Assays
If a standard curve is desired, use standards between 0 and 5.0 x 10-3 units of
j3-Galaclosidase. Prepare the following dilution series in 1X Reporter Lysis
Buffer immediately before use. Add 101J1of 1u/IJIj3-Galactosidase lo 9901J1of 1X
Reporter Lysis Buffer and vortex. Then add 1OIJIof this 1:100 dilution to 9901J1of
1X Reporter Lysis Buffer and vortex to make al: 10,000 stock solution. Using
this stock, prepare 501J1of each j3-Galactosidase standard per well as described
below.
~Galactosldase
Standard (milliunits)
Volume of
1:10,000 Stock
Volume of 1X
Reporter Lysis Buffer
o
1.0
2.0
3.0
4.0
5.0
OIJI
101J1
201J1
301J1
401J1
50!.!I
501J1
401J1
301J1
201J1
101J1
O!.!I
1. Follow Ihe protocol described in Section IV.B, Steps 4-8.
2. Plot the absorbance at 420nm versus concentration of j3-Galactosidase
standards. An example of a standard curve prepared by the 96-well plate
method is shown in Figure 2.
VI. In situ Staining of Cells for ~Galactosldase Activity
Cells transfecled with the pSV-j3-Galactosidase Control Vector and expressing
j3-galactosidase can be visualized by microscopy (4). The cells appear blue following
fixation and incubation with the substrate X-Gal (5-bromo-4-chloro-3-indolyl-j3-D-
galactopyranoside). For comparison, it is important to include control cells that have
not been transfected with a j3-galactosidase vector in order lo visualize the level of
background activity due to endogenous j3-galactosidase or its isozymes. The follow-
ing protocol is for use with a 60mm culture dish.
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Figure 2. A sample of the standard curve for the 96-well assay. This standard curve was
prepared as described in Section V.B.Samples were incubated for 30 minutes at 37°C.
5.0
A. Staining Protocol
Materials to Be Supplied by the User
(Solution compositions are provided in Section VillA)
• PBS lX buffer (Mg2+-and Ca2+-free)
• glutaraldehyde solution
• X-Gal solution
1. Wash the cells twice with PBS 1X buffer. Remove all of the final wash buffer.
2. Fix the cells by adding 2ml of glutaraldehyde solution and incubating for
15 minutes.
3. Remove the glutaraldehyde solution and rinse gently 3 times with PBS 1X
buffer. It is important to remove residual glutaraldehyde, which could inhibit
j3-galactosidase activity.
4. Add 1ml of X-Gal solution per plate of cells. Incubate the cells at 37°C
between 1-16 hours until the cells are visibly stained. The exact incubation
time must be optimized for each set of transfections.
5. Remove the X-Gal solution. Cover the cells with lX PBS.
6. View the cells with a phase contrast or light microscope. To obtain a
permanent record of the results, photograph in situ stained cells on the
same day of the experiment.
7. For long-term storage (weeks to months) of in situ stained cells, store the
cells under 70% glycerol at 4°C.
VII. References
1. Rosenthal, N. (1987) Identification of regulatory elements of cloned genes with
functional assays. Meth. Enzymol. 152, 704-20.
2. Schenborn, E. and Goiffon, V. (1993) A new lysis buffer for luciferase, CAT and
j3-galactosidase reporter gene co-transfections. Promega Notes 41, 11.
e
Promega
CD lfs
standard curve is used,
prepare fresh enzyme
dilutions each time the
assay is performed.
CD Caution:
Glutaraldehyde is a
carcinogen. Avoid
contact with skin and
avoid inhalation. Use in
a fume hood and
discard waste according
to your institution's
procedures.
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